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The anticarcinogenic potential of dietary natural compounds on colorectal 
carcinoma: Effects on signaling pathways related to cell proliferation and cell death 
 
Abstract 
Colorectal cancer (CRC) is the third most prevalent cancer worldwide and the 
incidence is highly influenced by diet. Epidemiological studies have supported the idea 
that some dietary food components may influence the risk of CRC through modulation of 
several biological processes, including proliferation, survival and cell death. The 
PI3K/Akt and MAP kinases (ERK, JNK and p38) pathways are frequently altered in CRC 
and components of these pathways are important molecular targets for CRC treatment. 
Moreover, the apoptotic and non-apoptotic pathways of cell death have been shown good 
targets for anticancer drugs. The aim of the thesis was to identify potentially 
anticarcinogenic natural compounds and characterize their effects on signaling pathways 
related to proliferation and cell death, in CRC cell lines. The role of these natural 
compounds in combination with 5-fluorouracil (5-FU) was also evaluated. 
Initially, the anticarcinogenic effect of some water extracts (prepared as a tea) in 
two human colon carcinoma-derived cell lines, HCT15 and CO115 was studied. In 
chapter II, we demonstrated the anticarcinogenic activity of Salvia fruticosa (SF) and 
Salvia officinalis (SO), that seems to be due, at least partially, to the inhibition of the 
MAPK/ERK pathway, through effects upstream of BRAF. This effect was not due to 
rosmarinic acid (RA), the major phenolic compound present in these sage plants. In a 
subsequent study (chapter III), we showed the potential of Hypericum androsaemum 
(HA) in inhibiting cell proliferation and inducing apoptosis, at least in part, through 
inhibition of mutant BRAF and PI3K/Akt pathway, as well as, by the induction of p38 
and JNK MAP kinases. As in the case of RA also here the main phenolic compound 
present in HA extract, chlorogenic acid, tested alone did not show any of those effects. 
Taking into account the previous observations, we further evaluated the potential 
anticarcinogenic effects of quercetin (Q), luteolin (L) and ursolic acid (UA) in CRC cells. 
These phenolic compounds (Q and L) and triterpenoid (UA) are present (or appear as 
derivates) in the water extracts previously used, and have been demonstrated to modulate 
many steps of the carcinogenic process. In chapter IV, we found that Q and L have 
antiproliferative and proapoptotic effects that seem to be due, at least in part, to effects on 
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KRAS through regulation of both MAPK/ERK and PI3K pathways. UA demonstrated 
anticarcinogenic effects by acting on PI3K.  
In chapter V, we performed a combined study of Q, L and UA with the most 
common chemotherapeutic agent used in CRC treatment, 5-FU. Resistance to 5-FU 
arises, especially in tumors with p53 mutations, make combinations with other drugs a 
necessary strategy to increase 5-FU’s efficacy. In the first part of this study, we 
demonstrated that Q and L enhanced 5-FU-induced apoptosis and a synergistical effect 
was observed with Q in the p53 wild type CO115 cells. Q may increase 5-FU-induced 
apoptosis by modulating the mitochondrial pathway dependent on p53. In the second 
part, UA was observed to synergistically enhance 5-FU-induced apoptosis in the p53 
mutant HCT15 cells. The increase on apoptosis was not dependent on caspases and it was 
almost completely abrogated by an inhibitor of JNK, suggesting that in these cells UA 
induces apoptosis through JNK activation. Moreover, the increase of total cell death and 
the accumulation of LC3, induced by UA, were also dependent on JNK activation.  
In order to explore the remarkable induction of cell death by UA, which was not 
all explained by increased apoptosis, we verified the involvement of UA in the 
autophagic process (chapter VI). Interestingly, we found that UA inhibits autophagy in 
HCT15 cells at the maturation step, since no fusion events between lysosomes and 
autophagosomes were detected. Taking advantage of techniques established for MCF-7 
breast cancer cells, including the tandem fluorescent construct tagged with LC3 and the 
measurement of LC3 turnover using a luciferase-based real time assay, the results above 
were confirmed. Furthermore, UA increased lysosomal membrane permeabilization and 
decreased the total lysosomal hydrolases activities, indicating a possible impact on 
lysosomal biogenesis and/or a direct destabilizing effect on lysosomal membranes.    
In conclusion, this work adds SF, SO and HA to the list of potential plants to use 
in CRC dietary strategies, as well as, the natural compounds Q, L and UA present in 
human diet. These natural compounds control CRC progression by modulating important 
molecular targets, as well as, by enhancement of 5-FU efficiency. UA was the most 
promising compound, destabilizing the lysosomes and, consequently, inhibiting 
autophagy, which could sensitize cells to death and thus, may have a possible interest as 
adjuvant in cancer therapy.    
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Estudo do potencial anticarcinogénico de compostos naturais provenientes da dieta 
no cancro colorectal: Efeitos ao nível de vias de sinalização relacionadas com a 
proliferação e morte celular  
 
Resumo 
O cancro colorectal (CRC) é o terceiro cancro mais comum a nível mundial 
estando a sua incidência fortemente influenciada pela dieta. Estudos epidemiológicos 
revelam que compostos presentes na dieta podem influenciar o risco de CRC, modulando 
vários processos biológicos, incluindo a proliferação, sobrevivência e morte celular. As 
vias de sinalização PI3K/Akt e MAP kinases (ERK, JNK e p38) estão frequentemente 
alteradas no CRC e por isso, componentes destas vias constituem alvos moleculares 
importantes para o seu tratamento. Além disso, as vias apoptóticas e não-apoptóticas de 
morte celular têm demonstrado ser bons alvos de drogas anticarcinogénicas. A presente 
tese teve como objectivo identificar compostos naturais com potencial anticarcinogénico 
e caracterizar os seus efeitos ao nível das vias relacionadas com proliferação e morte 
celular em linhas de CRC. O papel destes compostos em combinação com o 5-
Fluorouracilo (5-FU) foi também abordado.   
Inicialmente, os efeitos anticarcinogénico de alguns extractos aquosos (preparados 
como chás) foram estudados em duas linhas celulares humanas de carcinoma do cólon, 
HCT15 e CO115. No capítulo II, demonstrou-se a actividade anticarcinogénica das 
plantas Salvia fruticosa (SF) e Salvia officinalis (SO), em que o seu efeito pareceu dever-
se, pelo menos em parte, à inibição da via MAPK/ERK, através de efeitos a montante do 
BRAF. O ácido rosmarínico (RA), composto fenólico maioritário presente nas Salvias 
não foi o responsável pelos efeitos observados. No capítulo III, demonstrou-se que o 
extracto aquoso de Hypericum androsaemum (HA) é capaz de inibir a proliferação 
celular e induzir a apoptose, pelo menos em parte, por inibir o BRAF mutado e a via 
PI3K/Akt, assim como, por induzir as MAP kinases p38 e JNK. Tal como no caso do RA, 
também o composto fenólico maioritário presente no extracto HA, o ácido clorogénico, 
testado sózinho, não mostrou nenhum destes efeitos.     
Tendo em conta os resultados anteriores, foi-se de seguida avaliar o potencial 
anticarcinogénico da quercetina (Q), luteolina (L) e ácido ursólico (UA). Estes compostos 
fenólicos (Q e L) e triterpenoide (UA) encontram-se presentes (ou aparecem como 
derivados) nos extractos aquosos anteriormente estudados, e têm a capacidade em 
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modular várias etapas do processo carcinogénico. No capítulo IV, observou-se o efeito 
antiproliferativo e pró-apoptótico da Q e L, que foi relacionado, pelo menos em parte, 
com efeitos no KRAS regulando as vias PI3K e MAPK/ERK. O efeito anticarcinogénico 
do UA foi observado ao nível do PI3K.       
No capítulo V, o efeito combinado da Q, L e UA com 5-FU, agente 
quimioterapêutico mais usado no tratamento do CRC, foi avaliado. O aumento das 
resistências ao 5-FU, especialmente em tumores com mutações no p53, leva a estratégias 
de combinações com outras drogas necessárias para aumentar a eficácia do 5-FU. Na 
primeira parte deste estudo, a Q e a L aumentaram a apoptose induzida pelo 5-FU, e um 
efeito sinergético foi obtido para a Q nas células CO115 com p53 normal. A Q 
provavelmente aumentou a apoptose induzida pelo 5-FU através da modulação da via 
mitocondrial dependente do p53. Na segunda parte, observou-se que UA 
sinergeticamente aumentou a apoptose induzida pelo 5-FU em células HCT15 com p53 
mutado. O aumento da apoptose não foi dependente das caspases e foi quase 
completamente inibido por um inibidor da JNK, sugerindo que nestas células o UA induz 
apoptose via activação da JNK. Além disso, o aumento da morte celular total e a 
acumulação do LC3, induzidos pelo UA, foi também dependente da activação da JNK.  
Por fim, para explorar o efeito marcante da indução da morte celular pelo UA, na 
qual não foi totalmente explicado pelo aumento da apoptose, foi estudado o involvimento 
do UA no processo autofágico (capítulo VI). Interessantemente, verificou-se que o UA 
inibiu a autofagia nas células HCT15 ao nível da maturação, uma vez que não foi 
detectado fusão entre lisossomas e autofagossomas. Estes resultados foram confirmados 
tirando vantagem de técnicas estabelecidas para a linha MCF-7 de cancro da mama, como 
a construção fluorescente tandem ligado ao LC3 e a medição do turnover do LC3 usando 
o ensaio de luciferase em tempo real. Adicionalmente, observou-se que UA aumentou a 
permeabilidade da membrana lisossomal e diminuiu a actividade total das hidrolases 
lisossomais, indicando um possível impacto na biogénese lisossomal e/ou uma 
destabilização directa na membrana dos lisossomas.     
Em conclusão, este trabalho adiciona SF, SO e HA, à lista de potenciais plantas a 
usar em estratégias alimentares contra o CRC, assim como a Q, L e UA presentes na 
dieta. Estes compostos naturais controlam a progressão do CRC modulando importantes 
alvos moleculares e aumentando a eficiência do 5-FU. O UA foi o composto mais 
promissor, destabilizando os lisossomas e, consequentemente, inibindo a autofagia, e por 
isso, possuindo elevado interesse como adjuvante na terapia do cancro. 
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Preface 
 
Several studies have been developed at the Department of Biology, in the 
University of Minho, with aromatic and medicinal plants that grow spontaneously or are 
cultivated in Portugal. Aromatic plants have a wide applicability, for example, in 
cosmetic, food, beverage and pharmaceutical industries. These plants are known to be 
rich in a number of bioactive compounds, which have demonstrated to possess different 
therapeutical properties. This research project arose from the interest to identify 
medicinal plants, such as Salvia and Hypericum species, with anticarcinogenic effects in 
colorectal cancer (CRC). The overall positive results obtained during the studies 
performed with these plants led us to elucidate which bioactive compounds, present in 
these water extracts, were behind these effects and their molecular targets. Thus, these 
natural compounds, which are also present in human diet, were studied.  
The possible mechanism of action of the extracts and natural compounds were 
focused on some signalling pathways related to proliferation and cell death. Several 
molecular markers of these pathways have also been shown, by the research group of 
cancer genetics in IPATIMUP, to be important targets in CRC therapy, and thus being 
suggested for this work. In addition, effects on lysosomes and/or regulation of the 
autophagic process have also been shown to be relevant molecular targets. In the 
Apoptosis Laboratory, Institute of Cancer Biology at the Danish Cancer Society, it was 
possible to identify and characterize the effects of one compound on these targets. All 
these studies were performed in vitro, taking advantage of several cancer cell lines 
harbouring different mutations. However, we are aware that studies in vivo are needed 
and crucial to validate our findings.    
In summary, this work was organized in seven chapters, where the first is a 
general introduction, with a brief review of the field from the last 10 years. The 
following five chapters are the results obtained during the four years, which were 
published or are soon to be published in peer-reviewed journals. Finally, in the last 
chapter, a global discussion of the work is presented to highlight the main findings and 
some implications of the results in cancer research. Additionally, future research goals 
are mentioned. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
GENERAL INTRODUCTION  
 
Overview of the past 10 years 
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1. CANCER  
 
In the past decades cancer has emerged as a major health issue being responsible 
for more than 10% of deaths worldwide. Cancer arises as a result of a stepwise process 
called carcinogenesis, that consists in the accumulation of genetic mutations and 
epigenetic changes that compromise the control of cell proliferation, survival, 
differentiation, migration and interaction with neighbor cells [Pelengaris and Khan, 
2006]. This multistep process can be divided in three phases: initiation, promotion and 
progression. A mutational event in a single cell results in irreversible changes that 
confer an intrinsic capacity to proliferate uncontrollably to form an adenoma (initiation). 
A continuous division of initiated cells facilitates the acquisition of further mutations 
and originates a mass of abnormal cells that gives rise to the carcinoma (promotion). 
Cells will then acquire the ability to invade and metastasize during the progression 
phase [Frank, 2007].  
The carcinogenesis model proposed by Fearon and Vogelstein in 1990 has 
colorectal cancer (CRC) as a good model for the study of morphology and genetic 
stages in cancer progression [Frank, 2007]. Using this model, they identified a mutation 
in the tumor suppressor adenomatous polyposis coli (APC) gene as the first event 
involved in premalignant lesion to initiate the formation of a malignant tumor. 
Disruption of the APC pathway may be sufficient to start a small adenoma, affecting 
cell division through disturbing of the Wnt signaling. Then, mutations in the oncogene 
v-ki-ras 2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and in the tumor 
suppressor gene tumor protein p53 (TP53) appear later in tumor progression, leading to 
the formation of a carcinoma. However, other genetic changes in other key important 
genes, including in DNA mismatch repair (MMR) genes, which result in multiple errors 
in repetitive DNA sequences during DNA replication, can also arise during the 
carcinogenesis process contributing to cancer development [Frank, 2007; Souglakos, 
2007]. 
Genetic alterations can occur as germline mutations, resulting in inherited cancer 
predisposition that appear in hereditary tumors, or more commonly occur in somatic 
cells (somatic mutations), where their accumulation in association with several 
environmental factors give rise to sporadic tumors [Pelengaris and Khan, 2006; 
Souglakos, 2007]. The presence of inherited mutations can start cancer initiation, but 
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other modifications such as somatic mutations and epigenetic alterations are still needed 
for cancer to develop. Numerous studies now point to the crucial interplay between 
these last changes and environmental factors as key determinants of tumor progression 
[Pelengaris and Khan, 2006].   
 
1.1. Colorectal Cancer (CRC) 
 
Colorectal cancer (CRC) is the third most common type of cancer worldwide 
being mainly a disease of industrialized countries, such as North American, parts of 
Europe, Australia, New Zealand and Japan, remaining relatively uncommon in low-
income countries, such as in Africa and much of Asia [WCRF/AICR, 2007]. Although 
the overall 5-year survival rate of CRC has increased during the past 2 decades from 
51% to 65%, its incidence and mortality are continually increasing [Gralow et al., 
2008]. Approximately 1 in 3 people who develop CRC die of this disease and 90% of 
CRC cases appear in patients after age 50 [Souglakos, 2007]. 
 CRC is divided in sporadic, inherited and familial. The majority of the patients, 
around 70% of the cases, have sporadic CRC (nonhereditary) in which there is no 
evidence of CRC in family history. In this case, the patients are usually older than 50 
years of age, environmental factors being most likely responsible for this high 
incidence. The other remaining types of CRC have an associated genetic component 
with patients having an inherited predisposition to develop CRC [Souglakos, 2007]. The 
two well-described CRC genetic syndromes are subdivided according to whether or not 
colonic polyps are manifested: the familial adenomatous polyposis (FAP) and the 
hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome, which 
accounts about 1% and 3-4% of all CRC, respectively [Rustgi, 2007]. The familial CRC 
is the least well understood syndrome, where up to 25% of the affected patients have a 
family history, but present low risk of developing CRC compared to the inherited type 
[Souglakos, 2007].  
Carcinogenesis in the colon epithelium results from the accumulation of multiple 
genetic mutations where the mutation in the APC gene has an important role in the early 
process of CRC, in both inherited and sporadic tumors (Fig. 1). Mutations in ß-catenin 
gene, which, as APC, are involved in Wnt signaling, have also been demonstrated to 
play a key role in the first events of CRC, appearing in most sporadic CRC with normal 
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or wild-type (wt) APC. Subsequently, mutations in TP53 and KRAS genes appear later 
during adenoma progression. Other genetic alterations in Bcl-2-associated X protein 
(BAX), SMAD4, transforming growth factor β receptor II (TGFβ-RII), cyclooxygenase 2 
(COX2) and phosphotase and tensin homologue (PTEN) genes had also found to be 
frequently involved in CRC development [Soreide et al., 2006; Souglakos, 2007]. 
Additionally, alterations in genes encoding enzymes involved in the DNA MMR 
system, which lead to microsatellite instability (MSI), have been demonstrated to 
contribute to the CRC progression, in both hereditary and sporadic CRC. In HNPCC 
cases, 90% of the tumors are MSI due to germline mutations in hMSH2 and hMLH1 
mismatch repair genes, while in sporadic CRC approximately 15% of tumors have MSI 
due to alterations in hMLH1 gene [Soreide et al., 2006].  
 
 
 
Fig. 1. Schematic representation of some key genetic alterations during colorectal cancer (CRC) 
carcinogenesis.  Mutations in the adenomatous polyposis coli (APC) and ß-catenin genes occur in the 
initiation process of CRC carcinogenesis, while mutations in the KRAS and TP53 genes appear during 
the adenoma progression. Mutations in Bcl-2-associated X protein (BAX), SMAD4, transforming 
growth factor β receptor II (TGFβ-RII), cyclooxygenase 2 (COX2) and phosphotase and tensin 
homologue (PTEN) genes have also found to be involved in CRC development. Genetic alterations in 
DNA mismatch repair genes (MMR), such as MLH1, MSH2 and MSH6, also aride during the 
carcinogenesis process. Adapted from [Soreide et al., 2006; Souglakos, 2007]. 
 
1.2. CRC and Nutrition 
 
1.2.1. Importance of Diet 
Genetic and environmental risk factors modulate CRC, diet being considered the 
most important environmental factor contributing to the high CRC incidence [Davis and 
Hord, 2005; Souglakos, 2007]. Many studies have reported a relationship between 
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nutritional factors and CRC, supporting the idea that dietary constituents may affect 
CRC by reducing or enhancing its risk [Ryan-Harshman and Aldoori, 2007]. Recently, 
an international review from the World Cancer Research Fund (WCRF) heightened the 
implication of food and nutrition in CRC, although there are some inconsistencies 
between different studies [WCRF/AICR, 2007].  
The WCRF adverts that there are convincing evidences that red and processed 
meat are risk factors of CRC, while diets containing dietary fibre, garlic, milk and 
calcium most likely protect against this disease. Additionally, the report of the WCRF 
indicates that, although with limited evidence, fish and foods containing folate, vitamin 
D and selenium may also protect against CRC. The benefits of fruit and vegetables 
consumption have appeared controversial among different studies, but there seems to be 
a significant association between their consumption and a reduced risk of CRC 
incidence [WCRF/AICR, 2007].  
More recently, different reports discussed the effects of diet in CRC. One study 
showed that high consumption of fruit and vegetables is associated with a reduced risk 
of CRC, although their results suggest that probably only specific types of fruit and 
vegetables, or their related nutrients, may confer CRC protection [van Duijnhoven et 
al., 2009]. Other recent report demonstrated that an intake of fish was statistically 
associated with a decrease risk of having CRC [Hall et al., 2008]. A diet poor on 
calcium and vitamin D consumption was also showed to induce CRC tumors on long-
term feeding in mice, implying that their intake may protect against CRC development 
[Newmark et al., 2009]. In aggrement with that, calcium intake was able to reduce CRC 
promotion induced by red meat in rats [Pierre et al., 2008]. Besides the previous report 
of WCRF 2007, these examples shows that consumption of fruits, vegetables, fish, 
calcium and vitamin D could be included in the list of foods that convincingly reduce 
the risk of CRC. 
 
Overall, an appropriate diet may minimize CRC risk, suggesting the possible 
benefit of preventive strategies based on dietary supplements and a potential therapeutic 
role for the compounds responsible for these effects. 
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1.2.2. Variability in Nutritional Responses 
The variability of results concerning the effects of dietary constituents on CRC, 
and the variation in CRC incidence among and within populations with similar dietary 
patterns, suggests the involvement of individual responses to a dietary constituents 
[Davis and Milner, 2004; Davis and Hord, 2005]. In fact, it has been found that several 
food components are able to modify the expression of a number of genes, which suggest 
an interaction between nutrition/diet and the individual’s genome (nutrigenomic), as 
well as, to influence protein expression (proteomic). However, for a bioactive food 
component to influence a key molecular event in a cell or organism, at a given moment 
(metabolomic), it is necessary to reach the target at an effective concentration and with 
an appropriate timing of exposure [Davis and Milner, 2004; Davis and Hord, 2005].  
Several types of diets and food constituents have been found to alter the 
expression of certain genes and/or proteins, allowing the identification of genetic 
susceptibilities towards these particular dietary components. For example, Diergaarde et 
al, showed that red meat consumption could enhance the development of MSI-L and 
MSS carcinomas in particular, whereas fruit consumption can decrease this risk of MSI-
H carcinomas that exhibit alterations in hMLH1 [Diergaarde et al., 2003]. In addition, 
the authors also demonstrated that consumption of fruits and dietary fiber might also 
decrease the risk of CRC in individuals with HNPCC [Diergaarde et al., 2007]. A study 
performed with different types of vegetables pinpointed their capacity to modulate 
specific genes involved in the prevention of CRC, such as CASP3 [van Breda et al., 
2005]. Another study demonstrated an increase of PKC isozyme expression in rats fed 
with red meat, suggesting a possible mechanism of red meat on CRC carcinogenesis 
[Pajari et al., 2000]. Interestingly, the consumption of beef, pork and other meat 
products were associated with CRC tumors with wild-type KRAS gene, suggesting that 
they may exert their action through a pathway independent of a KRAS mutation [Brink 
et al., 2005].  
 
Thus, all these studies suggest that certain genes can be modulated and modified 
by specific dietary components, being essential to consider the genomic profile of each 
individual to determine who may or may not respond to CRC dietary interventions. 
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2. CANCER CELL SIGNALLING RELATED TO 
PROLIFERATION AND CELL DEATH 
 
 Carcinogenesis involves an accumulation of genetic alterations that in turn lead 
to alterations in important biological pathways of cell proliferation and cell death, such 
as phosphotidylinositol-3 kinase (PI3K)/protein kinase B (PKB/Akt), mitogen-activated 
protein kinases (MAPKs) [extracellular-signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK) and p38] and apoptotic and non-apoptotic pathways.  
 
2.1. RAS Signaling 
 
The small GTP-binding protein Ras is a common upstream molecule of several 
signaling pathways, including PI3K/Akt, MAPK/ERK and RAlGDS (Ral guanine 
nucleotide-dissociation stimulator). Three Ras proteins, H-Ras, K-Ras and N-Ras, have 
been identified differing in the ability to activate different pathways. KRAS is the most 
frequently mutated RAS isoform in human cancers. Ras is activated by changes from the 
inactive Ras-GDP conformation to active Ras-GTP form through farnesylated or 
geranylgeranylated in cysteine residue. Ras is able to bind to the p110 catalytic subunit 
of class I PI3K, resulting in its translocation to the plasma membrane and consequent 
PI3K activation. Ras is also able to recruit the protein Raf to the plasma membrane and 
thus activate the MAPK/ERK pathway (Fig. 2) [McCubrey et al., 2006; Schubbert et 
al., 2007].  
The upregulation of PI3K/Akt and Raf/MAP/ERK pathways by the oncogene 
RAS cooperates to regulate various cellular responses and generate resistance to therapy 
[Barault et al., 2008]. Moreover, it was found that Ras could downregulate PTEN 
expression through the Raf/MAPK/ERK pathway promoting activation of the PI3K/Akt 
pathway, which strengthens the connection between these two pathways [Vasudevan et 
al., 2007]. 
 
2.1.1. Mutations on KRAS in CRC 
It is known that about 30% of sporadic CRC tumors have mutations in KRAS 
[Oliveira et al., 2007; Barault et al., 2008]. In addition, CRC patients that display KRAS 
mutation alone or in combination with BRAF mutation (~0.4%) have bad prognosis and 
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poor survival [Oliveira et al., 2007]. It has been demonstrated that KRAS mutations 
have effects at tumor initiation, on cell growth and progression, as well as, in promoting 
invasion, angiogenesis and resistance to CRC therapy [Jiang et al., 2009].  
 
2.2. PI3K/Akt Pathway 
 
2.2.1. PI3K 
The phosphotidylinositol-3 kinases (PI3Ks) are a family of lipid kinases that are 
classified according to sequence homology and subtract specificity into class I, class II 
and class III. Class I PI3K is the major class and is involved in cell growth, proliferation 
and apoptosis [Zhao and Vogt, 2008]. Class I PI3K, a heterodimeric protein, is 
composed by a p110 catalytic subunit and a p85 regulatory subunit, both of which 
expressed in various isoforms. This class of PI3K can be activated by receptor tyrosine 
kinases (RTK), such as PDG-R, EGF-R or IGF-R through interaction with 
phosphotyrosine residues, and by G protein-coupled receptors, such as RAS. The 
activation of PI3K leads to the conversion of the lipid substrate phosphoinositol 4,5-
bisphosphate (PIP2) to the second messenger, the phosphatidylinositol-3,4,5-
triphosphate (PIP3) at the inner side of the plasma membrane (Fig. 2). PIP3 binds to 
target proteins that contain pleckstrin homology (PH) domains, such as PKA, PKC and 
Akt/PKB, the latter being the primary downstream mediator of PI3K effects [Vara et 
al., 2004; Michl and Downward, 2005; Zhao and Vogt, 2008].  
 
2.2.2.  Akt 
Akt is the human homologue of the viral oncogene v-Akt. Three members of the 
Akt family (Akt1, Akt2 and Akt3) have been identified and are ubiquitously expressed 
with their levels variable depending upon the tissue type [Vara et al., 2004; Blanco-
Aparicio et al., 2007]. The PH domain of Akt binds to PIP3 inducing conformational 
changes in the molecule, which make a threonine residue (T308) accessible for 
phosphorylation by the activated protein serine/treonine kinase 3´-phosphoinositide-
dependent kinase-1 (PDK-1). Full activation of Akt is also associated with 
phosphorylation of a serine 473 (S473), located in the C-terminal tail of Akt, by the 
target of rapamycin complex 2 (TORC2). Phosphorylations of T308 and S473 residues 
are essential for a complete activation of Akt function [Vara et al., 2004; Michl and 
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Downward, 2005; Blanco-Aparicio et al., 2007; Manning and Cantley 2007]. 
Subsequently, Akt phosphorylates a number of subtracts that play a central role in cell 
proliferation and cancer progression (Fig. 2).  
Akt can promote cell growth and affect the cell metabolism by indirectly 
activating the mammalian target of rapamycin complex 1 (mTORC1) and inhibiting the 
glycogen synthase kinase-3 (GSK-3). In addition, Akt is also able to phosphorylate the 
cyclin-dependent kinase inhibitors p27 and p21 affecting cell cycle progression. Akt can 
also block the function of proapoptotic proteins by directly phosphorylating and 
inhibiting BAD, procaspase-9 and the transcription factor Forkhead box (FOXO), as 
well as, by phosphorylating MDM2 and promoting its translocation to the nucleus 
where it negatively regulates p53 expression [Vara et al., 2004; Manning and Cantley, 
2007].  
 
2.2.3. PTEN 
 The activation of Akt has also been partially related to the loss of PTEN 
(phosphatase and tensin homologue deleted on chromosome 10), a tumor suppressor 
gene that functions as an intracellular inhibitor of the PI3K pathway. PTEN 
dephosphorylates PIP3 to generate PIP2, acting as a negative regulator for PI3K-
induced signaling (Fig. 2) [Vara et al., 2004; Blanco-Aparicio et al., 2007]. In addition, 
it was also reported that PTEN mediates effects, independently of Akt, on cell cycle and 
apoptosis [Blanco-Aparicio et al., 2007].     
 
2.2.4. PI3K/Akt Deregulation in CRC 
Nearly 40% of CRC tumors have been demonstrated to have alterations in one 
of the genes related with PI3K signaling [Parsons et al., 2005]. Approximately 30% of 
CRC tumors have showed somatic mutations in PIK3CA gene that encodes the p110α 
subunit of class I PI3K [Samuels and Velculescu, 2004; Michl and Downward, 2005; 
Barault et al., 2008]. This mutation has been demonstrated to occur as a primary genetic 
event in CRC, having a relevant importance in the carcinogenic process [Velho et al., 
2008].  
CRC cell lines with PIK3CA mutation have shown the capacity to proliferate 
and survive under environmental stresses [Wang et al., 2007], as well as, to be more 
resistant to apoptosis and to have high metastatic potential [Guo et al., 2007]. Moreover, 
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mutation in PIK3CA gene have been shown to occur more frequently in combination 
with other mutations in other components of the PI3K pathway, such as KRAS or BRAF, 
than in isolation, suggesting a possible synergistic effect in the signaling pathways 
controlled by them for an efficient malignant transformation [Velho et al., 2005; Oda et 
al., 2008]. More recently, a mutation in PIK3R1 gene, which encodes the p85α 
regulatory subunit, was found, which turns it to a novel oncogene with important effect 
on CRC development [Li et al., 2008].  
 
 
Fig. 2. Schematic representation of PI3K/Akt and MAPK/ERK pathways. The G protein-coupled 
receptor RAS activated by, for example, growth factors and receptor tyrosine kinases (RTK), changes 
from the inactive RAS-GDP to active GTP, being able to activate the class I phosphotidylinositol-3 
kinases (PI3K) and the protein RAF. RAF phosphorylates MEK1/2 and consequently activates ERK1/2 
pathway. The Class I PI3K, composed by the p110 catalytic and p85 regulatory subunits, leads to the 
conversion of the phosphoinositol 4,5-biphosphate (PIP2) to the phosphatidylinositol-3,4,5-triphosphate 
(PIP3), which could be reverted by the negative regulator PTEN (phosphatase and tensin homologue 
deleted on chromosome 10). The pleckstrin homology (PH) domain of Akt binds to PIP3 being 
activated by phosphorylations on T308 and S473 residued, and its phosphorylation by the protein 
serine/treonine kinase 3´-phosphoinositide-dependent kinase-1 (PDK-1) lead to the Akt activation. 
Then, Akt phosphorylates a number os substratcts, such as Bad, Forkhead box (FOXO), caspase-9, p53, 
p21, p27, mammalian target of rapamycin complex 1 (mTORC1) and glycogen synthase kinase-3 
(GSK-3), which are involved on various cellular functions, apoptosis, cell cycle regulation, cell growth 
and metabolism. The protein RAS could be inhibited by farnesyltransferase inhibitors and the PI3K 
pathway could be surpressed by several drugs such as, LY294002 and wortmannin. Adapted from 
[Manning and Cantley, 2007; Zhao and Vogt, 2008].  
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Mutations in the AKT gene are not common in humans, however, some studies 
have reported an up-regulation of Akt in about 50% of CRC carcinomas, demonstrating 
its essential role in CRC progression [Itoh et al., 2002; Roy et al., 2002; Khaleghpour et 
al., 2004]. More recently, Carpten et al. found an AKT 1 mutation in CRC in the PH 
domain of Akt [Carpten et al., 2007]. This mutation results in an Akt conformational 
change and its increased membrane association, which lead to a constitutive activation 
of Akt. Alterations in PTEN tumor suppressor function by loss or reduction of protein 
expression has also been demonstrated to be frequent in sporadic CRC tumors [Goel et 
al., 2004; Nassif et al., 2004]. A deficient PTEN expression was associated with a 
predictor of local recurrence in CRC patients [Colakoglu et al., 2008].  
Overall, alterations in components of the PI3K pathway have been demonstrated 
to occur with high frequency in CRC tumors contributing for its progression and 
consequently with impact on therapy resistance. Thus, this pathway became an 
attractive target for the development of novel anticancer agents to treat CRC.  
 
2.3. MAP Kinase Pathways  
 
The mitogen-activated protein kinases (MAPKs) are a large family of serine-
threonine kinases that are often altered in human cancer [McCubrey et al., 2006]. There 
are three major subfamilies of MAPK related to cancer: the extracellular-signal-
regulated kinase (ERK)1/2, the c-Jun N-terminal kinase (JNK)1/2/3 and the p38 MAP 
kinase (p38) α/β/γ/δ.  
The MAPK activity is regulated through a cascade of activations, in which 
MAPKs are phosphorylated by the MAPK kinase (MAPKK, MKK or MEK), which 
themselves are phosphorylated by MAPKK kinase (MAPKKK or MEKK). These 
MAPKKK are each capable to regulate multiple MAPKKs that lead to the activation of 
different families of MAPK, resulting in the activation of ERK1/2, p38 or JNK [Cuevas 
et al., 2007]. These pathways are regulated by diverse extracellular and intracellular 
stimuli, including growth factors, cytokines, hormones and various cellular stresses. In 
turn, MAPK proteins phosphorylate a number of substrates involved in several cellular 
events, such as cell proliferation, survival, apoptosis, cell migration, differentiation and 
inflammatory response [McCubrey et al., 2006; Cuevas et al., 2007].       
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2.3.1. RAF/ERK Pathway 
MAPK/RAF/ERK is an important pathway involved in cell proliferation, 
apoptosis and cell cycle progression being activated primarily by mitogenic stimuli, 
such as growth factors [McCubrey et al., 2006].  
The mammalian Raf protein is a serine/threonine kinase present in three forms, 
A-Raf, B-Raf and C-Raf. These proteins recruited to the membrane bind to Ras and are 
subjected to phosphorylations/dephosphorylations on different domains and to 
dissociation with the Raf kinase inhibitory protein (RKIP) promoting Raf activation 
[McCubrey et al., 2006]. When activated, the protein Raf, a MAPKKK, can 
phosphorylate two MAPKK proteins, MEK1 and MEK2, which consequently activates 
the MAP kinases ERK1 and ERK2 (Fig. 3). [McCubrey et al., 2006]. Subsequently, 
ERK phosphorylates important cytoplasmic and nuclear targets [Cuevas et al., 2007].  
In the cytosol, ERK can activate NF-κB by phosphorylating and activating the 
inhibitor κB kinase, as well as, phosphorylate caspase 9 on residue Thr125 leading to its 
inactivation. In the nucleus, ERK1/2 promotes the phosphorylation of many 
transcription factors, including c-Jun, c-Myc and c-Ets-1 that are required for activator 
protein 1 (AP-1) expression [McCubrey et al., 2006].  
 
2.3.2. JNK and p38 Pathways 
The JNK and p38 MAP Kinases, also called stress-activated protein kinases 
(SAPK), are activated by environmental and genotoxic stresses and they regulate 
apoptosis, survival and inflammation. The effects of these kinases, that have been 
shown to be cell type-specific and dependent on intensity and duration of the stimuli, 
function either as tumor suppressors or oncoproteins [Wagner and Nebreda, 2009].  
The JNK protein kinase is encoded by three genes, MAPK8, MAPK9 and 
MAPK10, which encodes JNK1, JNK2 and JNK3, respectively, and they are 
alternatively spliced to create at least 10 isoforms. The proteins JNK1 and JNK2 are 
believed to be expressed in almost every cell and tissue type, whereas the JNK3 protein 
is mainly found in neuronal tissues and in the heart. JNK are mainly activated by the 
upstream MAPKK proteins, MEK4 and/or MEK7, that in turn activates a number of 
proteins (Fig. 3) [Weston and Davis, 2007; Wagner and Nebreda, 2009].  
The three JNKs have been shown to be involved in stimulating apoptotic 
signaling through different mechanisms. JNK can directly modulate the activities of 
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mitochondrial pro- and antiapoptotic proteins through  phosphorylation of several 
members of the Bcl-2 family, such as Bcl-2, BAD, BIM, as well as, stimulating the 
release of cytocrome c [Dhanasekaran and Reddy, 2008]. Activated JNK cal also 
translocate to the nucleus where it activates a number of transcription factors, such as c-
Jun, AP-1 and p53, increasing the expression of pro-apoptotic genes [Dhanasekaran and 
Reddy, 2008]. JNK have also been shown to be involved in inflammation process since 
it can be activated by TNF-α, a proinflammatory cytokine [Wagner and Nebreda, 2009].  
The p38 MAP Kinases are encoded by four genes, MAPK14, MAPK11, 
MAPK12 and MAPK13, which encode p38α, p38β, p38γ, p38δ, respectively, and are 
mainly activated by MEK3, MEK6 and in some cases by MEK4 (Fig. 3). The p38α is 
highly abundant in most of cell types being the best known p38 MAPK, whereas p38β 
seems to be expressed at very low levels and p38γ and p38δ expressions have more 
restricted pattern of expression [Wagner and Nebreda, 2009].  
It has been shown that p38 MAPK activates a wide range of subtracts, such as 
transcription factors, protein kinases, cytosolic and nuclear proteins [Coulthard et al., 
2009]. The p38 plays an important role in inflammation by modulating the transcription 
factor NF-κB and regulating the induction of the pro-inflammatory mediator 
cyclooxygenase 2 (COX-2) and the production of many cytokines, such as TNFα and 
interleukins [Wagner and Nebreda, 2009]. In addition, p38 is also envolved in the 
negative regulation of cell cycle progression, as well as, in the induction of apoptosis 
and modulation of cell migration and differentiation [Coulthard et al., 2009; Wagner 
and Nebreda, 2009]. 
 
Since JNK and p38 MAPK pathways can be activated by the same stimulus and 
share several upstream regulators, they may cooperate to synergistically activate the 
same subtracts. Nevertheless, there are evidences indicating that the two stress-activated 
pathways could also have opposite effects or that p38 negatively regulate JNK activity 
in several contexts [Wagner and Nebreda, 2009]. 
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Fig. 3.  Schematic representation of MAPK signaling pathways (ERK, p38 and JNK). RAS activates 
RAF that in turns phosphorylates MEK1/2 and consequently activates ERK1/2 pathway. ERK pathway 
is involved in various biological responses, such as cell proliferation, survival, cell migration and 
differentiations and it could be inhibited by the grugs BAY 43-9006 and PD98059. The JNK and p38 
pathways are stimulated by various stresses that lead to effects on survival, apoptosis and inflammatory 
response. The p38 isoforms are mainly activated by MEK3 and MEK6 and could be inhibeted by 
SB203580, while the JNK 1/2/3 are mainly activated by MEK4 and MEK7 and could be inhibited by 
SP600125. Adapted from [Malemud, 2007]. 
 
2.3.3. Activation of MAP Kinases in CRC 
Activation of MAPK/ERK pathway has been demonstrated to be involved in 
CRC progression. Mutations upstream of this pathway are frequent in CRC, including 
mutations in KRAS and BRAF genes, participating in the upregulation of ERK signaling 
[Fang and Richardson, 2005]. About 5-10% of sporadic CRC tumors have mutations in 
BRAF [Oliveira et al., 2007; Barault et al., 2008] and these mutation have been 
correlated with cell growth and inhibition of apoptosis [Ikehara et al., 2005]. Moreover, 
MEK has also shown to be frequently phosphorylated in CRC tumors, which 
constitutivly activates the MAPK/ERK pathway [Lee et al., 2004].  
Mutations in JNK and p38 are not frequent in CRC, instead, alterations in the 
expression of these proteins and/or mutations in components of JNK and p38 pathways 
have been demonstrated. Loss-of-function mutation in the MKK4 gene, which activates 
both JNKs and p38α, were found in ~5% of CRC tumors [Wagner and Nebreda, 2009]. 
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A recent study, however, found a significant downregulation of MAPK activity in some 
CRC samples, suggesting that CRC tumors must be carefully evaluated for MAP 
kinases inhibitor therapy [Gulmann et al., 2009].  
The importance of SAPK in CRC has been demonstrated in several studies. It 
was shown that mutated KRAS activates p38γ, by inducing its expression, this being 
essential to maintain the Ras mutated phenotype and promoting CRC carcinogenesis 
[Tang et al., 2005]. Moreover, a cross talk between JNK and Wnt signaling was also 
found where an activation of JNK increases the expression of Wnt target genes, 
contributing to accelerate CRC tumorogenesis [Sancho et al., 2009].      
 
2.4. Apoptosis 
 
Apoptosis is a mechanisms of cell death in which several molecules are 
activated or inactivated working as a team for a controlled cellular self-destruction 
called programmed cell death. Apoptosis is essential to maintain homeostasis by 
removing unwanted, injured and infected cells and its dysfunction or deregulation is 
implicated in cancer progression [Degterev and Yuan, 2008]. During apoptosis, typical 
cellular morphologic changes occur, including nuclear chromatin condensation and 
fragmentation, membrane blebbing, cell shrinkage, loss of contact to its neighboring 
cells and the formation of apoptotic bodies [de Bruin and Medema, 2008; Degterev and 
Yuan, 2008].  
On the other hand, necrosis, another form of cell death, differently from 
apoptosis, is an uncontrolled form of death due to a violent environmental perturbation. 
In this case, an early disruption of the cell membrane occurs accompanied by organelle 
swelling, mitochondrial dysfunction and a collapse of cell structure, which result in the 
release of the cellular contents to the milieu causing damage to surrounding cells and a 
strong inflammatory response [de Bruin and Medema, 2008; Degterev and Yuan, 2008]. 
 
2.4.1. Classical Apoptotic Pathways 
The classical apoptotic pathways can be initiated via different stimuli, at the 
plasma membrane by death receptors (extrinsic pathway) or at the mitochondria 
(intrinsic pathway), and involve the activation of proteolytic enzymes called cysteine 
aspartic acid specific proteases (caspases) [Degterev and Yuan, 2008].  
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Caspases are synthesized as inactive proenzymes, being activated by 
autoproteolytic cleavage or being cleaved by other caspases at specific aspartic acid 
residues. They are subdivided, depending on their activity and subcellular localization, 
into proinflammatory and proapoptotic caspases. The latter are grouped as initiator 
(caspases 8, 9 and 10) or activator (caspases 3, 6 and 7) caspases. At the end, caspases 
modulate the activity of a variety of substrates, including the poly-(ADP-ribose) 
polymerase (PARP), a nuclear enzyme involved in initiating DNA repair, that losses its 
repair activity when cleaved by caspases [Degterev and Yuan, 2008].   
 
2.4.1.1. The Mitochondrial (intrinsic) Pathway  
The intrinsic pathway of apoptosis is activated by a variety of stress stimuli, 
including DNA damage, heat and ultraviolet radiation through p53 tumor suppressor 
protein. This activation leads to the insertion of the pro-apoptotic B-cell lymphoma 
protein-2 (Bcl-2) family proteins Bax and Bak into the outer mitochondrial membrane 
(OMM) causing mitochondria damage and the release of cytochrome c to the cytosol. 
The activity of Bax and Bak is modulated by the anti-apoptotic Bcl-2 family members, 
such as Bcl-2, Bcl-Xl and Mcl-1 that prevent cytochrome c release, whereas the pro-
apoptotic BH3 members of the Bcl-2 family, such as Bad, Bik, Bim, Bid, Puma and 
Noxa restored Bax and Bak activation. It is the ratio between anti-apoptotic and pro-
apoptotic members of Bcl-2 family that tightly regulate the permeability of the OMM 
and the release of cytochrome c. Subsequently, cytochrome c interacts with the 
apoptotic protease activating factor-1 (Apaf-1) and recruits the initiator pro-caspase-9, 
in the presence of ATP, to promote the formation of the apoptosome. This interaction 
leads to the cleavage and activation of caspase 9 that mediates the activation of the 
effector caspases 3, 6 and 7 to execute apoptosis (Fig. 4) [Ghavami et al., 2009; Pradelli 
et al., 2010].  
In addition to cytochrome c, mitochondria can also release a large number of 
other pro-apoptotic molecules, including second mitochondrial-derived activator of 
caspase/direct IAP-binding protein with low pI (Smac/Diablo), Omi/high temperature 
requirement protein A (HtrA2), endonuclease G (EndoG) and apoptosis-inducing factor 
(AIF) (Fig. 4). Smac/Diablo and Omi/HtrA2 promote caspase activation through 
inhibition of the inhibitor of apoptosis proteins (IAPs), while AIF and EndoG are able to 
cause DNA damage without caspase involvement [Ghavami et al., 2009; Pradelli et al., 
2010]. 
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The nuclear factor-κB (NF-κB) is a transcription factor that has been implicated 
in apoptosis by promoting and regulating the transcription of important anti-apoptotic 
genes such as the Bcl-2 family member Bcl-Xl [Naugler and Karin, 2008]. 
 
 
Fig. 4. The molecular mechanisms of apoptosis. Apoptosis pathways can be initiated at the plasma 
membrane by death receptors (extrinsic pathway) or at the mitochondria (intrinsic pathway). Stimulation 
of death receptors, such as FASR or TRAIL-R, results in the formation of death inducing signaling 
complex and the recruitment of the initiators caspases 8 or 10. Caspase 8 cleaves and activates the 
effector caspases 3, 6 and 7 to induce apoptosis, as well as, cleaves the pro-apoptotic protein Bid, 
generating the truncated form (tBid) that cause mitochondria damage and release of cytochrome c. The 
mitochondrial membrane permeabilisation is regulated by the pro-apoptotic B-cell lymphoma protein-2 
(Bcl-2) family proteins Bax and Bak and the pro-apoptotic BH3 members of the Bcl-2 family, such as 
Bad, Bik, Bim, Bid, Puma and Noxa, which cause the release of cytochrome c, and the anti-apoptotic Bcl-
2 family members, such as Bcl-2, Bcl-Xl and Mcl-1 that prevent this occurrence. The protein p53 can 
interact with members of the Bcl-2 family to induce the release of cytochrome c. Following, in the 
cytosol, cytochrome c interacts with the apoptotic protease activating factor-1 (Apaf-1) and recruits the 
initiator caspase-9, in the presence of ATP, to promote the formation of the apoptosome, that in turns 
activate the effectors caspases 3, 6 and 7 to execute apoptosis. The transmembrane channels across the 
mitochondrial outer membrane can also release other proteins, such as second mitochondrial-derived 
activator of caspase/direct IAP-binding protein with low pI (Smac/DIABLO), Omi/high temperature 
requirement protein A (HtrA2), endonuclease G (EndoG) and apoptosis-inducing factor (AIF) that 
translocate to the nucleus to induce apoptosis without caspase involvement, or they could also activate 
caspase pathway by inhibiting the inhibitor of apoptosis proteins (IAPs). Adapted from [Ghavami et al., 
2009; Qiao and Wong, 2009]. 
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2.4.1.2. The Death Receptor (extrinsic) Pathway  
In the extrinsic pathway, apoptosis is mediated by the activation of the 
transmembrane death receptors located in the cell membrane and they are activated by 
extracellular ligands. The binding of TNF family members, such as Fas-L or TRAIL-L, 
to their receptors causes the formation of death inducing signaling complexes and the 
recruitment, cleavage and activation of the initiator caspases 8 or 10. These caspases, in 
turn activate a cascade of other caspases that leads to the activation of the effector 
caspases 3, 6 and 7 to execute cell death. Thus, both classical apoptotic pathways 
(intrinsic and extrinsic pathway) converge in the activation of the same activator 
caspases. In addition, these apoptotic pathways could also crosstalk at the level of the 
mitochondria, since caspase 8 can also cleave and activate the pro-apoptotic protein Bid, 
generating the active or truncated form (tBid) that in turn cause mitochondria damage 
and release of cytochrome c (Fig. 4) [Ghavami et al., 2009; Pradelli et al., 2010]. 
 
 
2.4.2. Others Relevant Pathways to Apoptosis 
 
2.4.2.1. Lysosomal Cell Death Pathway 
 Lysosomes are the main compartment for intracellular degradation and 
subsequent recycling of cellular constituents. They have a number of lysosomal 
hydrolases, such as cathepsin proteases, capable of digesting all major cellular 
macromolecules, being implicated in the control of cell death at several levels [Boya 
and Kroemer, 2008; Kirkegaard and Jaattela, 2009]. Lysosomal cell death pathway can 
activate apoptotic effectors, such as mitochondria and/or caspases, triggering cells to 
death by classical apoptosis. An induction of lysosomal membrane permeabilization 
(LMP) causes the release of cathepsins to the cytosol, which can activate pro-apoptotic 
Bcl-2 proteins, such as Bid, Bax and Bak, leading to mitochondrial membrane 
permeabilization and the release of cytochrome c, and subsequently, to the induction of 
apoptosis [Boya and Kroemer, 2008; Kirkegaard and Jaattela, 2009]. However, a 
massive induction of LMP results in an uncontrolled death by necrosis [Boya and 
Kroemer, 2008]. In addition, lysosomes are also able to break down the extracellular 
matrix, stimulating angiogenesis and migration, downregulate signaling from receptor 
tyrosine kinases, as well as, participate in the final step of the autophagic process 
[Kirkegaard and Jaattela, 2009].  
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A wide range of apoptotic stimuli can induce the LMP [Boya and Kroemer, 
2008; Kirkegaard and Jaattela, 2009]. The TNF death receptor family in the presence of 
the death domain-containing receptor interacting protein-1 (RIP-1) can trigger LMP and 
cell death. There are also evidences that p53 can induce LMP upstream of mitochondrial 
pathway. Oxidative stress has also been shown to induce LMP through generation of 
reactive oxygen species (ROS), which cause oxidation of lysosomal membrane lipids, 
resulting in the destabilization of the lysosomal membrane and leading to the release of 
lysosomal contents. Moreover, PI3K pathway has also been reported to function as an 
LMP inhibitor by regulating the lysossomal compartment through control of maturation, 
size, activity and stabilization of lysosomes [Boya and Kroemer, 2008; Kirkegaard and 
Jaattela, 2009].  
The induction of LMP has recently emerged as an effective way to kill cells, 
especially cancer cells resistant to apoptosis, and a number of compounds that induce 
lysosomal cell death are being discovered [Groth-Pedersen and Jaattela, 2010].  
 
2.4.2.2. PI3K and MAPK Pathways 
PI3K and MAPK pathways may also be implicated in the induction of apoptosis, 
since they are able to regulate the Bcl-2 family proteins and the protein p53. The protein 
Akt is able to phosphorylate BAX by inhibiting its conformational changes, which 
avoid its translocation to the mitochondria and cytochrome c release. Akt also 
phosphorylates Mdm2 by enhancing its nuclear localization that, in consequence, 
negatively regulates p53 expression [Manning and Cantley, 2007; Stiles, 2009].  
It has also been demonstrated that ERK1/2 is able to phosphorylate pro-
apoptotic Bcl-2 proteins, such as Bad and Bim, promoting their degradation and, thus, 
preventing cytochrome release [Balmanno and Cook, 2009]. In addition, JNK and p38 
kinases were also shown to regulate the expression of Bcl-2 proteins, such as Bax and 
BAD, modulating the membrane mitochondrial permeabilization [Wagner and Nebreda, 
2009]. 
 
2.4.2.3. Role of p53 in Apoptosis  
The tumor suppressor p53 mediates critical functions within cells, including 
inhibition of proliferation by induction of cell cycle arrest and induction of apoptotic 
cell death [Chari et al., 2009]. The p53 protein has a very short life and it is usually 
present at low levels within normal cells, although it can be transiently stabilized and 
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activated in response to several stresses, including hypoxia, heat shock and DNA 
damage agents. The stability of p53 is regulated by the E3 ubiquitin ligase and by the 
protein MDM2 that mediate the ubiquitination of p53 and allow its degradation by the 
proteosome, maintaining low the levels of p53. Moreover, MDM2, which can 
ubiquitinate itself and regulate its own stability, is a transcription target of p53 in a 
mechanism where p53 controls the expression of its own regulator [Chari et al., 2009].  
Upon p53 activation, this protein translocates to the nucleus where it binds to 
specific DNA sequence elements within the regulatory regions of target gene promoters 
regulating the transcription of several genes, such as Apaf-1, BAX, PUMA, NOXA, 
cathepsin D, TNF family members and some caspases [Chari et al., 2009]. In addition 
to its transcriptional regulator activity, p53 can also directly activate components of the 
apoptotic machinery through interaction with the members of the anti-apoptotic and 
pro-apoptotic Bcl-2 family proteins to induce the mitochondrial pathway [Vaseva and 
Moll, 2009] .  
 
2.4.3. Deregulation of Apoptosis in CRC 
Deregulation of apoptosis has been linked to cancer development and resistance 
to CRC treatment [Qiao and Wong, 2009]. In CRC, alterations in caspase activation, the 
central modulators of apoptosis, have been identified, including mutations in caspase 3, 
caspase 7 and caspase 8  [Hector and Prehn, 2009], as well as, mutations in caspase 4 
and caspase 5 [Ghavami et al., 2009]. Alterations in the Bcl-2 family members, such as 
high expressions of Bcl-2 and Bcl-Xl anti-apoptotic proteins and decreased expressions 
of the pro-apoptotic proteins Bax and Bak have also been demonstrated in CRC [Hector 
and Prehn, 2009]. In fact, overexpression of Bcl-2 protein was related with negative 
prognostic factor in CRC [Qiao and Wong, 2009].  
The death receptors Fas and TRAIL have been shown to be constitutively 
expressed in CRC [Qiao and Wong, 2009]. Moreover, mutations in the tumor 
suppressor gene TP53 have been reported in around 45% of CRC cases and clinical 
evidences suggest that p53 mutations associate with lower survival for patients treated 
by chemotherapy [Iacopetta, 2003]. 
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2.5. Autophagy 
 
Autophagy, which means self-eating in Greek, is responsible to the elimination 
of damaged structures and cell organelles, as well as, pathogens and long-lived proteins, 
contributing to the homeostatic function of the cell under normal conditions. Under 
stress, such as starvation, growth factors deprivation and/or hypoxia, autophagy is 
induced to provide essential nutrients and remove damaged constituents in order to 
promote cell survival. Autophagy is therefore a mechanism of survival that maintains 
the metabolic activity of the cell through lysosomal recycling of intracellular nutrients 
[Mathew et al., 2007; Brech et al., 2009; Morselli et al., 2009].  
In cancer cells, autophagy has been suggested to have a dual role. In one way, 
autophagy can stimulate oncogenesis by promoting cancer cells survival allowing their 
adaptation to adverse metabolic conditions. On the other hand, autophagy can also 
function as a tumor suppressor by inducing cellular self-degradation that leads to 
autophagic cell death [Brech et al., 2009; Morselli et al., 2009]. 
 
2.5.1. The Autophagic Process 
Autophagy is characterized by the capacity of cells to sequester and engulf 
cellular proteins, organelles and cytoplasm in an isolate membrane or phagophore that 
closure to form a double membrane structure named autophagosome. These 
autophagosomes undergo a maturation process fusing with lysosomes to form the 
autolysosomes, where the sequestered contents are then degraded by lysosomal 
hydrolyses and the amino acids and sugars recycled into the cytosol. The formation of 
the autophagosome is controlled by autophagy-related (atg) proteins that participate in 
the sequestration of intracellular constituents and in the elongation of the phagophore 
membrane to form the autophagosome. The fusion between autophagosomes and 
lysosomes is required for the completion of the autophagic process [Mathew et al., 
2007; Mizushima, 2007; Brech et al., 2009].  
The mechanism that leads to the formation of autophagosomes was first 
identified in yeast, where it was discovered over more than 30 Atg genes. Many Atg 
homologs have subsequently been identified and characterized in higher eukaryotes, 
suggesting that autophagy is a highly conserved pathway through evolution [He and 
Klionsky, 2009]. The first identified regulator of autophagy was Beclin 1 that functions 
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as a haploinsufficient tumors suppressor. Beclin 1 is the human homologue of 
Atg6/Vps30, which is a key regulator of autophagy in yeast. Beclin 1 was also found to 
be crucial for autophagy induction in mammalian cells, since it is involved in 
autophagosome formation by recruiting proteins from the cytosol, which will be used 
for autophagic degradation, or in supplying the autophagic pathway with membrane 
components. The expression level of Beclin 1 is therefore usually increased during 
autophagy [Brech et al., 2009]. Beclin-1 is part of the class III PI3K complex, where it 
allows the recruitment of others essential Atg proteins to the membrane and produces 
the lipid PI3 required for the formation of the phagophore. Moreover, Beclin 1 also 
contains a BH3 domain that mediates its interaction with Bcl-2 and other anti-apoptotic 
proteins inhibiting its function, whereas its dissociation is required for autophagic 
induction [Mathew et al., 2007; Brech et al., 2009; He and Klionsky, 2009]. 
The microtubule-associated protein 1 light chain 3 (MAP1LC3) is an ubiquitin-
like protein Atg8 that is cleaved during the autophagic process producing an active 
cytosolic precursor form, LC3-I, which subsequently conjugates with a phospholipid via 
a ubiquitylation-like system to form the active LC3-II. LC3-II then becomes a 
component of the inner membrane of the autophagosome and, following fusion with 
lysosomes, LC3-II is rapidly degraded by lysosomal enzymes [Mathew et al., 2007; He 
and Klionsky, 2009; Mizushima et al., 2010]. The relative amounts of LC3-II reflect the 
abundance of autophagosomes, which can occur in both induction and inhibition of the 
autophagic process. The level of mammalian polyubiquitin-binding protein 
p62/sequestosome 1 (SQSTM1), also called p62, which is associated with ubiquitinated 
proteins and interact with LC3-II incorporating into autophagolysosomes, has been 
demonstrated to be a reflex of autophagic fluxes [Pankiv et al., 2007; Mizushima et al., 
2010].  
 
2.5.2. Some Modulators of Autophagy 
Autophagy is a multistep process that could be altered in cancer cells at the 
levels of induction, regulation and lysosomal degradation [Hoyer-Hansen and Jaattela, 
2008]. Several cancer-associated alterations in genes that regulate various signaling 
cascades such as PI3K, MAPK and p53 pathways, have been implicated in up- or down-
regulation of autophagy [Brech et al., 2009; Corcelle et al., 2009; Maiuri et al., 2009; 
Morselli et al., 2009]. 
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2.5.2.1. PI3K Pathway 
The best known regulator of autophagy in human cells is the mammalian target 
of rapamycin (mTOR) kinase, a downstream component of the class I PI3K pathway, 
which downregulates autophagy when activated in response to growth factor signaling, 
nutritional status and energy level [Brech et al., 2009; Morselli et al., 2009]. Activated 
Akt promotes phosphorylation of the protein encoded by the tuberous sclerosis complex 
(TSC) 2 tumor suppressor gene, blocking the interaction between TSC2 and TSC1 and 
preventing the formation of the TSC1/TSC2 complex. The inhibition of this complex 
prevents the stimulation of the GTPase activity of Rheb, causing the presence of the 
active GTP-bound form that directly binds and activates the mammalian target of 
rapamycin complex 1 (mTORC1). Consequently, mTORC1 takes part in multiple 
signaling cascades that control cell growth, protein synthesis and promote mRNA 
translation through phosphorylation of its downstream targets, the kinase p70S6K1 and 
the elongation factor 4E-BP1. In addition, mTORC1 is also involved in the autophagic 
process by directly interacting with atg proteins (Fig. 5). The mTORC1 interacts with 
the autophagic regulator kinase ULK1 and the protein atg13 leading to the inactivation 
of the complex Atg13-ULK1 causing suppression of autophagy [Brech et al., 2009; 
Corcelle et al., 2009; He and Klionsky, 2009]. 
Nevertheless, studies have demonstrated that distinct classes of PI3K control 
autophagy in opposite directions. While products of class I PI3K have showed to inhibit 
autophagy, class III PI3K has been demonstrated to promote autophagy. The class III 
PI3K is part of a complex of proteins where Beclin-1, UVRAG and Bif-1 belong, which 
are essential to the formation of autophagosome [Brech et al., 2009; Corcelle et al., 
2009; Mizushima et al., 2010]. 
 
2.5.2.2. MAPK Pathways 
Similar to Akt, ERK1/2 has also been reported to regulate the formation of 
autolysosomes by inhibiting the complex TSC1/TSC2 through TSC2 phosphorylation 
[Ma et al., 2005] and consequently inducing the suppression of autophagy. Moreover, it 
was also demonstrated that ERK1/2 regulates the maturation of autophagosomes by 
affecting the lysosomal membrane protein LAMP-2, promoting the formation of large 
defective autolysosomes and thus blocking autophagy (Fig. 5) [Corcelle et al., 2007; 
Corcelle et al., 2009].  
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It has also been demonstrated that p38 pathway playa a role in autophagy by 
inhibiting the formation of autolysosomes, functioning as a negative regulator of 
autophagy [Corcelle et al., 2007; Webber and Tooze, 2010]. Thus, ERK and p38 
kinases can control autophagy, however, possesing opposing effects (Fig. 5) [Corcelle 
et al., 2007; Corcelle et al., 2009].   
Recent studies have also demonstrated the role of JNK pathway in autophagy 
induction via different forms. Activation of JNK can upregulate Beclin-1, since JNK 
phosphorylates Bcl-2 in three residues resulting in the dissociation of the complex Bcl-
2/Beclin 1 and the release of Beclin 1 (Fig. 5) [He and Klionsky, 2009]. In addition, the 
JNK target, c-Jun transcription factor, has also been shown to upregulate the 
transcription of autophagic genes, such as Beclin-1, and thereby increasing autophagy 
[He and Klionsky, 2009; Li et al., 2009]. Recently, it was also found that JNK can 
induce the lysosomal protein damage-regulated autophagy modulator (DRAM) that play 
a key role in controlling autophagic cell death [Lorin et al., 2010]. 
 
2.5.2.3. p53 Protein 
Recent evidences indicate that p53 regulates autophagy exerting, however, 
contradictory effects dependent on its localization in the cell [Tasdemir et al., 2008]. In 
the cytoplasm, p53 despite inducing mitochondrial membrane permeabilization and 
apoptosis, it can inhibit autophagy. In the nucleus, p53 acts as an inducer of apoptosis 
and an autophagy-promoting transcription factor [Tasdemir et al., 2008]. Moreover, it 
was also demonstrated that some variants of p53 mutations that localize the protein to 
the cytoplasm repress autophagy, while p53 mutants with nuclear distribution failed to 
inhibit autophagy [Morselli et al., 2008].  
In the cytoplasm, basal levels of p53 mediate an inhibition of autophagy directly 
at the endoplasmatic reticulum. However, an activation of p53 by cellular stresses and 
oncogenic signals have been reported to induce autophagy [Vousden and Ryan, 2009]. 
It has been demonstrated that p53 activates the AMP-activated kinase (AMPK), which 
is known to phosphorylate TSC2 or directly inhibit mTORC1, inducing autophagy (Fig. 
5) [Feng et al., 2005b; Corcelle et al., 2009]. Other p53 target genes such as Bax and 
PUMA, besides contributing to the induction of apotosis, have also recently been shown 
to be positive regulators of autophagy [Yee et al., 2009].  
In the nucleus, p53 can promote autophagy via transcriptional upregulation of 
the gene coding for the lysosomal protein DRAM (damage-regulated autophagy 
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modulator), a p53 target gene, which also contributes to damage-induced cell death 
[Crighton et al., 2006].  
 
 
 
 
 
Fig. 5. Schematic model of the autophagic process and their regulation by the major signaling pathways 
in mammals. Autophagy begins with an isolate membrane that sequesters and engulfed cellular proteins, 
organelles and cytoplasm to form a double membrane structure named autophagosomes, during the 
initiation phase. These autophagosomes fuse with lysosomes to undergo a maturation process forming the 
autolysosomes. Then sequestered contents are degraded by lysosomal hydrolyses and the amino acids and 
sugars recycled into the cytosol. The autophagic process is regulated by several important signaling 
pathways. The activation of the class I PI3K inhibits the formation of the complex tuberous sclerosis 
complex 1/2 (TSC1/TSC2) that in turn activates Rheb. This protein induces the mammalian target of 
rapamycin complex 1 (mTORC1) that is involved in protein synthesis and mRNA translation through 
phosphorylation of its downstream targets, the kinase p70S6K1 and the elongation factor 4E-BP1. In 
addition, mTORC1 also inhibits the autophagy-related proteins (atg) causing the suppression of 
autophagy. The mTORC1 can be inhibited by various drugs, such as rapamycin and its analogues, CCI-
779 and RAD-001. Contrarily, an activation of the class III PI3K promotes autophagy by inducing the atg 
proteins. This is negatively regulated through Beclin-1 interaction with Bcl-2, which could be disrupted 
by the JNK pathway to induce autophagy. The activation of the AMP-activated kinase (AMPK) by p53 
can also induce the formation of the complex TSC1/TSC2 promoting autophagy. Additionally, ERK and 
p38 pathways have been showed opposite effects in the control of autophagy during the maturation step. 
Adapted from [Brech et al., 2009; Corcelle et al., 2009; He and Klionsky, 2009]. 
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2.5.3. Impact of autophagy in CRC 
The autophagic process is regulated by important signaling pathways that are 
frequently altered in CRC. Activating mutations in class I PI3K, Akt and Ras, or 
inactivating mutation in PTEN, have been shown to decrease autophagy through 
activation of mTORC1 [Maiuri et al., 2009; Morselli et al., 2009].  
In advanced CRC cases, a high activity of mTOR has been observed, which is 
associated with increased in vitro and in vivo cell growth, demonstrating the importance 
of mTOR pathway in CRC progression [Zhang et al., 2009a] and the possible role of 
autophagy in CRC. In addition, an inhibition of p38α in CRC cell lines showed to cause 
autophagic cell death, suggesting an involvement of the p38 pathway in autophagy in 
CRC [Comes et al., 2007].  
 
3. THERAPY IN CRC  
 
3.1. Some Compounds Modulators of Cancer Cell Signaling  
 
3.1.1. Inhibitors of KRAS  
KRAS is an important therapeutic target due to the fact that activates important 
signaling pathways. Farnesyltransferase inhibitors have been developed to inhibit RAS 
(Fig. 2), however, pre-clinical results were disappointing because Ras could bypass 
farnesyltransferase blockage through the other related enzyme, the 
geranylgeranyltransferase [Schubbert et al., 2007; Sousa et al., 2008].  
 
3.1.2. Inhibitors of PI3K Pathway 
The strategy to target PI3K pathway consists in the use of inhibitors for 
individual components of this pathway, such as PI3K, Akt, PDK-1 and mTOR, [Cheng 
et al., 2005; Granville et al., 2006]. A number of drugs have been developed and some 
of them are in preclinical evaluation or in clinical trial showing synergistic effect with 
different types of therapies and the ability to overcome therapy resistances [Hennessy et 
al., 2005; LoPiccolo et al., 2008]. However, it should be kept in mind that targeting 
PI3K pathway is likely to be most effective in cases where tumors bear activation of this 
pathway, suggesting that a proper selection of patients is important [LoPiccolo et al., 
2008]. Interestingly, it was found recently that PDK-1 is not only important in 
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regulating components downstream of PI3K signaling but also in phosphorylating 
components downstream of MAPK pathway, showing the importance of PDK-1 as a 
target in CRC therapy regulating two different pathways [Lu et al., 2010].  
The best known pharmacological inhibitors of PI3K are wortmannin and 
LY294002 (Fig. 2), which target the p110 catalytic subunit of class I PI3K with 
antitumor activity in vitro and in vivo [Hennessy et al., 2005; LoPiccolo et al., 2008]. 
Wortmannin, a natural fungal metabolite, although it was shown its ability to inhibit 
PI3K at low concentrations, was found to be soluble in organic solvents and insoluble in 
water, which may limit its use in clinical trials [Cheng et al., 2005]. LY294002 is a 
derivate of the flavonoid quercetin, which is effective in inhibiting PI3K, requiring, 
however, a higher concentration when compared with wortmannin. LY294002 has low 
solubility in water and, it not only inhibits the ATP binding site of PI3K, but also other 
downstream components of the PI3K pathway [Cheng et al., 2005; Granville et al., 
2006].  
Despite the poor solubility and high toxicity of wortmannin and LY294002, 
these commercially available PI3K inhibitors in combination with chemotherapeutic 
agents have been shown effective results, demonstrating the advantage of their use in 
combination therapies. These compounds are not clinically useful but could provide 
powerful tools to study the cellular effects of PI3K inhibition and to develop other PI3K 
inhibitors [LoPiccolo et al., 2008]. Derivates of LY294002 and wortmannin are being 
developed to bypass their undesirable properties [Hennessy et al., 2005; Granville et al., 
2006]. 
 
3.1.3. Inhibitors of BRAF 
A number of RAF inhibitors have been developed and some of them have 
entered clinical trials [Halilovic and Solit, 2008]. One of the first RAF inhibitors in 
clinical trial was sorafenib (BAY 43-9006), however this drug showed to inhibit both wt 
and mutant BRAF (V600E), with also effects on another subset of RTK (Fig. 3). A 
second generation of RAF inhibitors have been developed that have greater selectivity 
for mutant BRAF [Halilovic and Solit, 2008]. In fact, more recently, it was found that 
ATP-competitive RAF inhibitors block MAPK signaling pathway, decreasing tumor 
growth in mutant BRAF (V600E) tumors, but surprisingly, they activate RAF-MEK-
ERK signaling in mutant KRAS and wt BRAF tumors, enhancing tumor growth 
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[Hatzivassiliou et al., 2010; Poulikakos et al., 2010]. These findings suggest RAF 
inhibitors are only effective in tumors in which BRAF is mutated.  
 
3.1.4. Inhibitors of MAPK Pathways 
Several compounds have been found to inhibit the enzyme activity of MAP 
kinases [Malemud, 2007]. One of them, PD98059 (Fig. 3), showed to inhibit MEK1 and 
MEK2 and partially MEK5 with an impact on ERK signaling [McCubrey et al., 2006]. 
Second-generation MEK inhibitors have also been developed with better 
pharmacological properties, higher effect against MEK activity and longer duration of 
suppression, demonstrating good results in clinical trials [Fang and Richardson, 2005]. 
Alterations in PI3K pathway, such as mutations in PIK3CA gene, have been recently 
found to be a major mechanism of acquired resistance to MEK inhibitors, suggesting a 
combination therapy of PI3K and MEK inhibitors to increase sensitivity to MEK 
inhibition [Wee et al., 2009].  
Inhibitors of p38α and JNK have been developed to trigger death in cancer cells 
when combined with other chemotherapeutic drugs [Coulthard et al., 2009; Wagner and 
Nebreda, 2009]. SP600125 is a commonly used JNK inhibitor demonstrating, however, 
little specificity and selectivity for the different JNK isoforms [Wagner and Nebreda, 
2009]. SB203580 is an inhibitor of p38α/ß that acts through blockage of the ATP 
binding site [Coulthard et al., 2009] (Fig. 3). Although there are a number of p38 and 
JNK inhibitors in ongoing clinical trials, it is essential to take in consideration the type 
of tumor for JNK and p38 targeted therapy [Wagner and Nebreda, 2009].  
 
3.1.5. Potential Molecular Targets to Cell Death 
Most of the chemotherapeutic drugs induce cell death by apoptosis through 
receptor or mitochondrial pathways. Molecules involved in these pathways have been 
demonstrated to be good targets in the discovery of new anticancer drugs [Qiao and 
Wong, 2009; Tan et al., 2009]. The alteration of the balance between pro-apoptotic and 
anti-apoptotic Bcl-2 family proteins, the cell surface death receptors, such as Fas, 
TRAIL and TNF and inhibition of components of the PI3K and MAPK signaling have 
been shown to be good strategies to trigger apoptosis [Qiao and Wong, 2009; Tan et al., 
2009]. Currently, strategies to restore p53 function and/or to specifically target 
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regulators of p53, such as Mdm2, have appeared [Vaseva and Moll, 2009], with a 
number of novel compounds demonstrated to modulate p53 [Wang and Sun, 2010].  
Furthermore, lysosomes have also been increasingly recognized as a promise 
target for cancer treatment, by allowing cell death to occur even in cells with defects in 
the classical apoptotic pathways [Kirkegaard and Jaattela, 2009]. Various drugs have 
been identified that affect the integrity of the lysosome membranes by inducing LMP, 
which results in cathepsin-mediated cell death [Kroemer and Jaattela, 2005]. 
 
3.1.6. Inducers/Inhibitors of Autophagy 
The impact of autophagy on cancer cells seems to depend on tumor type, in its 
intrinsic properties and on the nature of the cytotoxic therapy that is combined with it 
[Brech et al., 2009]. Many compounds present in clinical have shown the ability to 
inhibit or induce autophagy with anticancer effects. Inhibitors of autophagy have been 
shown more likely to succeed when they are combined with other types of cytotoxic 
drugs that activate a protective autophagy. On the other hand, inducers of autophagy 
that trigger autophagic cell death in various cancer cells, may succeed when tumors 
have defects on the apoptotic machinery [Hoyer-Hansen and Jaattela, 2008].   
Rapamycin, produced naturally by the bacterium Streptomyces hygroscopicus, 
was the first identified compound to target mTOR, which possesses poor aqueous 
solubility and strong immunosuppressive properties. Rapamycin was found to inhibit 
mTOR with anti-proliferative effects against several cancer cell lines and to induce 
autophagy in vitro and in vivo. Various analogues of rapamycin, such as CCI-779 and 
RAD-001, have been developed and entered in clinical trials with promising results 
when combined with other chemotherapeutic drugs (Fig. 5) [LoPiccolo et al., 2008]. On 
the other hand, a number of different autophagic inhibitors were also developed. The 
drug 3-methyladenine is one example that showed to specifically inhibit autophagy 
through effects on class III PI3K [Tan et al., 2009]. 
 
3.2.  Clinical Chemotherapeutic Drugs  
 
In CRC, chemotherapeutic agents have been developed over time and they have 
showed different mechanisms of action. The genetic variability is an important factor 
that regulates the response and toxicity of a drug and the introduction of genetic tests to 
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individualize treatment will allow better response to these therapeutic agents [Bhushan 
et al., 2009]. Currently, drugs such as 5-Fluorouracil (5-FU), oxaliplatin, irinotecan, 
capecitabine, bevacizumab cetuximab and panitumumab, are used as clinical options 
and in most of the cases in combinations to increase CRC treatment efficacy [Bhushan 
et al., 2009; De Dosso et al., 2009; Segal and Saltz, 2009].   
 
3.2.1. 5-Fluorouracil (5-FU) 
The best known and most used chemotherapeutic agent in CRC treatment is 5-
FU that has been used in clinical since more than 40 years [Bhushan et al., 2009]. 5-FU 
is a nucleoside analog that incorporates its active metabolites, the fluorodeoxyuridine 
triphosphate (FdUTP) and fluorodine triphosphate (FUTP), into RNA and DNA leading 
to the disruption of their synthesis. In addition, 5-FU inhibits the enzyme thymidylate 
synthase (TS) that is essential in DNA synthesis and repair [Warusavitarne and 
Schnitzler, 2007; Bhushan et al., 2009]. Resistance to 5-FU appears in tumors with 
alterations in enzymes associated with 5-FU mechanisms of action, including high TS 
expression [Warusavitarne and Schnitzler, 2007; Bhushan et al., 2009]. Moreover, 5-FU 
is also able to induce apoptosis through intrinsic and extrinsic pathways and thus defects 
in these apoptotic pathways contribute to 5-FU resistance [Hector and Prehn, 2009].  
Currently, the response rate to 5-FU has increased when used in combination 
with other chemotherapeutic drugs, such as irinotecan and oxiplatin [De Dosso et al., 
2009; Segal and Saltz, 2009].  
 
3.2.2. Other Chemotherapeutic Drugs 
A number of drugs had appeared to improve survival rate being used alone or in 
combination with 5-FU. Capecitabine is a prodrug that is converted to 5-FU at the site 
of the tumor and administered orally, demonstrating a good response rate [De Dosso et 
al., 2009; Segal and Saltz, 2009]. Irinotecan, a derivate from the natural alkaloid 
camptothecin, was a second-line agent following failure of 5-FU. This 
chemotherapeutic drug has effect by interacting with the enzyme topoisomerase I, 
which causes transient single-strand DNA breaks that are stabilized by irinotecan, 
leading to DNA fragmentation and cell death.[Bhushan et al., 2009; Segal and Saltz, 
2009]. Oxaliplatin is a platinum compound that forms a cross-link between 
complementary DNA strands, thereby blocking DNA replication and transcription 
Cristina Xavier 
34 
 
leading to apoptosis [Bhushan et al., 2009; De Dosso et al., 2009; Segal and Saltz, 
2009].  
More recently, inhibitors of growth factor receptors have appeared. 
Bevacizumab, a monoclonal antibody directly targets the vascular endothelium growth 
factor (VEGF), was shown to inhibit angiogenesis or new blood vessel formation. 
Cetuximab and panitumumab, two monoclonal antibodies developed to target the 
human epidermal growth factor receptor (EGFR), showed  to block the binding of EGF 
to its receptor, which is overexpressed in up to 80% of CRC tumors and responsible for 
a poor prognosis [Bhushan et al., 2009; De Dosso et al., 2009; Segal and Saltz, 2009]. 
 
3.2.3. Resistance and Limitations  
Even though a wide range of chemotherapeutic drugs are available for the 
treatment of CRC, resistances and limitations to the above drugs have been shown. 
Different types of tumors have different behaviors and consequently have different 
responses to CRC therapy. It is also essential to keep in mind that the use of a specific 
drug that inhibits only one target may not be enough against CRC progression. Thus, it 
is important to know the biology of the tumor and its mutations in signaling mediators 
to choose the best treatment.  
Mutations in the MMR genes and in the TP53 have been shown to influence the 
cellular response to some chemotherapeutic agents [Warusavitarne and Schnitzler, 
2007; Bhushan et al., 2009]. CRC cells with loss of MMR system, especially when 
combined with loss of p53, have showed to generate high cisplatin resistance during 
sequential drug exposure [Lin and Howell, 2006]. In addition, despite some 
controversy, evidences have also demonstrated a reduced response of CRC MSI tumors 
to 5-FU treatment [Jover et al., 2006; Warusavitarne and Schnitzler, 2007]. CRC tumors 
with mutations in TP53, TS enzyme and/or alterations on Bcl-2 family proteins have 
also shown to be resistant to 5-FU-induced apoptosis [Violette et al., 2002; Adamsen et 
al., 2007; Warusavitarne and Schnitzler, 2007]. Moreover, poor prognosis and reduced 
sensitivity to 5-FU were also shown to CRC tumors with MSI status and p53 
overexpression or high TS activity, compared with tumors without these alterations 
[Mori et al., 2004; Warusavitarne and Schnitzler, 2007]. The use of TS inhibitors, such 
as CDK inhibitors, in combination with 5-FU has been shown to reduce TS expression, 
improving 5-FU responses [Takagi et al., 2008]. 
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The use of drugs inhibiting only one signaling pathway has failed in some 
subsets of tumors. For example, deregulation of the Ras/Raf/MAPK/ERK pathway in 
cancer cells has been associated with resistance to PI3K inhibitors, suggesting 
combined targeting of PI3K and MEK to an effective anticancer strategy [Yu et al., 
2008]. Another example is the resistance of CRC tumors to cetuximab and 
panitumumab, which happen when tumors harbor PIK3CA mutation/PTEN loss and/or 
RAS/BRAF mutations. These mutations are present downstream of EGFR and, therefore, 
related signaling pathways are activated even if EGF receptor is inhibited [Jhawer et al., 
2008; Laurent-Puig et al., 2009; Siddiqui and Piperdi, 2010].  In fact, panitumumab was 
the first drug to be approved for use only in cases without mutation of RAS, being 
required the applicability of genetic tests before EGFR therapy [Baselga and Rosen, 
2008]. MEK inhibitors, such as BRAF inhibitors, have also shown to be good 
candidates in cases where MAPK/ERK1/2 is activated, however, they demonstrate less 
favorable response in the presence of RAS or tyrosine kinases mutations, such as PI3K, 
where these alternative downstream pathways could substitute ERK in maintaining cell 
survival [Balmanno and Cook, 2009].  
 
4. POTENTIAL OF NATURAL COMPOUNDS TO MODULATE 
MOLECULAR SIGNALING PATHWAYS IN CRC  
 
Cancer cells are known to have alterations in multiple signaling pathways, which 
could lead to a disappointing inefficiency of specific synthetic inhibitors used as 
anticarcinogenic agents in cancer treatment, which only target one pathway. On the 
other hand, many natural compounds have been shown to modulate multiple cellular 
signaling pathways being usually classified as multi-target agents [Surh, 2003; 
Aggarwal and Shishodia, 2006; Sarkar et al., 2009], being therefore interesting 
compounds for anticancer interventions. In fact, an enormous progress in the 
characterization of natural products-related anticancer effects has been made. Not 
surprisingly, 60% of all cancer drugs that are used clinically are either natural products 
or owe their origin to a natural source [Heinrich et al., 2003]. Thus, natural compounds 
are continuing to be widely studied as possible anticancer agents and/or as enhancers of 
therapeutic responses of chemotherapeutic drugs when combined with them.  
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In CRC, several bioactive food components have been shown to modulate cell 
signaling pathways related to proliferation and cell death, being the PI3K/Akt and 
MAPKs (ERK, JNK and p38) pathways, as well as, molecules involved in apoptosis the 
most promising targets of these compounds [Aggarwal and Shishodia, 2006; Khan et 
al., 2008; Rajamanickam and Agarwal, 2008; Ramos, 2008; Sarkar et al., 2009]. In 
addition, effects on the autophagic process have also been demonstrated for some 
natural compounds, which may be used in order to sensitize cells to death [Singletary 
and Milner, 2008].  
 
4.1.  Medicinal Plants  
 
The National Cancer Institute (NCI) identified a large number of plant-based 
foods with anticancer properties through beneficial effects in a single or multiple 
molecular targets [Surh, 2003]. With respect to tea (from the plant Camellia sinensis), 
although some studies did not found positive effects, many epidemiological and 
laboratory studies have been found a positive correlation between tea consumption and 
reduction of human cancer risk, including CRC [Yang and Landau, 2000; Yang et al., 
2007].  
Many other plant extracts have been shown to provide a rich source of bioactive 
food compounds especially of phenolic compounds, which are considered to play an 
important role as anticarcinogenic agents due to their antioxidant properties [Yang et 
al., 2001; Yang et al., 2008]. Reactive oxygen species (ROS) and free radicals, 
produced by cancer cells, activate a number of genes and signal transduction pathways 
that mediate cancer cell proliferation and survival. Therefore, radical scavenging 
activity by the phenolic compounds present in plant foods by reducing ROS levels 
contribute to a decrease in the activity of redox-sensitive pathways, thus decreasing 
cancer progression [Loo, 2003; Fruehauf and Meyskens, 2007]. In addition, direct 
interactions between plant food constituents and multiple key elements in signaling 
transduction pathways have been reported [Surh, 2003; Ramos, 2008].    
 
4.1.1. Genus Salvia 
The word Salvia comes from the Latin salvare that means “to save”. Plants of 
the genus Salvia (family Lamiaceae) are aromatic plants that have been used by folk 
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medicine since Roman times due to its antiseptic, anti-inflammatory and hypoglycemic 
properties, among others. About 100 Salvia species have been characterized. They are 
plants native to the Mediterranean region and are cultivated nowadays all over the world 
[Topcu, 2006]. Studies have shown biological antioxidant effects of Salvia (sage), 
which have become an important source of bioactive compounds with health benefits 
for cosmetic and pharmaceutical industries [Lima, 2006; Lima et al., 2007].   
Due to the increasing scientific evidences of natural antioxidants in inhibiting 
cancer cell proliferation [Loo, 2003], sage plants have been suggested to be a natural 
source of potential antitumor agents. The anticarcinogenic effect of sage was 
demonstrated in several species, such as Salvia miltiorrhiza and Salvia menthaefolia, 
where their antiproliferative activity on several types of tumor cells was osberved [Liu 
et al., 2000; Fiore et al., 2006].  
 
4.1.1.1. Salvia fruticosa and Salvia officinalis 
The anticancer activity of Salvia fruticosa (SF) and Salvia officinalis (SO), to 
our knowledge, were never reported until now. The compositions of the water extracts 
(tea) produced from these plants and used in this work are presented in Table 1. 
Rosmarinic acid (RA) is the major phenolic compound present in both sages, 
constituting about 58% of all phenolic compounds present in SF water extract and 70% 
in SO water extract [Lima, 2006; Lima et al., 2007]. In addition, derivatives of luteolin, 
6-hidroxyluteolin-7-glucoside (in SF) and luteolin-7-glucoside (in SO) are present as 
the major flavonoids in the sage extracts. Both sages also contain an important bioactive 
triterpenoid, ursolic acid, in their composition, although present at very low 
concentration in the water extracts (Braga et al., unpublished results).   
Studies have demonstrated that RA, in the water extracts, is a major contributor 
to the antioxidant activity at cellular level of SO [Lima et al., 2007]. In fact, this 
phenolic compound has shown to possess high antioxidant and anti-inflammatory 
activities [Lima et al., 2006]. Effects of RA on several signaling pathways in cancer 
cells were also reported. RA showed to inhibit ERK phosphorylation in colon and breast 
cancer cells [Scheckel et al., 2008] and activate PKA without effects on Akt and p38 in 
melanoma cells [Lee et al., 2007]. Studies also reported effects of RA on induction of 
apoptosis via mitochondrial pathway in human hepatoma cells [Lin et al., 2007] and 
human Jurkat lymphoma cells [Kolettas et al., 2006]. Therefore, RA could be one of the 
bioactive compounds present in sages. 
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4.1.2. Genus Hypericum 
 
Plants of the genus Hypericum (family Hypericaceae), which contain a variety of 
phenolic compounds, are been attributed some medicinal properties. There are about 
twenty seven species of this genus, where H. androsaemum and H. perforatum are 
widely used as herbal drugs in Portugal [Valentao et al., 2003].      
 
4.1.2.1. Hypericum androsaemum 
Hypericum androsaemum (HA) is a medicinal plant, native to Europe and Asia 
and traditionally used in Portugal as diuretic, hepatoprotector, cholagogue, and also 
used in kidney failure and in the relief of digestive tract disorders [Guedes et al., 2004]. 
Studies in vitro have confirmed its reputed antioxidant and hepatoprotective activities 
[Valentao et al., 2002; Valentao et al., 2004b], although these results were not observed 
in in vivo studies [Valentao et al., 2004a]. The effects of HA have been attributed, at 
least in part, to the presence of several flavonoids, such as quercetin and its glycosides, 
Table 1 - Composition (µg/mg extract) in phenolic compounds and ursolic acid 
of Salvia fruticosa and Salvia officinalis water extracts after lyophilization 
([Lima, 2006; Azevedo, 2008] and Braga P. et al., unpublished results). 
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and phenolic acids, such as chlorogenic acid [Valentao et al., 2004b]. However, the 
anticancer activity of HA was never been studied, as far as we know.  
The composition of HA water extract (tea) produced from this plant and used in 
this work is presented in Table 2. Chlorogenic acid (CA; 5-caffeoylquinic acid) and its 
isomer (3-caffeoylquinic acid) are the main phenolic compounds present, and quercetin 
and derivatives of quercetin represent the major flavonoids. Studies have demonstrated 
that CA has high antioxidant properties and antitumor effects in several cancer cells [Jin 
et al., 2005; Belkaid et al., 2006], where effects on MAPK and NF-κB signaling were 
reported [Feng et al., 2005a]. Anticarcinogenic effects of CA in CRC, however, have 
not been observed [Xie et al., 2009; Park et al., 2010]. 
 
4.1.2.2. Hypericum perforatum 
Hypericum perforatum (HP), also known as St. John´s wort, is the Hypericum 
specie more studied and used for its medicinal properties. This plant is found 
throughout the world and it is known for its high pharmacological activities, including 
antidepressant, antiviral and antibacterial properties [Barnes et al., 2001]. The 
anticarcinogenic activity of HP has been reported in several cancer cell types [Martarelli 
et al., 2004; Roscetti et al., 2004; Skalkos et al., 2005; Stavropoulos et al., 2006].  
The composition of HP water extract (tea) produced from this plant and used in 
this work is presented in Table 2. This plant has the glycoside of quercetin, quercetin 3-
rutinoside (also known as rutin), as the major constituent. Hypericin, which is also 
present in this plant, has been found in some Hypericum species (its main source), being 
extensively studied for its enormous applications in the photodynamic therapy, 
including in cancer therapy. This compound, when irradiated with visible light, is 
capable to generate ROS that are toxic when produced at high levels leading cells to 
death [Barnes et al., 2001; Kitanov, 2001]. Although the anticancer effects of HP could 
be related with the presence of hypericin even if in small amounts, other studies have 
demonstrated that different types of compounds could be responsible for the plant’s 
anticancer effects [Roscetti et al., 2004; Skalkos et al., 2005]. Effects on MAP Kinases 
have also been reported for this plant [Karioti and Bilia, 2010]. 
 
4.1.2.3. Hypericum undulatum 
Hypericum undulatum (HU), a plant native to Europe and north of Africa, is one 
of the less studied herbal plants, being used for the same ailments as HP. A study in 
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vitro found high antioxidant activity of HU, as well as, an inhibitory effect on 
acetylcholinesterase with beneficial effects on memory [Ferreira et al., 2006]. The 
composition of HU water extract (tea) produced from this plant and used in this work is 
presented in Table 2. This plant has glycosides of quercetin, quercetin 3-galactoside 
(also known as hyperoside) and quercetin 3-glucoside (also known as isoquercitrin), as 
the major constituents. Hypericin is also present in HU’s composition. 
 
4.2. Flavonoids  
 
Phenolic compounds are highly abundant in fruits, vegetables, cereals and 
medicinal plants with more than 8000 different phenolic compounds described. They 
are characterized by the presence of one or more phenolic rings being divided in 
different classes based on their chemical structure. The most abundant dietary phenolic 
compounds are the flavonoids (such as quercetin, resveratrol, kaempferol, genistein, 
myricetin and luteolin) and phenolic acids (such as rosmarinic acid and clorogenic 
Table 2 – Composition (µg/mg extract) in phenolic compounds of Hypericum androsaemum, Hypericum 
perforatum and Hypericum undulatum water extracts after lyophilization (Lima E. et al., unpublished results). 
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acid), that accounts of 60% and 30%, respectively, of all polyphenols [Nichenametla et 
al., 2006; Ramos, 2008].  
Flavonoids are the largest class of phenolic compounds with more than 5000 
varieties described and ubiquitously distributed in most of plants [Yang et al., 2001]. 
Studies in vitro and in vivo have shown the potential of some flavonoids to modulate 
many steps of the carcinogenic process, although being dependent on tissue, cell type 
and doses [Nichenametla et al., 2006; Ramos, 2008].  
 
4.2.1. Quercetin 
Quercetin (3,3´,4´,5,7-pentahydroxyflavone; Fig. 6) 
is one of the main flavonoids present in the human diet 
and it can be found in many fruits, vegetables and 
beverages, particularly in onions, apples, cherries, 
broccoli, tomatoes, barriers, tea, red wine and leek 
[Ramos, 2008].  
 
Quercetin (Q) usually occurs in the diet as glycosides in which at least one 
hydroxyl group is substituted by a sugar. Onion is the major vegetable source of 
quercetin glycosides. The sugar group is frequently bound at the 3-position forming 
different conjugates, such as quercitrin, isoquercitrin, hyperoside and rutin. These 
conjugated metabolites are found in circulating blood, being stable precursors that could 
be converted to the active aglycone (i.e. quercetin without a sugar group) and exert its 
function at the target site [Murakami et al., 2008]. Q is known for its prominent dietary 
antioxidant activity and its strong anti-inflammatory capacities [Boots et al., 2008].  
Studies with Q have demonstrated its anticarcinogenic potential in many types of 
cancer cells. The ability of Q to inhibit several tyrosine kinases especially PI3K, has 
been shown and compounds such as LY294002, a PI3K inhibitor, have been designed 
based on quercetin’s structure [Walker et al., 2000]. Effects of Q in suppressing 
survival and inducing apoptosis through PI3K/Akt and/or MAPK/ERK pathways have 
been found for several types of cancer cells, such as hepatoma [Granado-Serrano et al., 
2008], neural [Spencer et al., 2003], skin epidermal [Lee et al., 2008] and breast [Gulati 
et al., 2006], while in lung cancer cells ERK activation was required for quercetin-
induced apoptosis [Nguyen et al., 2004].  
Fig. 6. Chemical structure of 
quercetin. 
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In CRC, effects of Q on PI3K/Akt and MAPK/ERK signaling pathways were 
also reported. Studies on gene expression have demonstrated effects of Q in genes 
involved in the MAPK signal pathways [van Erk et al., 2005], as well as, in cell cycle 
and apoptosis regulation genes [van Erk et al., 2005; Murtaza et al., 2006]. Proteomic 
studies also showed effects of Q via inhibition of Akt [Kim et al., 2005b] and MAP 
kinase p38 [Wenzel et al., 2004], as well as, induction of the mitochondrial pathway of 
apoptosis [Kim et al., 2005b; Volate et al., 2005]. One of the most relevant reported 
effects of Q is its ability to effectively inhibit the expression of the 3 types of RAS 
proteins (H-Ras, K-Ras and N-Ras) in different CRC cell lines [Ranelletti et al., 2000]. 
A specific inhibition on mutated RAS was then described where Q only decreased RAS 
protein level in cells expressing oncogenic RAS [Psahoulia et al., 2007b]. In addition, it 
was found that Q sensitizes CRC cells to apoptotic death in tumors cells resistant to 
death receptor TRAIL directed therapies [Psahoulia et al., 2007a].  
Studies in vivo were also performed to validate the anticarcinogenic activity of Q 
in CRC. This flavonoid showed to decrease 75% of aberrant crypt foci (ACF) incidence 
in azoxymethane (AOM)-induced CRC mice [Volate et al., 2005]. A more recent study 
[Warren et al., 2009] also showed a reduction on ACF development in AOM model, 
however, without effects on PI3K/Akt signaling. In contrast with data from cell culture 
experiments, in this in vivo study a decrease in COX-1 and COX-2 expression was 
found, suggesting that effects on proliferation and apoptosis may result from the ability 
of Q to suppress the expression of proinflammatory mediators. This was confirmed by 
another study where authors showed that AMPK-COX-2 signaling is important in 
quercetin-mediated cancer control [Lee et al., 2009].    
 
4.2.2. Luteolin 
 Luteolin (3 ,´4 ,´5,7-tetrahydroxyflavone; Fig. 7) is an important member of the 
flavonoid family being present in various fruits and 
vegetables, such as parsley, thyme, celery, oregano, 
green chili and peppers [Ramos, 2008]. Luteolin (L) 
usually occurs in the diet as luteolin-7-O-glucoside, 
being biotransformed into the aglycone, luteolin, in the 
intestine by microorganisms and hydrolases. This 
compound is structurally related with Q but has no Fig. 7. Chemical structure of luteolin. 
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hydroxyl group at position 3, which renders it more lipophilic. This higher lipophilicity 
may explain the potent intracellular antioxidant activity because it may confer better 
access to intracellular targets within the cell [Lima et al., 2006]. Besides its antioxidant 
activity, some studies have demonstrated the anticarcinogenic activity of L in several 
cancer cell lines, such as leukemia [Ko et al., 2002], pancreatic [Lee et al., 2002] and 
human hepatoma [Chang et al., 2005; Lee et al., 2005; Lee et al., 2006] cells.  Effects 
on PI3K/Akt and MAPK/ERK pathways [Lee et al., 2006], JNK signaling [Lee et al., 
2005] and the involvement of the mitochondrial pathway [Chang et al., 2005; Lee et al., 
2005] were also reported to contribute to cell growth inhibition and induction of 
apoptosis in human hepatoma cells. 
In CRC, some reports have also shown that L has anticarcinogenic effects. In 
particular, studies demonstrated apoptosis induction by L mediated through 
downregulation of Bcl-2 and Mdm-2 proteins, by increased caspase activities [Lim do et 
al., 2007] and by inhibition of TNF [Shi et al., 2004]. Effects on cell cycle arrest were 
also found in different CRC cell lines [Wang et al., 2004; Lim do et al., 2007]. It was 
also found that L is able to inhibit NF-κB signaling and suppress MAP kinases [Kim et 
al., 2005a]. Activation of JNK was also reported [Shi et al., 2004]. In addition, L was 
able to sensitize colon cancer cells to cisplatin-induced apoptosis, one of the most 
commonly cancer therapeutic agent, via increase of p53 protein level and activation of 
JNK pathway [Shi et al., 2007]. 
Studies in vivo were also performed where L was able to reduce the incidence of 
ACF and enhance the activity of antioxidants enzymes in AOM-induced colon 
carcinogenesis mice [Ashokkumar and Sudhandiran, 2008]. In addition, L decreased the 
multiplicity of foci and their incidence in 1,2-dimethyl hydrazine (DMH)-induced 
tumorigenesis in mice [Manju and Nalini, 2007], confirming the potential of this natural 
compound as possible anticancer agent in CRC. 
 
4.3. Triterpenoids 
 
Triterpenoids are compounds structurally related to steroids synthesized by great 
number of plants. They are especially abundant in ginseng, legumes and oats, among 
others. Currently, more than 80 different triterpenoid structures have been identified, 
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which are spread in the plant kingdom in the form of free acid or aglycones and their 
importance in medicine have been growing [Ikeda et al., 2008].  
 
4.3.1. Ursolic acid  
Ursolic acid (Fig. 8), a natural pentacyclic 
triterpenoid carboxylic acid, is the major 
component of some traditional medicinal herbs, 
such as rosemary, sage, olive, oregano, and it is 
also found in some fruits, such as apple, blueberry, 
cranberry and guava.  
 
A wide range of biological functions has been known for ursolic acid (UA), such 
as anti-inflammatory, hepatoprotective and anticancer combined with low toxicity 
[Ikeda et al., 2008]. The potential of UA to modulate several important signaling 
pathways related to proliferation and cell death was also demonstrated in several types 
of cancers with few studies reported in CRC.  
In CRC, UA showed the ability to suppress MAP Kinases [Shan et al., 2009], 
activate caspases [Andersson et al., 2003; Shan et al., 2009] and to induce cell cycle 
arrest [Li et al., 2002]. In other cell types, such as prostate cancer cell lines [Kassi et al., 
2007; Zhang et al., 2009b; Zhang et al., 2010a; Zhang et al., 2010b] and leukemia cells 
[Liu and Jiang, 2007], UA induced apoptosis through phosphorylation of Bcl-2, 
activation of caspases and induction of JNK pathway, while in breast cancer cells [Yeh 
et al., 2010] UA suppressed the JNK pathway. Effects on PI3K/Akt and/or MAPK/ERK 
pathways are also reported in prostate [Zhang et al., 2010a], breast [Yeh et al., 2010], 
endometrial [Achiwa et al., 2007] and ovarian [Wang et al., 2009] cancer cells, as well 
as, effects on cell cycle progression in lung cancer cells [Hsu et al., 2004]. In addition, 
effects on angiogenesis through inhibition of VEGF levels and effects on the expression 
of matrix metalloproteinases MMP-2 and MMP-9 proteins were reported in B16F-10 
melanoma cells [Kanjoormana and Kuttan, 2010].  
UA has also been linked to anti-inflammatory activity in several studies in 
melanoma [Manu and Kuttan, 2008], leukemia [Shishodia et al., 2003] and breast 
cancer [Yeh et al., 2010] cells, where an inhibition of the nuclear transcription factor 
NF-κB activity by UA was reported. More recently, UA, at low doses, was also found to 
Fig. 8. Chemical structure of ursolic acid. 
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be able to sensitized cancer cell lines to chemotherapeutic agents, such as taxol and 
cisplatin, through suppression of NF-κB, helping in the induction of apoptosis and the 
reduction of the necessary drug doses for cancer treatment [Li et al., 2010]. An effect on 
mitochondrial membrane permeability through decrease of sodium pump NA+-K+ 
ATPase by UA was recently reported in several liver cancer cell lines [Yan et al., 2010].  
 
4.4. Natural Compounds in Clinical Trials 
 
For a compound to enter clinical trial many steps are required. The compound 
must be promising in vitro and in vivo to proceed for in-depth efficacy evaluation 
concerning toxicity and pharmacokinetics. The compounds that prove to have low 
toxicity and high efficiency in animal models are allowed to enter for clinical evaluation 
in studies involving humans. Only compounds successfully arriving the phase III are 
considered as possible future chemotherapeutic drugs [Kakizoe, 2003]. It is not high the 
number of natural compounds that have passed through this process. 
 
4.4.1. Curcumin 
Curcumin, a polyphenol, is an active principle of the herb Curcuma longa, 
commonly known as turmeric and it is one of the most well studied natural compounds. 
Curcumin possesses anticancer effects on different stages of carcinogenesis in several 
cancer cell lines and exhibits antitumor activity in animal models, including in CRC. 
Curcumin is able to downregulate the activity of multiple kinases and to interact with 
important targets, affecting different signaling pathways. Current clininal trials of 
curcumin are ongoing for different diseases, including pancreatic and colorectal cancers, 
oral premalignat lesions and in conditions linked to inflammation such as psoriasis and 
alzheimer´s disease. Although with poor bioavailability, curcumin was remarkably well 
tolerated and safe in phase I clinical trial, thus a promising outcome is awaited [Goel et 
al., 2008; Hatcher et al., 2008]. Currently, some analogues of curcumin, such as JC-9, 
have progressed to phase II clinical trials against prostate cancer, demonstrating 
candidates to anticancer drugs [Lee, 2010]. 
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4.4.2. Resveratrol 
Resveratrol is a natural polyphenol found in grapes, red wine, berries, peanuts 
and other plants, which was first described as a phenolic component of the medicinal 
herb hellebore (Veratrum grandiflorum). The ability of resveratrol to bind several 
biomolecules involved in different signaling pathways has been shown to result in 
diverse biological effects with interest for anticancer treatment. Resveratrol has 
anticancer effects in vitro and in vivo, with effects on cell proliferation and death, 
inflammation, angiogenesis and metastasis processes. Although data in humans have 
revealed that resveratrol is pharmacologically quite safe, few clinical studies in humans 
have been performed. Clinical trials for patients with cancer and type 2 diabetes are 
underway. Because of its low bioavailability, structural analogues of resveratrol are also 
being improved as potential therapeutic agents for cancer treatment [Aggarwal et al., 
2004; Marques et al., 2009].    
 
Natural compounds are possible pharmacological agents’ themselfes or can be 
used as leads to design new compounds based on their structures creating synthetic 
analogues with better pharmacological activities.  
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Epidemiological studies have shown that nutrition is a key factor in 
modulating sporadic colorectal carcinoma (C RC) risk. Aromatic 
plants of the genus Salvia (sage) have been attributed many medic- 
inal properties, which include anticancer activity. In the present 
study, the antiproliferative and proapoptotic effects of water ex- 
tracts of Salvia fruticosa (SF) and Salvia officinalis (SO) and of 
their main phenolic compound rosmarinic acid (RA) were evalu- 
ated in two human colon carcinoma-derived cell lines, HCT15 and 
CO115, which have different mutations in the MAPK/ERK and 
PI3K/Akt signalling pathways. These pathways are commonly al- 
tered in CRC, leading to increased proliferation and inhibition of 
apoptosis. Our results show that SF, SO, and RA induce apoptosis 
in both cell lines, whereas cell proliferation was inhibited by the 
two sage extracts only in HCT15. SO, SF, and RA inhibited ERK 
phosphorylation in HCT15 and had no effects on Akt phosphory- 
lation in CO115 cells. The activity of sage extracts seems to be due, 
at least in part, to the inhibition of MAPK/ERK pathway. 
 
 
 
INTRODUCTION 
    Cancer is an important health problem and one of the most 
common forms is colorectal carcinoma (CRC). Phosphatidyli- 
nositol 3-kinase (PI3K)/Akt and mitogen-activated protein ki- 
nase/extracellular signal-regulated kinase (MAPK/ERK) sig- 
nalling pathways play critical roles in cell proliferation and 
survival and are frequently activated in CRC (1–3). Deregula- 
tion of these pathways is also thought to determine response to 
treatment (4). Mutations of KRAS and BRAF in sporadic CRC 
(70–80% of total cases) (5) are alternative in which the former 
 
 
constitutively activates both MAPK/ERK and PI3K/Akt path- 
ways, and the latter activates the MAPK/ERK pathway (3,4,6– 
8). As presented by Schubbert et al. (9), mutations in CRC of 
either KRAS or BRAF genes occur in 32% and 14% of cases, 
respectively. Studies have also shown that CRC is frequently 
associated with mutations in genes that encode for PI3K, p110 
catalytic subunit PI3KCA, and PTEN (an endogenous inhibitor 
of PI3K activity), resulting in an overexpression of Akt (10– 
13). Considering the high incidence of CRC, inhibitors of these 
pathways are actively being searched for use in the control of 
cancer progression (14–16). 
    Epidemiologic studies have shown that Western type diets, 
poor in vegetables and fruits, are risk factors known to be as- 
sociated with CRC, suggesting that nutritional factors may also 
be preventive and also helpful in the control of cancer (17–19). 
In fact green and black tea consumption has been shown to 
be effective in the initiation, promotion, and progression stages 
of carcinogenesis, although effects on colon cancer are incon- 
clusive (20). Plants of the genus Salvia (sage) such as Salvia 
miltiorrhiza and Salvia menthaefolia have also been suggested 
to have anticancer properties based on antiproliferative activ- 
ity on tumor cells (21,22). In addition, reactive oxygen species 
(ROS) have been reported to play a role in signalling trans- 
duction enhancing proliferation and survival of cancer cells. 
Antioxidant phytochemicals, through their ROS scavenging ac- 
tivity, may suppress altered redox-sensitive signalling events in 
cancer (23,24). 
    Salvia fruticosa (SF) and Salvia officinalis (SO), poorly stud- 
ied with regard to their anticancer activity, are Mediterranean 
medicinal and aromatic plants that contain ros marinic acid (RA; 
Fig. 1) as major phenolic compound in their water extracts. RA 
constitutes about 58% of all phenolic compounds present in SF 
water extract and 70 %  in SO water extract (25 ,26).  T his phenolic 
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FIG. 1.   Chemical structure of rosmarinic acid. 
 
com pou nd has high antioxidant and anti-inflam matory activities 
(22,27), but little is known about its effects on cancer cells and 
especially on CRC. 
    In the present article, we report on the antiproliferative and 
proapoptotic effects of 2 Salvia water extracts, SF and SO, 
and their major phenolic compound, RA, in 2 human colon 
cancer-derived cell lines, HC T15 and CO 115 , throug h effects on 
the MA P K/E R K and PI3K/Akt pathways and caspase-mediated 
apoptosis. These 2 cell lines possess different activating muta- 
tions in these 2 pathwa ys: HCT15 has a KR AS ( G13 D) mutation 
(28), whereas CO115 has a BRAF (V599E) mutation (29). 
    In view of these genetic differences, we further speculate on 
the mechanisms behind the antiproliferative and proapoptotic 
effects of sage extracts and RA and the involvement of PI3K/Akt 
and MAPK/ERK signalling pathways in these effects. 
 
MATERIAL AND METHODS 
Reagents and Plant Extracts 
    All reagents and chemicals used were of analytical grade. 
Wortmannin (W), RA, and staurosporine were purchased from 
Sigma-Aldrich  (St.  Louis,  MO)  and  PD-98059  (PD)  was 
from Calbiochem (San Diego, CA). The primary antibodies 
anti-phospho-Akt (Ser473), anti-Akt total, anti-phospho-PTEN 
(Ser380/Thr382/383), anti-PTEN total, anti-p44/42 MAPK to- 
tal, and anti-cleaved caspase-9 (Asp315) were purchased from 
Cell  Signalling (Danvers, MA); the  anti-phospho-ERK and 
caspase-3 (H-277) were from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA); and the anti-β -actin was from Sigma-Aldrich. 
The secondary antibodies HRP donkey antirabbit and sheep an- 
timouse were from GE Healthcare (Bucks, United Kingdom). 
    The water extracts of Salvia fruticosa and Salvia officinalis 
were prepared as previously described by Lima et al. (30) by 
pouring boiling water onto the dried plant material (at a ratio of 
150 ml of water to each 2 g of plant) and allowing it to steep 
for 5 min. After filtering, the water extract was lyophilized to 
dryness. The extracts of both sages were made using batches 
of the plants whose composition, in terms of phenolics com- 
pounds, have already been published (25,26). In brief, SF water 
extract contains as major phenolic compound RA (71.5 µ g/ml), 
6-hydroxyluteolin-7-glucoside (22.7 µg/ml),  a not identified 
flavone heteroside (28.6 µg/ml), and the remaining phenolic 
com pou nds re present 0.8 µg/ml. S O w ater extract contain as ma- 
jor phenolic compounds RA (52.0 µg/ml), luteolin-7-glucoside 
(19.7 µg/ml) and the remaining phenolic compounds represent 
2.7 µg/ml. 
    Stocks solutions of PD and W were made in dimethyl sul- 
foxide (DMSO), and aliquots were kept at –20∘C. Therefore, 
DMSO (0.5%) was included in cell culture for the other condi- 
tions (controls and extracts/RA) to exclude any possible DMSO 
effect. 
 
Cell Culture  
    HCT15 and CO115 human CRC-derived cell lines were a    
gift from Dr. Raquel Seruca (IPATIMUP, University of Porto, 
Portugal) and were maintained in culture at 37∘ C in a humidified 
5% CO2  atmosphere in RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 10 mM HEPES, 0.1 mM pyruvate, 1% 
antibiotic-antimycotic solution (Sigma-Aldrich), and 10% fetal 
bovine seru m (F BS; EU standard; Ca mbrex, Verviers, Belgium). 
Cells were seeded onto 6-well plates at a density of 0.75 × 105 
(HCT15) and 1.0 × 105 (CO115) cells/well. Incubations with
 
different con centrations of sage extracts an d R A were performed 
in serum free medium for 48 h to quantify BrdU incorporation 
and TUN EL  positive cells and for 24 h for Western blot analysis. 
 
Assessment of Proliferation by BrdU Incorporation 
    Preliminary experiments using the MTT assay were per- 
formed in order to choose concentrations of SF and SO extracts 
that inhibited around 50% cell proliferation without cytotoxic 
effects. RA was tested in similar concentrations to the ones 
found in the extracts at the concentrations used and also did 
not induce cytotoxic effect. After 45 h of treatment with sage 
extracts or RA at different concentrations, bromodeoxyuridine 
(BrdU; Sig ma- Aldrich) was added to the culture medium to give 
a final concentration of 10 µM and then incubated for another 
3 h. Both adherent and nonadherent cells were collected from 
each sample, fixed with 4% paraformaldehyde for 15 min at 
room temperature, and then attached into a polylysine-treated 
slide using a Shandon Cytospin (Thermo Fisher Scientific Inc, 
Waltham, MA). Cells were incubated with HCl 2 M for 20 min, 
washed in PBS containing 0.5% Tween-20 and 0.05% BSA 
(TPBS-B) and then incubated with monoclonal mouse anti- 
BrdU antibody (DakoCytomation, Glostrup, Denmark) for 1 h 
at room temperature . After washing in TP B S-B, cells were incu- 
bated with antimouse IgG FIT C-conjugated secondary antibody 
(Sigm a-Aldrich) for 1 h at room tem perature, washed again, and 
then incubated with Hoechst for nuclei staining. The percentage 
of proliferating cells was calculated as the ratio between BrdU 
positive cells and total number of cells (nuclei staining with 
Hoechst), from a count higher than 500 cells per slide under a 
fluorescent microscope. Results are presented as mean ± SEM
 
of at least 3 independent experiments. 
 
Assessment of Apoptosis by TUNEL Assay 
    Cells treated as above for 48 h were collected (both float- 
ing and attached cells) and fixed with 4% paraformaldehyde for 
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15 min at room temperature and then attached into a polylysine- 
treated slide using a Shandon Cytospin. Cells were washed in 
PBS and permeabilized with 0.1% Triton X-100 in 0.1% sodium 
citrate for 2 min on ice. TUNEL assay was performed using a 
kit from Roche (Mannheim, Germany) following the manufac- 
ture’s instructions. Cells were incubated with Hoechst for nuclei 
staining. The percentage of apoptotic cells was calculated from 
the ratio between TUNEL positive cells and total number of 
cells (nuclei staining with Hoechst) from a count higher than 
500 cells per slide under a fluorescent microscope. Results are 
presented as mea n ± SE M  of at least 3 indepen dent experiments. 
 
Protein Extraction and Western Blotting 
    After 24 h of treatment with sage extracts or RA at the high- 
est concentration used in the BrdU and TUNEL assay, cells 
were washed with PBS and lysed for 15 min at 4∘C with ice 
cold RIPA buffer (1% NP-40 in 150 mM NaCl, 50 mM Tris (pH 
7.5), 2 mM EDTA), supplemented with 20 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 20 mM Na2 V 3 O4 and 
protease inhibitor cocktail (Roche). Protein concentration was 
quantified using a Bio-Rad DC protein assay (Bio-Rad Labo- 
ratories, Inc., Hercules, CA) with BSA as a protein standard. 
Twenty micrograms of protein for each sample were separated 
by SDS gel electrophoresis and then electroblotted to a Hybond- P 
polyvinylidene difluoride membrane (GE Healthcare). Mem- 
branes were blocked in TPBS (PBS with 0.05% Tween-20) con- 
taining 5% (wt/vol) non-fat dry milk or BSA, incubated with the 
primary antibody, and followed by the secondary antibody 
conjugated with IgG horseradish peroxidase. Membranes were 
washed 3 times with TPBS between the different incubations. 
Immunoreactive bands were detected using the Immobilon so- 
lutions (Millipore, Billerica, MA) under a chemiluminescence 
detection system, the Chemi Doc XRS (Bio-Rad Laboratories, 
Inc.). Band area intensity was quantified using the Quantity One 
software from Bio-Rad. β -actin was used as a loading control. 
Results are presented as mean ± SEM of at least 3 independent
 
experiments. 
 
 
Statistical Analysis 
    One-way ANOVA followed by the Student–Newman–Keuls 
test was used to perform statistical analysis for BrdU, TUNEL, 
and Western blot data. GraphP ad Prism 4.0 software (San Diego, 
CA) was used, and P values ≤ 0.05 were considered statistically 
significant. 
 
 
RESULTS 
 
Effects on Cell Proliferation 
    To test the effects of SF, SO, and RA on cell proliferation of 
human colon cancer cells, 2 different colon carcinoma-derived 
cell lines, HCT15 and CO115, were used. 
    Based on prelimin ary experiments using the MT T assay (data 
not shown) in which cells were incubated with several concen- 
 
 
trations of sage extracts for 48 h, concentrations of each extract 
that were not cytotoxic and inhibited cell proliferation around 
50% were chosen for the subsequent studies. Since RA is the 
main phenolic compound of these extracts, we also tested RA 
in similar concentrations to the ones found in the extracts under 
our experimental conditions. 
    The effects of sage extracts and RA on cell proliferation of 
both cell lines were tested using the BrdU incorporation as- 
say. As shown in Fig. 2A, a significant inhibition of HCT15 
cell proliferation by both SF and SO was observed at all con- 
centrations tested. Levels of BrdU incorporation significantly 
decreased from 26.2% in the control to 4.7% in HCT15 cells 
treated with 50 µg/ml of SF and SO extracts. In CO115 cells, SF 
and SO did not significantly inhibit cell proliferation (Fig. 2B). 
No significant inhibition of cell proliferation was observed in 
neither of the cell lines when treated with RA (Fig. 2). Compar- 
ing the effects of sage extracts in the 2 cell lines, we observed 
that SF extract was somewhat more active than SO, and HCT15 
cells were more sensitive to the sage extracts. 
 
 
 
 
 
 
 
 
 
FIG. 2.   Effect of different concentrations of Salvia fruticosa (SF), Salvia 
officinalis (SO), and rosmarinic acid (RA) for 48 h on bromodeoxyuridine 
(BrdU) incorporation in A: HCT15 and B: CO115 cells. Values are mean ± 
standard error of the mean of at least 3 independent experiments. ∗ P  ≤ 0.05
 
and ∗ ∗ ∗ P ≤ 0.001 when compared to control. DMSO, dimethyl sulfoxide.
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FIG. 3.   Effect of different concentrations Salvia fruticosa (SF), Salvia offic- 
inalis (SO), and rosmarinic acid (RA) on apoptosis for 48 h as assessed by 
the TUNEL assay of A: HCT15 and B: CO115 cell lines. Values are mean ± 
standard error of the mean of at least 3 independent experiments. ∗ P  ≤ 0.05,
 
∗ ∗ P ≤ 0.01, and ∗ ∗ ∗ P ≤ 0.001 when compared to control. TUNEL, terminal de-
 
oxynucleotidyl transferase-mediated dUTP nick-end labeling; DMSO, dimethyl 
sulfoxide. 
 
 
Effects on Apoptosis 
    The  ability of SF, SO, and RA to induce apoptosis in hu- 
man CRC-derived cells were studied using the TUNEL assay. 
As shown in Fig. 3, both Salvia extracts and RA significantly 
induced apoptosis in a concentration-dep ende nt manner in both 
HCT15 and CO115 cells. Apoptotic cells in HCT15 increased 
from 0.4% in the control to 6.6%, 5.8%, and 2.5% in SF, SO, 
and RA treatments, respectively, at the higher concentrations 
tested (Fig. 3A). In CO115 cells, apoptotic cells increased from 
1.8% in the control to 6.8%, 3.8%, and 3.6% in the conditions 
treated with the higher concentrations tested of SF, SO, and RA, 
respectively (Fig. 3B). Since the basal levels of apoptosis were 
higher in the CO115 cell line, overall it seems that the HCT15 
cells were more sensitive to the extracts and RA. Again, SF 
extract showed to be more active than SO extract and RA alone. 
    The involvement of caspases 3 and 9 in the apoptosis in- 
duction by sage extracts and RA was also studied by Western 
blot. After 24 h of treatment with the highest concentrations 
used of SF, SO, and RA, we did not observe cleaved caspase-9 
 
 
 
and caspase-3 in either cell line in contrast with the reference 
compound, staurosporine (data not shown). 
 
Effects on MAPK/ERK Pathway 
    The effects of sage extracts and RA for 24 h  were studied 
on the MAPK/ERK pathway by Western blot. Salvia extracts 
and RA significantly decreased phospho-ERK protein levels 
in HCT15 cells (Fig. 4A), whereas no effects were observed 
in CO115 cells (Fig. 4B). The reference inhibitor of phospho- 
ERK, PD-98059 (PD), was effective in both cell lines (Fig. 4) 
in a similar way to SF, SO, and RA in HCT15 cells. 
 
Effects on PI3K/Akt Pathway 
    The  effects  of  sage  extracts and  RA  on  the   expression  
of phospho-Akt and phospho-PTEN (a negative regulator of 
PI3K/Akt pathway) were also tested. Phospho-Akt was ob- 
served in CO115; however, it was not detected in HCT15 in 
mediu m with and without serum (data not shown). Neither of the 
Salvia extracts nor RA inhibited significantly the expression of 
phospho-Akt in CO115 cells (Fig. 5A). A significant inhibition 
of Akt phosphorylation was observed for the reference PI3K 
inhibitor, wortmannin (W). HCT15 cells expressed phospho- 
PTEN, and this expression was not significantly changed by 
Salvia extracts, RA or W (Fig. 5B). CO115 cells did not express 
phospho-PTEN or total PTEN in medium with and without 
serum (data not shown). 
 
 
DISCUSSION 
    To assess the potential of sage in the control of CRC pro- 
gression, the antiproliferative and proapoptotic effects of Salvia 
fruticosa (SF) and Salvia officinalis (S O) water extracts and their 
main phenolic compound, rosmarinic acid (RA), were studied 
in two human CR C-derived cell lines, HCT15 and CO115. Both 
sage water extracts (SF and SO) were effective in inhibiting pro- 
liferation in a concentration-dependent manner in HCT15 but 
not in CO115 cells. SF, SO, and RA induced apoptosis. SF was 
more effective than SO with regard to both antiproliferative and 
proapo ptotic effects. To identify the bioactive comp oun d behind 
these effects, sage’s major phenolic compound (RA) was tested 
individually at concentrations similar to those present in the 
extracts. However, RA was found not to have antiproliferative 
activity but to be proapoptotic in both cell lines, although to less 
extent than sage extracts. In view of these results, it seems that 
other active compounds present in the extracts may be respon- 
sible for the antiproliferative and proapoptotic effects of SF and 
SO. 
    The 2 cell lines used harbor different activating mutations: 
HCT15 has a KRAS (G13D) activating mutation (28) with po- 
tential to constitutively activate both PI3K/Akt and MAPK/ERK 
pathways, whereas CO115 harbors a BRAF (V599E) mutation 
(29) that affects the MAPK/ERK pathway. The highest sensi- 
tivity of HCT15 could be a result of these genetic differences. 
HCT15 cells, even though presenting an activating mutation of 
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FIG. 4.   Effects of Salvia fruticosa 50 µg/ml (SF50), Salvia officinalis 50 µg/ml (SO50), and rosmarinic acid 100 µM (RA100) for 24 h on the expression of 
phospho-extracellular-regulated kinase (p-ERK) in A: HCT15 cells and B: CO115 cells. PD-98059 50 µM (PD50) was used as a reference inhibitor of p-ERK. 
Values are mean ± standard error of the mean of at least 3 independent experiments. ∗ P ≤ 0.05 and ∗ ∗ ∗ P ≤ 0.001 when compared to control. DMSO, dimethyl
 
sulfoxide; W, wortmannin. 
 
 
 
 
 
 
FIG. 5.   Effects of Salvia fruticosa 50 µg/ml (SF50), Salvia officinalis 50 µg/ml (SO50), and rosmarinic acid 100 µM (RA100) for 24 h on the expression of 
phospho-v-akt murine thymoma viral oncogene homolog (p-Akt) in A: CO115 cells and phosphophosphatase and tensin homolog (p-PTEN) in B: HCT15 cells. 
Wortmannin 1 µM (W1) was used as a reference inhibitor of phosphatidylinositol 3 kinase. No p-Akt expression was observed in HCT15 cells, and no PTEN 
expression was observed in CO115 cells. Values are mean ± standard error of the mean of at least 3 independent experiments. ∗ ∗ P  ≤ 0.01 when compared to
 
control. DMSO, dimethyl sulfoxide; W, wortmannin. 
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the RAS oncogene, did not express phospho-Akt possibly as a 
consequence of the high levels of the strong negative regulator 
of this pathway, phospho-PTEN, found in this cell line. In these 
cells, the antiproliferative effects of SF and SO correlate with an 
inhibition of phospho-ERK. However, RA showed a significant 
inhibition of phospho-ERK without inhibiting HCT15 cell pro- 
liferation. Inhibition of phospho-ERK seems, therefore, not to 
be the only factor involved in inhibition of cell proliferation in 
this cell line. Our findings are in agreement with previous stud- 
ies (6,31), which have shown that an inhibition of MAPK/ERK 
pathway in KRAS mutated cell lines is not sufficient to inhibit 
cell proliferation. Therefore, the KRAS mutated HCT15 cells 
do not depend exclusively on MAPK/ERK pathway to prolifer- 
ate, and as a result, SF and SO seem also to be inhibiting other 
proliferation pathways, which in these cells do not include Akt 
phosphorylation (Fig. 6). 
    In CO115 cells, where SF and SO did not have antipro- 
liferative effect, there was no inhibition of phospho-ERK or 
phospho-Akt. RA also did not inhibit proliferation of CO115 
cells. However, in contrast to the effects on the other cell line, RA 
was without effect on phospho- ER K. Inhibition of MAPK/ERK 
pathway by sage extracts and RA in HCT15 and not CO115 
indicates that the effect may be upstream of BRAF and could be 
on KRAS (Fig. 6). In CO115 cells, a potential inhibition of RAS 
by sage extracts would not result in antiproliferative effects due 
to the downstream activating mutation of BRAF (Fig. 6). An 
inhibition of RAS oncogene has also been recently shown for 
quercetin, a common, natural-occurring, phenolic compound 
(32,33). It seems that the effects of RA depend on cell type 
and/or genetic background because others have also shown that 
RA decreases ERK phosph orylation in cardiac muscle cells,  but 
it is without effect on Akt and ERK in melanoma cells (34,35). 
 
 
    SF, SO, and RA induced apoptosis in both cell lines. It 
seems, however, that under these conditions, apoptosis is not 
dependent on the cleavage of either caspase-9 or caspase-3 in 
both cell lines. Nevertheless, some authors have shown that 
RA promotes apoptosis in human Jurkat cells and HepG2 cells 
via the mitochondrial pathway and Bcl-2 suppression in which 
caspases are involved (36–38). Also, the mitochondrial path- 
way was induced by RA in activated T cells from rheumatoid 
arthritis patients (39). It seems, therefore, that the induction of 
caspase pathways by RA is cell type specific and/or dependent 
on concentration and time of exposure, which may explain the 
discrepancy between these and our results. The inhibition of 
MAPK/ERK pathway may contribute, at least in part, to the 
effects on apoptosis in HCT15 cells. 
    Besides a possible interaction with KRAS, sage extracts may 
act as antiproliferative and proapoptotic in these cancer cell 
lines through their antioxidant activity. It is known that cancer 
cells produce increased amounts of ROS, in particular hydrogen 
peroxide, which could inhibit protein fosfatases and also be 
associated with signalling events in MAPK pathways that lead 
to activation of redox-sensitive transcription factors, mediating 
cancer cell proliferation and survival (23,24). Therefore, the 
radical scavenging activity of the phenolic compounds present 
in the sage extracts may be reducing the ROS levels in these 
cancer cells contributing also to a decreased activity of redox- 
sensitive proliferative pathways through RAS signalling. Based 
on RA results, the effects described in this study seem, however, 
not to be totally explained by the antioxidant properties of the 
sage extracts. 
    In conclusion, our results show that SF and SO water ex- 
tracts inhibit proliferation and induce apoptosis in CRC-derived 
cell lines, whereas RA was only effective on the induction of 
 
 
 
 
 
 
FIG. 6.   Model for the inhibition of extracellular-regulated kinase (ERK) phosphorylation by Salvia fruticosa (SF), Salvia officinalis (SO), and rosmarinic acid 
(RA) in HCT15 but not in CO115 cells. SF, SO, and RA inhibit mutant V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) leading to a decrease on 
the levels of phospho-ERK in HCT15 cell line. In CO115 cells, SF, SO, and RA do not change ERK phosphorylation levels due to a V-raf murine sarcoma viral 
oncogene homolog B1 (BRAF) activating mutation downstream of RAS oncogene. The missing phosphatase and tensin homolog (PTEN) in CO115 cells and 
phospho-v-akt murine thymoma viral oncogene homolog (Akt) in HCT15 cells were also observed in this study. MAPK, mitogen-activated protein kinase; PI3K, 
phosphatidylinositol 3 kinase. 
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apoptosis. Sage extracts and RA did not affect the PI3K/Akt 
pathway but inhibited the MAPK/ERK pathway in the KRAS 
mutated HCT15 cell line. The inhibitory effects of sage extracts 
on phospho-ERK seem to result from an inhibition of KRAS, 
upstream to BRAF, because it was not observed in CO115 cells. 
The inhibition of MA P K/E R K by sage extracts seems, however, 
not to completely explain the inhibition of cell proliferation in 
HCT15 because RA inhibits phospho-ERK without affecting 
cell proliferation. These data add S. fruticosa and S. officinalis 
to the list of potential sources of new active anticancer com- 
pounds useful in particular in tumors with a mutagenic KRAS 
activation and also suggest their possible use in dietary strategies 
for the control of CRC progression. 
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Abstract   
 MAP kinase and PI3K/Akt signalling pathways are commonly altered in 
colorectal carcinoma (CRC) leading to increased proliferation and inhibition of 
apoptosis. Several species of the genus Hypericum are medicinal plants to which 
digestive tract effects have been attributed. In the present study, the antiproliferative 
effects of the water extracts of H. androsaemum (HA), H. perforatum (HP) and H. 
undulatum (HU) were investigated in two human colon carcinoma-derived cell lines, 
HCT15 and CO115, which harbour activating mutations on KRAS and BRAF, 
respectively. Contrarily to HU and HP, HA significantly inhibited cell proliferation and 
induced apoptosis in both cell lines. HA decreased BRAF and phospho-ERK 
expressions in CO115 cells, but not in HCT15. HA also decreased Akt phosphorylation 
in CO115, suggesting an inhibition of PI3K/Akt pathway. Furthermore, an induction of 
p38 and JNK stress-activated kinases were observed in both cell lines. Chlorogenic 
acid, the main phenolic compound present in the HA extract and less represented in the 
other two species, did, however, not show any of those effects. In conclusion, HA 
controlled CRC proliferation and specifically acted on mutant BRAF. 
 
 
Keywords: Chlorogenic acid, Colorectal Carcinoma, Hypericum androsaemum, MAP 
kinases, PI3K/Akt Pathway 
Cristina Xavier 
74 
 
 Introduction 
 
 Environmental factors, many of which diet related, are responsible for 70-80% of 
total cases of colorectal carcinoma (CRC), an important health problem worldwide [1, 
2]. Activating mutations of KRAS, BRAF and/or PI3K have been found in more than 
50% of CRC cases and constitutively activate the mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) and/or the 
phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathways [3, 4]. The constitutive 
activation of these pathways plays an important role during CRC progression and 
results in a higher cell proliferation rates and in inhibition of apoptosis [3, 5-7]. Since 
MAPK/ERK and PI3K/Akt pathways are involved in CRC progression and drug 
resistance, proteins associated with these pathways are good molecular therapeutic 
targets for drug discovery [8, 9]. 
 The stress-activated protein kinases, c-Jun N-terminal kinase (JNK) and p38 are 
two other major MAPK pathways also frequently deregulated in cancers, including 
CRC [9, 10]. These pathways are activated by diverse cellular stresses including UV 
light, X-rays, hydrogen peroxide, heat and osmotic shock and have been implicated in 
the control of cell proliferation, differentiation, migration, apoptosis and survival and 
their effects appear to be largely dependent on cell type and/or cellular context [10, 11].  
In particular, JNK activation is involved in the control of cell growth and proliferation, 
as well as apoptosis, since JNK may induce activation of the mitochondrial pathway 
[11, 12]. Activation of the p38 pathway has also been shown to promote growth arrest, 
to induce apoptosis by activating p53 and to block tumor growth. On the other hand, 
p38 inactivation has been shown to induce cell proliferation and enhance cellular 
transformation [13, 14]. Therefore, p38 and JNK MAP kinases may also be considered 
as potential targets for cancer therapy [10]. 
 Plants of the genus Hypericum (family Hypericaceae) have been attributed 
important medicinal properties. Hypericum perforatum (HP), also known as St. John’s 
wort, is the species more studied and it is known for its high pharmacological activities, 
such as antidepressant, antiviral and antibacterial properties [15]. The anticarcinogenic 
activity of HP has also been reported in several cancer cell types, but not in CRC cells 
[16-19]. Its antitumor effects have been related with one of its main constituents, 
hypericin [20-22]. Hypericum androsaemum (HA) is less known and it is used as 
diuretic, hepatoprotector, cholagogue, and also in kidney failure and in the relief of 
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digestive tract disorders [23, 24]. Its anticarcinogenic activity has, to our knowledge, 
never been reported. Recent in vitro studies showed the antioxidant and 
hepatoprotective activities of HA water extract [25, 26]. The effects of HA have been 
attributed, at least in part, to the presence of several flavonoids, such as quercetin and its 
glycosides, and phenolic acids, such as chlorogenic acid [26]. Hypericum undulatum 
(HU) is the least known of the three species. Antioxidant activity and effects on 
memory have been found [27]. Plants containing a variety of phenolic compounds have 
been shown to play an important role as dietary antioxidants in cancer prevention [28, 
29]. However, evidence is increasing that the anticarcinogenic properties of plant food 
constituents is not only the result of their antioxidant activity. In fact, many of these 
natural compounds have been demonstrated to act on multiple key elements in 
signalling transduction pathways related to cellular proliferation and apoptosis [30, 31]. 
Since H. androsaemum, H. undulatum and H. perforatum (HP) are popularly 
consumed as herbal tea (water extract) for the relief of digestive tract disorders and they 
contain quercetin (mainly as glycosides), which we have shown in a previous study to 
possess anticarcinogenic activity against colon cancer cells [32], the antiproliferative 
and proapoptotic effects of the water extracts of these three Hypericum plants were 
tested in two human colon cancer-derived cell lines, HCT15 and CO115. These cell 
lines harbour different activating mutations that affect both MAPK/ERK and/or 
PI3K/Akt pathways: HCT15 has a KRAS (G13D) mutation [33] while CO115 harbour a 
BRAF (V599E) mutation [34], being representative of many CRC cases. The 
involvement of stress induced kinases p38 and JNK, and apoptotic markers were also 
studied.  
 
Materials and methods  
 
Reagents and Antibodies  
All reagents and chemicals used were of analytical grade. Wortmannin (W), LY-
294,002 (LY), staurosporine, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and chlorogenic acid (CA) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA); PD-98059 (PD) was from Calbiochem (San Diego, CA, USA). 
Stocks solutions of W, LY, PD and STS were made in dimethyl sulfoxide (DMSO) and 
aliquots were kept at -20 ºC. DMSO (0.5%, final concentration) was used in the other 
conditions (control and HA extract alone) to exclude any solvent effect.  
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The primary antibodies, anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-
PTEN (Ser380/Thr382/383), anti-PTEN, anti-p44/42 MAPK and anti-phospho-p38 
MAPK (Thr180/Tyr182) were purchased from Cell Signaling (Danvers, MA, USA); the 
anti-phospho-ERK, anti-Raf-B, anti-K-Ras, anti-PKC total, anti-PARP-1, anti-p38, anti-
phospho-JNK and anti-JNK were from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA, USA); the anti-caspase-3 was from Calbiochem (San Diego, CA); and the anti-β-
actin from Sigma-Aldrich. The secondary antibodies HRP donkey anti-rabbit and sheep 
anti-mouse were from GE Healthcare (Bucks, UK).  
 
Cell culture and conditions 
HCT15 and CO115 human colon carcinoma-derived cell lines were a gift from 
Dr. Raquel Seruca (IPATIMUP, University of Porto, Portugal) and were maintained in 
culture at 37 ºC in a humidified 5 % CO2 atmosphere in RPMI-1640 medium (Sigma-
Aldrich) supplemented with 10 mM HEPES, 0.1 mM pyruvate, 1 % antibiotic-
antimycotic solution (Sigma-Aldrich) and 6 % fetal bovine serum (FBS; EU standard, 
Cambrex, Verviers, Belgium). Cells were seeded onto six (2 ml) and twelve (1 ml) well 
plates at a density of 0.75×105 (HCT15) and 1.0×105 (CO115) cells/ml. Incubations for 
48 h with different concentrations of the water extracts were performed for MTT and 
TUNEL analysis, and for 24 h and 48 h for western blot. 
 
Preparation of HA extract 
 Plant of Hypericum androsaemum (HA) was cultivated at Canidelo, Northern of 
Portugal, in a farm owned by Cantinho das Aromaticas Lda., whereas Hypericum 
perforatum (HP) and Hypericum undulatum (HU) were obtained from Mapprod Lda., 
Braga, Portugal; plants are kept in active bank under the responsibility of the respective 
companies. The aerial parts of the plants were collected in July 2008 for HA and HU, 
and in July 2009 for HP; then, they were air-dried before being subjected to the water 
extraction by infusion. Batches of dried plant material are maintained at -20 ºC under 
the responsibility of CITAB with the accession numbers HA102008, HP072009 and 
HU122008, for HA, HP and HU, respectively. The plant infusions were prepared by 
pouring 150 ml of boiling deionized water onto 2 g of air-dried plant material and 
allowing it to steep for 5 min. After filtering, the water extracts were lyophilized to 
dryness and yields in terms of initial crude plant material dry weight of 27.0% (w/w), 
16.7% (w/w) and 13.0% (w/w), for HA, HP and HU, respectively, were obtained. 
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Phenolic compounds were analyzed by HPLC as previously performed [23] and, for 
HA, a similar composition with a previous report of a water extract was obtained [26]. 
The main phenolic compounds found in the plant water extracts differ in quantity 
between them. The following compounds are present. In HA: chlorogenic acid (CA) 
and isomer (3-O and 5-O-caffeoylquinic acid; 53.82 µg/mg), quercetin 3-galactoside 
(16.35 µg/mg), quercetin 3-glucoside (5.41 µg/mg), quercetin 3-rutinoside (2.73 µg/mg) 
and quercetin (1.32 µg/mg). In HU: quercetin 3-galactoside (34.12 µg/mg), quercetin 3-
glucoside (21.70 µg/mg), chlorogenic acid (CA) and isomer (3-O and 5-O-
caffeoylquinic acid; 14.85 µg/mg), quercetin (4.97 µg/mg), quercetin 3-rhamnoside 
(1.97 µg/mg), amenthoflavone (0.30 µg/mg) and hypericin (0.03 µg/mg). In HP: 
quercetin 3-rutinoside (38.07 µg/mg), quercetin 3-galactoside (16.00 µg/mg), quercetin 
3-glucoside (6.47 µg/mg), chlorogenic acid (CA) and isomer (3-O and 5-O-
caffeoylquinic acid; 5.75 µg/mg), quercetin (3.39 µg/mg), quercetin 3-rhamnoside (0.24 
µg/mg), amenthoflavone (0.33 µg/mg) and hypericin (0.03 µg/mg). CA is much more 
abundant in HA water extract than in the other two species where quercetin and related 
compounds are the most representative. 
 
Cell proliferation/viability assay 
MTT reduction assay was used as previously described [32]. Cells were treated 
with different concentrations of water extracts and CA for 46 h followed by two hours 
in the presence of MTT (final concentration 0.5 mg/ml). Hydrogen chloride 0.04 M in 
isopropanol was then used to dissolve the formazan crystals. The number of viable cells 
in each well was estimated by spectrophotometry. Results are presented as mean ± SEM 
of at least three independent experiments. 
 
Assessment of apoptosis by TUNEL assay 
 Cells treated with different concentrations of HA for 48 h were collected (both 
floating and attached cells) and fixed with 4% paraformaldehyde for 15 min at room 
temperature and then attached into a polylysine treated slide using a Shandon Cytospin 
4 (Thermo Scientific, Waltham, MA, USA). Cells were washed in PBS and 
permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. TUNEL 
(TdT mediated dUTP Nick End Labelling) assay was performed using a kit from Roche 
(Mannheim, Germany), following the manufacturer’s instructions. Cells were incubated 
with Hoechst for nuclei staining. The percentage of apoptotic cells was calculated from 
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the ratio between TUNEL positive cells and total number of cells (nuclei staining with 
Hoechst), from a count higher than 500 cells per slide under a fluorescent microscope. 
Results are presented as mean ± SEM of at least three independent experiments. 
 
Protein extraction and western blot 
 After incubation periods, cells were first washed with PBS and then lysed for 15 
min at 4 ºC with ice-cold RIPA buffer (1% NP-40 in 150 mM NaCl, 50 mM Tris (pH 
7.5), 2 mM EDTA), supplemented with 20 mM NaF, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 20 mM Na2V3O4 and protease inhibitor cocktail (Roche, Mannheim, 
Germany). Protein concentration was quantified using a Bio-Rad DC protein assay 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) with BSA as a protein standard. 
Twenty micrograms of protein from each sample were separated by SDS gel 
electrophoresis and then electroblotted to a Hybond-P polyvinylidene difluoride 
membrane (GE Healthcare). Membranes were blocked in TPBS (PBS with 0.05% 
Tween-20) containing 5% (w/v) non-fat dry milk or BSA, incubated with the primary 
antibody followed by the secondary antibody conjugated with IgG horseradish 
peroxidase. Immunoreactive bands were detected using the Immobilon solutions 
(Millipore, Billerica, MA, USA) under a chemiluminescence detection system, the 
Chemi Doc XRS (Bio-Rad Laboratories, Inc.). Band area intensity was quantified using 
the Quantity One software from Bio-Rad. β-actin was used as a loading control. Results 
are presented as mean ± SEM of at least three independent experiments.  
 
Statistical analysis 
 Student’s t-test or one-way ANOVA followed by the Student-Newman-Keuls 
test was used to perform statistical analysis for TUNEL and western blot data. 
GraphPad Prism 4.0 software (San Diego, CA, USA) was used and P-values ≤ 0.05 
were considered statistically significant.  
 
Results  
 
Anticarcinogenic effects of three Hypericum species  
 The effects of water extracts from H. undulatum, H. perforatum and H.  
androsaemum on cell viability/proliferation, in HCT15 and CO115 human colon 
carcinoma-derived cell lines, were investigated using the MTT assay. As shown in 
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Figure 1A, HCT15 cells were more resistant to HU extract than CO115 cells, while 
having the same sensitivity to the HP extract. However, effects on cell viability of both 
cell lines incubated with HU and HP were only observed from concentrations above  
200 µg/ml. The HA extract was the most efficient in inhibiting cell proliferation in a 
concentration-dependent manner in both cell lines, with an IC50 (the concentration that 
inhibited cell growth by 50%) of around 85 µg/ml in HCT15 and 65 µg/ml in CO115 
cells. The higher concentration tested of HA in HCT15 cells induced cell death by 
necrosis (negative value in Fig. 1A). Incubation of CRC cells with HA also significantly 
induced apoptosis in a concentration-dependent manner in both cell lines (Figure 1B). 
HA was the only extract with anticarcinogenic potential in CRC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effects of different 
concentrations of water extracts of 
Hypericum undulatum, Hypericum 
perforatum and Hypericum androsaemum 
on cell viability/proliferation assessed by 
MTT reduction (A). Effect of Hypericum 
androsaemum on apoptosis assessed by 
TUNEL assay (B), for 48 h, in HCT15 and 
CO115 cells. Values are mean ± SEM of at 
least 3 independent experiments. ** P≤ 0.01 
and *** P≤ 0.001 when compared to 
control. In A: line represents the inhibition 
of 50% of cell proliferation (IC50); the 
negative value mean that the cells reduction 
capacity after 48 h in that condition was 
below than the one obtained in the control in 
the beginning of the treatment period (0 h), 
being a indirect indication of cell death by 
necrosis. 
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In order to characterize effects of HA on signaling pathways related to 
proliferation and/or apoptosis, the IC50 concentration for each cell line (85 µg/ml for 
HCT15 and 65 µg/ml for CO115) and a concentration below this were used and the 
effects on the levels of relevant molecular targets followed in subsequent experiments 
by western blot.  
 
Effect of chlorogenic acid (CA) on cell proliferation  
 H. androsaemum was the most efficient plant water extract in inhibiting cell 
growth in HCT15 and CO115 CRC cell lines. In an attempt to find the compound 
responsible for these effects, the main phenolic present in this extract, chlorogenic acid 
(CA), which also distinguishes this extract from those of the other two plants, was 
evaluated individually at different concentrations, using MTT assay. CA is present at 
about 54 µg/mg in HA water extract, while in HU and HP CA is present in smaller 
amounts (about 15 and 6 µg/mg, respectively). No effects were observed on cell 
proliferation in both cell lines treated with CA up to 200 µM, which corresponds to a 
concentration 20 times higher than the one found in 100 µg/ml of HA (Figure 2). It 
seems therefore that the inhibition of cell proliferation produced by HA is not due to 
CA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of different concentrations of chlorogenic acid on cell viability/proliferation assessed by 
MTT reduction. 
 
Effects of HA on PI3K/Akt and MAPK/ERK pathways  
Constitutive activations of MAPK/ERK and PI3K/Akt pathways are present in a 
large number of CRC cases, leading to an increase of proliferation and an inhibition of 
apoptosis [3]. Phosphorylation of ERK and Akt, respectively, are indicators of their 
activation. As shown in Figure 3A, HA significantly decreased phospho-Akt protein 
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level in CO115 cells, in a concentration-dependent manner, after 24 h of incubation. 
This effect was not observed in HCT15 since there were no detectable amounts of 
phospho-Akt in these cells (data not shown), which is in agreement with previous 
observations [32]. As expected, reference inhibitors of PI3K, wortmannin (W) and LY-
294,002 (LY), also significantly decreased phospho-Akt levels. The effect of HA on 
phospho-PTEN, a negative regulator of PI3K/Akt pathway, was also tested. As shown 
in Figure 3B, HA did not change phospho-PTEN levels in HCT15 cells. As previously 
reported [32], no detectable expression of PTEN was observed in CO115 cells (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effects of Hypericum androsaemum (HA) for 24 h on the levels of phospho-Akt in CO115 cells 
(A), phospho-PTEN in HCT15 cells (B) and phospho-ERK in HCT15 and CO115 cells (C) at 85 µg/ml 
(HA85), 65 µg/ml (HA65) and 45 µg/ml (HA45), using western blot. β-Actin was used as loading 
control. Wortmannin 1 µM (W1) and LY-294,002 20 µM (LY20) were used as a reference inhibitor of 
PI3K and PD-98059 50 µM (PD50) was used as a reference inhibitor of phospho-ERK. Values are mean 
± SEM of at least 3 independent experiments. * P≤ 0.05,  ** P≤ 0.01 and *** P≤ 0.001 when compared to 
control.  
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Concerning effects on the MAPK/ERK pathway, a significant decrease in 
phospho-ERK protein level was observed in CO115 cells, but not in HCT15, induced by 
the higher concentration of HA tested (Figure 3C). As expected, a significant reduction 
of phospho-ERK levels in both cell lines was also induced by PD-98059 (PD), a 
reference inhibitor of the MAPK/ERK pathway. In addition, we also treated both cell 
lines with CA. This compound did not decrease phospho-Akt or phospho-ERK protein 
levels at 10 and 100 µM in both cell lines (data not shown). 
  
Effects of HA on BRAF and KRAS levels   
 Subsequently, since KRAS activates both MAPK/ERK and PI3K/Akt pathways 
and BRAF activates MAPK/ERK pathway, effects of HA on the protein expression of 
KRAS and BRAF oncogenes were studied. As shown in Figure 4A, the higher HA 
concentration tested was able to significantly decrease the levels of BRAF in CO115 
cells (cells with mutant BRAF), after 24 h. In HCT15 cells, which express the wild type 
BRAF, no effect of HA on BRAF protein expression was observed. No significant 
changes were observed in wild type or mutant KRAS levels induced by HA (Figure 
4B). CA did not change KRAS or BRAF levels at 10 and 100 µM in both cell lines 
(data not shown). 
 
 
Figure 4. Effects of Hypericum androsaemum (HA) for 24 h on BRAF (A) and KRAS (B) levels in 
HCT15 and CO115 cells at 85 µg/ml (HA85), 65 µg/ml (HA65) and 45 µg/ml (HA45), using western 
blot. β-Actin was used as loading control. Values are mean ± SEM of at least 3 independent experiments. 
* P≤ 0.05 when compared to control. 
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Effects of HA on p38 and JNK pathways  
 The effect of HA on p38 and JNK signalling pathways, two stress-activated 
protein kinases that are involved in the control of proliferation and induction of 
apoptosis [10], were also studied. Our results show a remarkable induction of phospho-
p38 expression at both concentrations tested and of phospho-JNK expression mainly at 
the higher concentration tested after 48 h in both cell lines (Figure 5A and 5B).  
 
Effects of HA on Caspase-3 and PARP-1 
 In order to verify the role of caspase activation on the apoptotic effect of the 
extract HA, we studied caspase-3 and Poly (ADP-ribose) polymerase-1 (PARP-1) 
expressions by western blot. As shown in Figure 5C, HA water extract increased 
cleaved caspase-3 and cleaved PARP-1 in CO115 cells. In HCT15, we did not observe 
cleaved caspase-3 or cleaved PARP-1, although a decrease in total PARP-1 was 
detected. A higher expression level of total PARP-1 was observed in HCT15 as 
compared to CO115 cells. The cleavage of caspase-3 and PARP-1 were also induced by 
staurosporine, an apoptotic inducer used here as positive control, in both cell lines (data 
not shown).   
 
 
 
 
 
 
Figure 5. Effects of Hypericum androsaemum (HA) for 48 h on the levels of phospho-p38 (A), phospho-
JNK (B) and caspase-3 and PARP-1 (C)  in HCT15 and CO115 cells at 85 µg/ml (HA85), 65 µg/ml 
(HA65) and 45 µg/ml (HA45), using western blot. β-Actin was used as loading control. Images are 
representative of at least 3 independent experiments.  
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Figure 6. Proposed model for the inhibition of cell proliferation and induction of apoptosis in colon 
cancer cells by Hypericum androsaemum (HA), in particular with effects on PI3K/Akt, MAPK/ERK, 
JNK and p38 signaling pathways. The anticarcinogenic effect of HA could be due to an inhibition of 
PI3K/Akt pathway, a decrease on BRAF mutation leading to an inhibition of MAPK/ERK pathway and 
an induction of both p38 and JNK signalling.  
 
Discussion 
 
 In the present study, the potential anticarcinogenic effects of water extracts of 
the medicinal plants H. androsaemum, H. perforatum and H. undulatum, as well as, the 
main phenolic constituent present in HA extract, chlorogenic acid (CA), were studied in 
vitro using HCT15 and CO115 human colorectal-derived cell lines. The extracts HU 
and HP did not show significant effects on cell viability in both cell lines. Previously we 
showed that quercetin has antiproliferative effects on these colorectal cancer cells [32], 
and since HU and HP water extracts are rich in quercetin and related compounds, these 
results were somewhat surprising. On the other hand, HA efficiently inhibited cell 
proliferation and induced apoptosis in a concentration-dependent manner in both cell 
lines. CO115 cells showed to be more sensitive to HA extract (IC50 ~65 µg/ml) when 
compared with HCT15 cells (IC50 ~85 µg/ml). As far as we know, this is the first report 
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of the anticarcinogenic effect of H. androsaemum, which is popularly used to treat 
problems of the gastrointestinal tract. Anticarcinogenic activities have been found for H. 
perforatum in other cell types [16-19] and related with one of its main constituents, 
hypericin [20-22], which is present in HP and HU water extracts (although at very small 
amounts) but not in the water extract of H. androsaemum [35]. These results suggest 
that the anticarcinogenic effects observed for HA reflect the presence of other 
compounds in this species. We, therefore, studied the antiproliferative effect of the CA, 
which is abundant in HA and present only in small amounts in HP and HU. However, 
this compound did not have any effect on cell proliferation in neither of the cell lines at 
the concentrations tested.  
The differences on genetic background of the two cell lines used allowed the 
study of the relevance of KRAS mutation versus BRAF mutation for HA’s effects. In 
CO115 cells (that harbour a BRAF mutation and overexpress Akt) a significant 
decrease of phospho-Akt expression was observed in a concentration-dependent 
manner. HA had no effect on PTEN, the endogenous inhibitor of PI3K, in HCT15 cells. 
These results show the ability of HA to decrease PI3K/Akt signalling probably by 
inhibiting PI3K activity, as happens with the inhibitors W and LY, and have also been 
shown for some flavonoids, such as quercetin [32, 36, 37]. HA was also able to decrease 
MAPK/ERK signalling in CO115 cells, as shown by a significant decrease in the 
phospho-ERK expression levels, an effect also observed with the inhibitor PD [38]. 
Importantly, HA also decreased BRAF expression in these cells. Since HA did not 
affect the expression of phospho-ERK or BRAF in HCT15, our results indicate that the 
HA water extract only affects mutant BRAF. Previous studies have shown that 
pharmacologic inhibition of RAF is highly effective at inhibiting the growth of BRAF 
mutant CRC cells [39]. Moreover, recent reports found that RAF inhibitors block 
MAPK signalling in tumor cells harbouring mutant BRAF but activate RAF-MEK-ERK 
pathway in cells harbouring wild-type BRAF, indicating the importance to inhibit 
specifically mutant BRAF to avoid secondary effects [40, 41]. It seems that the 
anticarcinogenic effects of HA in CO115 cells are, at least in part, related to an 
inhibition of PI3K/Akt and MAPK/ERK pathways, and the latter effect is associated 
with decreased levels of mutant BRAF (Figure 5). CA, the main phenolic compound 
present in HA water extract, has no effect on levels of phospho-Akt, phospho-ERK and 
BRAF in CO115 cells. 
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Regarding the RAS oncogene, no changes on the levels of KRAS induced by 
HA extract were observed in neither of the cell lines. Previously, we have shown that 
quercetin, at around 20µM, inhibits the proliferation of these cell lines in association 
with a decrease in KRAS levels [32]. Although the HA extract contains quercetin and 
glycosides of quercetin, their concentrations are low (less than 5µM), which may 
explain the lack of effect on KRAS. Mainly in the HCT15 cells that harbour the KRAS 
activating mutation, the HA-induced inhibition of cell proliferation and increased 
apoptosis seems to not result from effects on MAPK/ERK or PI3K/Akt pathways. Since 
no effect on cell proliferation was observed for CA when tested individually, other 
compounds or a synergism between the compounds present in the water extract of HA 
may be responsible for the inhibitory effects observed. Studies with CA in skin cancer 
have shown that this phenolic acid has an anti-inflammatory effect, interfering with NF-
kβ activation and COX-2 activity, and has an inhibitory effect on skin cancer promotion 
[42, 43]. However, studies in CRC agree with our results where no effect on colonic cell 
proliferation has been observed for CA [43, 44]. 
The effect of HA on two other major MAPK pathways, the p38 and JNK, were 
also studied, since these stress-activated kinases are also involved in the control of 
proliferation and/or apoptosis. HA significantly induced the phosphorylation of p38 and 
JNK in both cell lines (Figure 5). HA could act on an upstream regulator of both 
pathways which could explain, at least in part, the anticarcinogenic activity [10, 45] of 
HA in these cells, and in particular in HCT15 cells. An induction of caspase-3 and Poly 
(ADP-ribose) polymerase-1 (PARP-1) cleavage was also observed in CO115 cells when 
incubated with HA. The induction of JNK by the extract may contribute to the 
activation of the mitochondrial caspase cascade [12] and lead to the high levels of 
apoptosis observed in these cells. On other hand, in HCT15 cleavage of caspase-3 or 
PARP-1 were not observed despite the induction of JNK. In fact, these cells showed to 
be more resistant to apoptosis. Also in a previous studied [32], the ability of quercetin to 
induce apoptosis in HCT15 cells was weak, and independent of caspase induction. The 
p53 mutation in HCT15 cells [33] may explain the high apoptosis resistance of these 
cells [46, 47]. In HCT15, the antiproliferative effect of HA is much more relevant then 
the effect on apoptosis, which suggests that effects on cell cycle could be involved 
through induction of p38 [10].  
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Conclusion 
Our study shows that the water extract of H. androsaemum inhibits cell 
proliferation and induces apoptosis in CRC-derived cell lines more efficiently than H. 
perforatum, the most well known Hypericum species. The effects of HA may partially 
result from a specific inhibition of mutant BRAF, which leads to an inhibition of 
MAPK/ERK pathway only in BRAF mutant cells. Inhibition of PI3K/Akt pathway, as 
well as, an induction of both p38 and JNK pathways may also contribute to the 
anticarcinogenic activity of HA. Chlorogenic acid, the main phenolic compound present 
in the HA extract, seems not to be responsible for the anticarcinogenic effects observed. 
These data add H. androsaemum to the list of potential plants used in dietary strategies 
for the control of CRC progression and, as source of anticarcinogenic compounds. 
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ABSTRACT 
 
KRAS and BRAF mutations are frequent in colorectal carcinoma (CRC) and have the poten- 
tial to activate proliferation and survival through MAPK/ERK and/or PI3K signalling path- 
ways. Because diet is one of the most important determinants of CRC incidence and 
progression, we studied the effects of  the dietary phytochemicals quercetin  (Q),  luteolin 
(L) and ursolic acid (UA) on  cell proliferation and apoptosis in two human CRC derived cell 
lines, HCT15 and CO115, harboring KRAS and BRAF activating mutations, respectively. In 
KRAS mutated HCT15 cells, Q and L significantly decreased ERK phosphorylation, whereas 
in BRAF mutated CO115 cells the three compounds decreased Akt phosphorylation but had 
no effect on phospho-ERK. Our findings show that these natural compounds have antipro- 
liferative and proapoptotic effects and simultaneously seem to act on KRAS and PI3K but 
not on BRAF. These results shed light on the molecular mechanisms of action of Q, L and 
UA and emphasize the potential of dietary choices for the control of CRC progression. 
. 
 
 
 
 
1. Introduction 
 
    Colorectal carcinoma (CRC) is  the third most common 
cancer worldwide. In particular sporadic CRC correspond- 
ing  to  70–80%  of total cases [1]  is influenced by  environ- 
mental  factors,  many  of   which  diet  related  [2].   The 
mitogen-activated protein kinase/extracellular signal-reg- 
ulated  kinase (MAPK/ERK)  and the phosphatidylinositol 
3-kinase (PI3K)/Akt are signalling pathways that have been 
implicated in oncogenic transformation in CRC. They  con- 
fer  a  proliferative phenotype  and resistance to  therapy 
which is  reflected in  low  patient  survival [3–7]. Compo- 
nents of  MAPK/ERK and PI3K/Akt   pathways  constitute, 
therefore, molecular targets for  anticancer strategies [8– 
 
 
 
 
10].  Mutations of either KRAS (32%) or  BRAF (14%) genes 
occur alternatively [11]  in CRC, causing activation of either 
MAPK/ERK and PI3K pathways or  MAPK/ERK pathway, 
respectively. Activation of  MAPK/ERK pathway  regulates 
the expression of a  large number of proteins involved in 
the  control of cell proliferation, differentiation and apopto- 
sis [4,12]. Activation of PI3K gene and inactivation of PTEN, 
common in  CRC, result in  overexpression of downstream 
targets, including Akt and PKC, which promote cell growth 
and rescue from apoptosis [13–17]. 
Epidemiological studies show that cancer incidence is 
inversely correlated with the consumption of diets rich  in 
fruits and vegetables [18].  Natural compounds present in  
the  diet, such  as   resveratrol and  curcumin have been 
shown to  be  protective against cancer, contributing to  de- 
crease cancer risk  and progression rate through their ef- 
fects  on   signalling pathways  related  to  proliferation and 
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apoptosis [18,19]. Studies in  cell  lines and animal models 
have shown that flavonoids inhibit cell  proliferation and 
induce apoptosis in many types of cancer cells  through dif- 
ferent signalling pathways, which corroborate the sugges- 
tion that dietary choices may limit cancer progression [20– 
22].  Quercetin (Q) and luteolin (L) (Fig. 1)  are  two flavo- 
noids found in fruits, vegetables and aromatic plants with 
high antioxidant activity [23]  to  which anticancer proper- 
ties   in  CRC are  attributed [24–27]. In  addition, a  recent 
study  showed that  quercetin reduces the  formation of 
aberrant crypt foci  in  a rat colon cancer induction model, 
suggesting the importance of  this compound also  in  the 
prevention of colon cancer by decreasing cancer initiating 
events [28].  Although structurally related, the absence of 
the hydroxyl group at position 3 of L renders it more lipo- 
philic than Q which may confer better access to intracellu- 
lar targets. In agreement with this, we have previously 
shown that L  is  a  more potent intracellular antioxidant 
than Q, and that this was  related with its higher lipophilic- 
ity  [23].  Ursolic acid  (UA; Fig. 1), a natural pentacyclic tri- 
terpenoid  carboxylic acid,   present ubiquitously in  plant 
foods and  also   a  major constituent  in  some  medicinal 
plants possesses a wide range of biological activities, such 
as hepatoprotective and anti-inflammatory combined with 
low  toxicity [29–31]. However, contrarily to Q and L, UA is 
not   an  antioxidant at relevant cellular redox conditions 
[32].   Antitumor properties  have also   been attributed to 
UA and in colon cancer cells  UA has  been shown to induce 
apoptosis and inhibit proliferation [33–35]. Although po- 
tential  effects on   proliferation  have  been  described  for 
these three  compounds their effects on  MAPK/ERK and 
PI3K pathways have not  been established. 
In spite of the general benefit of plant rich  diets, varia- 
tion in  cancer incidence among individuals with similar 
dietary habits suggests interactions of  food  constituents 
with genetic factors [2,18]. In the present study we  report 
on  the effects of Q, L and UA on  two human derived cell 
lines which harbor different oncogene activating muta- 
tions, representative  of  a  large number  of  CRC: HCT15 
has  a  KRAS (G13D)  mutation [36]  whereas CO115  has  a 
BRAF (V599E)  mutation [37].  These mutations impact on 
MAPK/ERK and PI3K  pathways.  The relevance of  effects 
on  both these pathways for  successful cancer treatment 
has  recently been emphasized [38].  CRC remains a human 
malignant tumor often resistant to available treatment and 
knowledge of anticancer properties of dietary constituents 
may guide dietary choices for cancer patients with partic- 
ular genetic backgrounds and possibly also  suggest their 
use  in combination with conventional therapy in order to 
enhance therapeutic effects [39,40]. 
 
2.  Material and methods 
 
2.1.  Reagents and  antibodies 
 
Quercetin (Q), ursolic acid (UA), wortmannin (W) and 3- 
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- 
mide (MTT) were purchased from Sigma– Aldrich (St. Louis, 
MO,  USA). Luteolin (L)  was   from Extrasynthese  (Genay, 
France) and PD-98059 (PD)  from Calbiochem (San  Diego, 
CA). All other reagents and chemicals used were of analyt- 
ical grade. Stock  solutions of Q, L and UA were made in di- 
methyl sulfoxide (DMSO) and aliquots kept at —20 °C. 
Primary antibodies were purchased from the following 
sources: Cell Signaling (Danvers, MA, USA) the anti-p44/ 
42  MAPK (ERK1/2)  total, anti-phospho-Akt (Ser473), anti- 
Akt   total,  anti-phospho-PTEN (Ser380/Thr382/383)  and 
anti-PTEN total; Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA, USA) the anti-phospho-ERK1/2, Raf-B and K-Ras;  and 
Sigma–Aldrich the anti-b-actin. Secondary antibodies HRP 
donkey anti-rabbit and sheep anti-mouse were purchased 
from GE Healthcare (Bucks, UK). 
 
2.2.  Cell culture 
 
HCT15 and CO115  human colon carcinoma-derived cell 
lines were maintained at 37 °C in  a  humidified 5% CO2 
atmosphere in  RPMI-1640 medium  (Sigma– Aldrich) sup- 
plemented with 10 mM  HEPES, 0.1 mM  pyruvate, 1% anti- 
biotic/antimycotic solution (Sigma–Aldrich) and 10% fetal 
bovine serum (FBS; EU standard, Lonza, Ver viers, Belgium). 
Cells were seeded onto six  (2 ml)  and twelve (1 ml)  well 
plates at a  density of  0.75  x 105 (HCT15)  and 1.0 x 105 
(CO115) cells/ml.  Incubations  with  different  concentra- 
tions of test compounds were made in serum free  medium 
for 48 h for MTT test, BrdU incorporation and TUNEL assay, 
and for  24 h (Akt,  ERK and PTEN) or  6 h (BRAF and KRAS) 
for western blot  analysis. 
 
2.3.  Assessment of cell toxicity/proliferation by MTT reduction 
test 
 
A MTT reduction assay was  performed in order to select 
concentrations of the test compounds that were not  cyto- 
toxic and  significantly inhibited  cell   proliferation.  Cells 
were treated with test compounds for  46 h before the 2 h 
incubation  with  MTT   (final  concentration  0.5 mg/ml). 
Hydrogen chloride 0.04 M in  isopropanol was  then added 
to  dissolve the formazan crystals. The number of  viable 
cells  in each well  was  estimated by the cell capacity to re- 
duce MTT. The  results were expressed as percentage rela- 
 
 
 
Fig.  1.  Chemical structures of quercetin (Q),  luteolin (L) and ursolic acid (UA). 
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tive  to the control (cells without any  test compound). MTT 
reduction at the beginning of incubation (t = 0 h) was  sub- 
tracted from all  the experimental conditions used above, 
including the control. Since  the effects of the compounds 
were studied after 48 h of incubation and cells  grow signif- 
icantly within this time period, the point at the beginning 
of the incubation allows to distinguish between cell  death 
and inhibition of proliferation. MTT negative values indi- 
cate necrotic cell death due to cytotoxicity. Values between 
0% and 100% indicate inhibition of cell  proliferation. 
 
2.4.  Assessment of proliferation by BrdU incorporation 
 
After 45 h of treatment with test compounds at the cho- 
sen concentrations, cells  were incubated with bromode- 
oxyuridine 10 µ M (BrdU;  Sigma– Aldrich) for  another 3 h. 
Both  adherent and non-adherent cells  were collected from 
each sample, fixed with 4% paraformaldehyde for 15 min at 
room temperature and attached into a polylysine treated 
slide using a  Shandon Cytospin (Thermo Fisher Scientific 
Inc, Waltham MA, USA). 
Cells  were incubated with HCl 2 M for  20 min,  washed 
in  PBS containing 0.5% Tween-20 and 0.05% BSA (TPBS-B) 
and  then  incubated  with  monoclonal mouse  anti-BrdU 
antibody (DakoCytomation, Glostrup, Denmark) for  1 h at 
room temperature.  After   washing in  TPBS-B, cells   were 
incubated with anti-mouse IgG FITC conjugated secondary 
antibody  (Sigma–Aldrich) for  1 h  at room temperature, 
washed again and then incubated with Hoechst for  nuclei 
staining. The  percentage of  proliferating cells  was  calcu- 
lated as the ratio between BrdU positive cells  and total cell 
number (nuclei staining with Hoechst) from a count higher 
than 500  cells  per  slide under a fluorescence microscope. 
Results are  presented as mean ± SEM of at least three inde- 
pendent experiments. 
 
2.5.  Assessment of apoptosis by TUNEL assay 
 
Cells  treated with the test compounds at chosen con- 
centrations for  48 h  were collected (both floating and at- 
tached  cells) and  fixed  with  4%  paraformaldehyde  for 
15 min at room temperature and attached to  a polylysine 
treated slide using a Shandon Cytospin. Cells were washed 
in  PBS and permeabilized with 0.1% Triton X-100 in  0.1% 
sodium citrate  for  2 min on   ice.  TUNEL (TdT  mediated 
dUTP  Nick  End  Labelling) assay  was   performed using a 
kit from Roche  (Mannheim, Germany), follo wing the man- 
ufacture’s instructions. Cells were incubated with Hoechst 
for  nuclei staining. The  percentage of apoptotic cells  was 
calculated from the  ratio between TUNEL positive  cells 
and total number of cells  (nuclei staining with Hoechst), 
from a count higher than 500  cells  per  slide under a fluo- 
rescence microscope. Results are  presented as mean ± SEM 
of at least three independent experiments. 
 
2.6.  Protein extraction and  western blotting 
 
After treatment with the chosen concentration of test 
compounds,  cells   were washed with PBS and  lysed for 
15 min at 4 °C  with ice  cold   RIPA buffer (1%  NP-40 in 
150  mM  NaCl, 50 mM  Tris  (pH  7.5),  2 mM  EDTA), supple- 
 
mented with 20 mM NaF, 1 mM phenylmethylsulfonyl fluo- 
ride (PMSF), 20 mM Na2 V3O4 and protease inhibitor cocktail 
(Roche, Mannheim, Germany). Protein concentration was 
quantified using a Bio-Rad  DC protein assay (Bio-Rad Labo- 
ratories, Inc., Hercules, CA, USA) and BSA used as a protein 
standard. Twenty micrograms of total protein from each cell 
lysate were separated by SDS gel electrophoresis and then 
electroblotted  to   a  Hybond-P polyvinylidene difluoride 
membrane (GE Healthcare). Membranes were blocked in 
TPBS (PBS with 0.05% Tween-20) containing 5% (w/v) non- 
fat dry milk or BSA (bovine serum albumin), washed in TPBS 
and then incubated with primary antibody. After  washing, 
membranes were incubated with secondary antibody con- 
jugated with IgG horseradish peroxidase and immunoreac- 
tive  bands were detected using the Immobilon solutions 
(Millipore, Billerica, MA, USA) under a chemiluminescence 
detection system, the Chemi Doc XRS (Bio-Rad Laboratories, 
Inc.). Band area intensity was  quantified using the Quantity 
One software from Bio-Rad. b-actin was used as loading con- 
trol.  Results are  presented as mean ± SEM of at least three 
independent experiments. 
 
2.7.  Statistical analysis 
 
One-way ANOVA followed by  the Student-Newman– 
Keuls  test was  used to  perform statistical analysis, using 
GraphPad Prism 4.0  software (San  Diego,  CA, USA), and P- 
values ≤ 0.05  were considered statistically significant. 
 
3.  Results 
 
3.1.  Effects  of Q, L and UA on  cell  p ro life rat ion  
 
In order to choose doses that do not cause significant toxicity (necro- 
sis) and have antiproliferative effects on the two human CRC derived cell 
lines , HCT 15 and CO 11 5, a MTT assay was performed with different con- 
centrations of the test compounds. The  results showed that necrotic cell 
death  (negative values in Fig.   2)  occurred  in  HCT15 cells with  L  at 
20 µM and in CO115 with UA at 15 µM. All the test compounds inhibited 
cell proliferation in a concentration-dependent  manner in both cell lines 
as shown by  MTT  assay (Fig.  2). Both reference inhibitors, wortmannin 
(W) and PD-98059 (PD),  at the higher tested concentration did not induce 
cell toxicity. Based on MTT results, three concentrations of Q, L and UA (2 
in case of CO1 15 ce lls ) that inhibited cell proliferation without significant 
toxic effects, were selected and used in the following BrdU and TUNEL 
assays. 
For the BrdU incorporation assay, cells were treated with compounds 
for  48 h.  As shown in Fig.  3, a significant inhibition of  proliferation indi- 
cated by  lower levels of  BrdU incorporation  was observed for  Q,  L and 
UA in both cell lines, in a dose dependent manner. In HCT15 ce lls , the lev- 
els  of  BrdU incorporation  decreased  from 22.0%  in  the   cont ro l  t o  5.2% , 
3.4%  and 9.8%  in cells treated  with Q  20 µM,  L 15 µM  and UA  4 µM , 
respectively (Fig.  3a). In  CO115 cells,  the percentage of  cell proliferation 
significantly decreased  from 19.1%   in the  control to 3.8%,  11.1%   and 
10.2%  in cells treated with Q 15 µM, L 12 µM and UA 10 µM , respectively 
(Fig. 3b). The  structurally-related flavonoids, Q and L, showed different re- 
sponses in the two cell lines: L was a stronger proliferation inhibitor in 
HCT15 than  in CO115, whereas  Q was more effective in CO115 than in 
HCT15. The   reference inhibitors, W,  a PI3K  inhibitor, and PD,  a phos- 
pho-ERK inhibitor,   significantly  inhibited  cell  proliferation  in  HCT15 
and CO115 cells, respectively (Fig.  3). 
 
3.2.  Effects  of Q, L and UA on  apoptos is  
 
The ability of the test compounds to induce apoptosis was addressed 
by the TUNEL assay. As shown in Fig.  4, all compounds significantly in- 
duced  apoptosis  in  both  HCT15 and  CO115 cells. Apoptotic cells in 
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Fig.  2.  Effect of  treatment with different concentrations of  quercetin (Q),  luteolin (L) and ursolic acid (UA)  for  48 h 
on MTT  reduction in HCT15 (a)  and CO115 (b)  cells. Wortmannin  (W) and PD-98059 (PD)  were used as reference 
inhibitors of  PI3K/Akt and MAPK/ERK  pathways, respectively. Values are mean ± SEM  of at least three independent 
experiments. *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001 when compared to control.  
 
 
HCT15 increased from 0.3% in the control to 4.4%, 3.9% and 6.6% in cells 
treated  with  the  higher concentrations of   Q,  L  and UA,  respectively 
(Fig. 4a). In CO115 cells, apoptotic cells increased from 1.9% in the control 
to 36.2%,  15.1%  and 12.4%  in cells treated with the higher concentrations 
of Q, L and UA, respectively (Fig. 4b). Between the two flavonoids, Q seems 
to be a more potent inducer of apoptosis in both cell lines compared to L. 
In  addition, UA sho wed  t o be th e  most  e ffect ive  in  HCT1 5, where it in- 
duced 20 times more apoptosis at 4 µM when compared with control.  
 
3.3.  Effects  of Q, L and UA on  ERK phosphorylation 
 
Activation of MAPK/ERK pathway is representative of a large number  
of CRC cases and the phosphorylation of ERK is an indicator of this activa- 
tion. We observed high levels of  phospho-ERK in both cell lines (Fig.  5). 
Incubations with L (15 µM ) and Q (20 µM ) significantly decreased phos- 
pho-ERK protein  level in HCT15 cells (Fig.  5a), but not in CO115 cells,  
while UA did not have any effect on either of  the cell lines (Fig.  5a and 
b).  A significant reduction of  phospho -ER K by  PD,  a reference inhibitor 
of  MAPK/ERK  pathway, was observed in both cell lines. Interestingly, L 
was a stronger inhibitor of ERK in HCT15 ce lls  than the reference inhibitor 
PD and than the structure-related compound Q. 
 
3.4.  Effects  of Q, L and UA on  Akt phosphorylation 
 
Because MAPK/ERK  and PI3K/A kt pathways are both activated by RAS, 
we also checked if th e PI3K/A kt  pathway was affected by  the test com- 
pounds, measuring  phospho-Akt and phospho-PTEN expression  levels. 
In  HCT15 cells, there  were  no detectable  amounts  of  phospho-Akt, in 
incubations with and without serum (Fig.  6a). High expression  levels of 
phospho-PTEN were  detected  in HCT15 cells but  were  not  altered  by 
the  test  compounds (data  not  shown). In   CO115 cells, phospho-Akt 
expression was observed and significantly decreased by   Q  (15 µM ),  L 
(12 µM )  and UA (10 µM ),  as shown in Fig.  6b. Wortmannin, a reference 
PI3K   inhibitor,  also significantly decreased  Akt   phosphorylation, con- 
trarily to PD  that did not alter phospho-Akt levels in CO115 cells. Phos- 
pho-PTEN and total PTEN  expression were not observed in CO115 cells,  
in medium with and without serum, in contrast with what was observed 
with HCT15 cells (Fig.  6c ). The  lack of  phospho-Akt  in HCT15 and PTEN 
signal in CO115 cells was reproducible and checked in the presence of  a 
positive reactive sample (Fig.  6a and c).  These observations seem, there- 
fore, also not to be the  result of  protein degradation during protein 
extraction or sample preparation.  
 
3.5.  Effects  of Q, L and UA on  KRAS and BRAF exp ress ion  
 
To check if the effects of the test compounds reflect direct effects on 
KRAS or BRAF, expression of  these proteins was also monitored by  wes- 
tern blot. As shown in Fig. 7, Q and L remarkably decreased the expression 
of  KRAS but not BRAF in both cell lines. UA  significantly changed the 
expression of KRAS only in HCT15 ce lls , but not as efficiently as the flavo- 
noids. No  significant changes were induced by  UA in BRAF expression. 
 
4.  Discussion 
 
The effects of quercetin (Q), luteolin (L) and ursolic acid 
(UA), natural compounds common in  diets rich  in  fruits 
and vegetables, were studied in two different human colon 
carcinoma-derived  cell   lines representative  of  common 
CRC cases. We observed that the three test compounds, 
at concentrations that did not induce significant cell toxic- 
ity  (necrosis), inhibited proliferation and induced apopto- 
sis    in    both  cell    lines  in    a   concentration-dependent 
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Fig.  3.  Effect on cell proliferation of different concentrations of quercetin (Q), luteolin (L), ursolic acid (UA) and 
reference compounds, wortmannin (W) and PD-98059 (PD),  for  48 h in HCT15 (a)  and CO115 (b)  cells, using the 
BrdU incorporation  assay. Values are mean ± SEM  of  at least three independent experiments. *P ≤ 0.05, **P ≤ 0.01 
and ***P ≤ 0.001 when compared to control. 
 
 
 
manner. The  purpose of the present study was  to  identify 
in  HCT15  and CO115  cells  molecular targets for  Q, L and 
UA related with their antiproliferative and proapoptotic ef- 
fects.  HCT15 and CO115 have activating mutations of KRAS 
and BRAF, respectively. 
Q and L decreased the expression of phospho-ERK in the 
KRAS mutated HCT15 cell line  but not  in the BRAF mutated 
CO115  cell line.  These results suggest that the BRAF muta- 
tion in CO115  cells  overrides any  inhibitory effect of Q and 
L on  phospho-ERK, indicating that  these flavonoids act  on 
KRAS upstream of BRAF (Fig. 8). This was  further confirmed 
by  a decrease in  the expression of KRAS but not  BRAF  in- 
duced by both flavonoids. Our  findings corroborate recent 
reports where quercetin treatment resulted in a reduction 
of  Ras  protein levels in  colon cell  lines expressing onco- 
genic Ras [41,42]. A recent study in skin epidermal cell line, 
showed a different effect of quercetin, which in these cells 
inhibited both Raf and MEK activity [43].  In addition, we 
observed in HCT15 cells  that Q and L decreased phospho- 
ERK levels as efficiently as PD-98059 (PD), a specific inhib- 
itor  of MEK downstream of RAF [44].  Inhibition of prolifer- 
ation and induction of apoptosis by Q and L in HCT15 cells 
does however not  seem to  be  due to  phospho-ERK inhibi- 
tion alone since PD inhibited  phospho-ERK but was  with- 
out  effect on  cell  proliferation and induction of apoptosis. 
This  finding is  in  agreement with other reports [10,45], 
 
which showed that tumor cells  carrying KRAS mutation 
do  not   rely   only   on  MAPK/ERK pathway to  proliferate. 
Since  HCT15 cell  proliferation was  inhibited by  wortman- 
nin  (W), a PI3K inhibitor, it seems that inhibition of prolif- 
eration by Q and L treatment could be through inhibition of 
PI3K dependent pathways. Contrarily to  a previous report 
[46],  we  did  not  detect phospho-Akt in HCT15 cells,  which 
could be explained by the high levels of phospho-PTEN ob- 
served (Fig. 8). It is known that other downstream targets 
of  PI3K  besides Akt  also   contribute to  cell  proliferation 
and apoptosis, such as PKC, which is known to be inhibited 
by Q and L [47–51]. PKC isozymes have been shown to  be 
commonly deregulated in  colon cancer and other natural 
compounds, such as curcumin, have also  shown to  inhibit 
PKC in  CRC cells  [17].  Thus,  inhibition of  proliferation in 
HCT15 cells  by Q and L seems to be due to effects on KRAS, 
affecting not  only  the MAPK/ERK pathway but also  other 
alternative pathways, such as PI3K/PKC pathway. However, 
apoptosis induced by Q and L in HCT15 cells  does not  seem 
to  be  due to  inhibition of  PI3K, since W  did  not   induce 
apoptosis in this cell  line.  Other apoptotic targets of these 
compounds should be  considered. 
Studies have shown that BRAF mutated cell  lines rely 
more on  MAPK/ERK pathway for  proliferation than KRAS 
mutated cell  lines [10,45]. Ho wever, our  results show that 
the dependence of CO115  cells  on  MAPK/ERK pathway for 
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Fig.  4.  Effect on apoptosis of different concentrations of quercetin (Q), luteolin (L) and ursolic acid (UA) and reference 
compounds, wortmannin (W) and PD-98059 (PD),  for  48 h in HCT15 (a)  and CO115 (b)  cells, using the TUNEL assay. 
Values are mean ± SEM of at least three independent experiments. *P ≤ 0.05,**P 6 0.01 and ***P ≤ 0.001 when 
compared to control. 
 
 
 
 
 
Fig.  5.  Effects of  treatment with quercetin (Q),  luteolin (L) and ursolic acid (UA)  for  24 h on phospho-ERK 
expression  in HCT15 and CO115 cells, using western blot. β-Actin was used as loading control. (a)  HCT15 cells 
were treated with L 15 µM  (L15), Q 20 µM  (Q20) and UA 4 µM  (UA4) in serum free medium. (b)  CO115 cells were 
treated  with 12 µM L (L12), 15 µM Q (Q15) and 10 µM UA (UA10) in serum free medium. Wortmannin 1 µM (W1) 
and PD-98059 50 µM (PD50) were used as reference inhibitors of PI3K and MEK, respectively, in both cell lines. Values 
are mean ± SEM of at least three independent experiments. *P ≤ 0.05 and ***P ≤ 0.001 when compared to control. 
 
 
proliferation is not  exclusive, since all test compounds in- 
hibit  proliferation  without  affecting phospho-ERK levels. 
CO115  cells,  besides harboring a BRAF mutation, also  pres- 
ent high PI3K activity [52].  In agreement with this, a high 
expression of phospho-Akt was  observed while PTEN was 
not  detectable. Our   results show a significant decrease in 
phospho-Akt expression by  Q, L and UA. These suggest an 
inhibition of PI3K activity, in  addition to  an  inhibition  of 
KRAS (Fig.  8).  Several studies have shown that quercetin 
and analogs are  potent inhibitors of PI3K activity [53,54]. 
Ho we ver, W although inhibiting phospho-Akt, did  not  in- 
hibit proliferation or  induce apoptosis. The  effect of  the 
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Fig.  6.  Effects of treatment with quercetin (Q), luteolin (L) and ursolic acid (UA) for  24 h on phospho-Akt expression 
and phospho-PTEN levels in HCT15 and CO115 cells, using western blot. β-Actin was used as loading control. (a)  
HCT15 cells were cultured in medium without and containing 2% or 10% serum (FBS) and CO115 cells were cultured 
in serum free medium. (b)  CO115 cells were treated with UA 10 µM (UA10), Q 15 µM (Q15) and L 12 µM (L12) in 
serum free medium. Wortmannin 1 µM (W1) and PD-98059 50 µM (PD50) were used as reference inhibitors of PI3K 
and MEK, respectively. (c)  CO115 cells were cultured in medium without and containing 2% or 10% FBS and HCT15 
cells were cultured in serum free medium. Values are mean ± SEM of at least three independent experiments. ***P ≤ 
0.001 when compared to control. 
 
 
 
natural compounds on  PI3K may,  therefore, only  partially 
explain their antiproliferative and proapoptotic activities 
in  CO115  cells.  The  inhibition of  phospho-Akt and phos- 
pho-ERK by Q and L has  been reported in human hepatoma 
cell  line  (HepG2) and brain tumors [55–57]. 
Regarding UA, our   results show that this compound 
does not affect phospho-ERK expression, being only  effec- 
tive  in inhibiting phospho-Akt in CO115 cells. It seems that 
UA  does  not   affect significantly  KRAS (although it  de- 
creased expression levels in  HCT15  cells) and has  PI3K as 
one  of its  molecular targets. Interestingly, it was  the most 
efficient proliferation inhibitor and inducer of apoptosis in 
HCT15 cells,  which do not  express phospho-Akt. Contrarily 
to  the effects of  the antioxidants Q and L, the antitumor 
properties of  UA  through redox-sensitive pathways are 
most likely   not   the result of  its  reactive oxygen species 
scavenging ability, since it was  previously shown that UA 
is inactive as  free  radical scavenger [32].  Interestingly, all 
test compounds showed to  be  more efficient than the ref- 
erence compounds, PD and W, in  inhibiting cell  prolifera- 
tion   and   inducing  apoptosis.  Their    wider   range   of 
molecular targets is therefore advantageous in the control of 
tumor progression [26]  and the importance of modulat- ing  
several signal transduction pathways associated with 
carcinogenesis is once again reinforced. 
In summary, the antiproliferative and proapoptotic ef- 
fects of Q and L seem to  be,  at least in part, due to  effects on  
KRAS through regulation of both MAPK/ERK and  PI3K 
pathways. The  BRAF mutation overrides the compounds‘ 
inhibition of KRAS on  the MAPK/ERK pathway but not  on 
the PI3K pathway. UA seems to  act  on  PI3K where Q and L 
may also  act,  independently of KRAS mutation. The  re- 
sults of  this study suggest, therefore, the applicability of 
these phytochemicals in dietary strategies and as possible 
adjuvants in  CRC therapy both in  KRAS and BRAF gene 
mutation profiles. 
 
 
 
 
 
Fig.  7.  Effects of treatment with quercetin (Q), luteolin (L) and ursolic acid (UA) for 6 h on KRAS and BRAF expression in 
HCT15 (a)  and CO115 (b)  cells, using western blot. β-Actin was used as loading control. Images and values are 
representative of three independent experiments. 
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Fig.   8.  Schematic representation  of  possible targets  
of  quercetin  (Q), luteolin (L) and ursolic acid (UA) on 
MAPK/ERK  and PI3K/Akt pathways in HCT15 and  
CO115 cell  lines,  which  may  lead  to  inhibition  of   
cell proliferation and induction of apoptosis. 
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Abstract  
Background: Colorectal carcinoma (CRC) is a common cause of cancer-related death. 
Tumors with microsatellite instability (MSI) have been shown to be resistant to 
chemotherapy with 5-fluorouracil (5-FU), the most widely used pharmacological drug 
for CRC treatment. It is therefore essential to find compounds that could contribute to 
treatment efficacy through increases in sensitivity to this drug.  
Aim and Methods: In this study, we used two MSI human CRC derived cell lines, 
CO115 that is wild-type for p53 and HCT15 that harbors a p53 mutation. The sensitivity 
of these cells to 5-FU was evaluated and the effects on apoptosis induction of co-
incubation of the flavonoids, quercetin (Q) or luteolin (L), with 5-FU were performed 
using TUNEL assay. The mechanisms of apoptotis induction of these flavonoids were 
assessed by western blot. 
Results: Our results demonstrate that CO115 is more sensitive to 5-FU than the p53 
mutant HCT15. The two cell lines also responded differently to the induction of 
apoptosis by the flavonoids. Apoptosis induction was higher and dependent on caspase 
activation in CO115 cells but not in HCT15 cells. In HCT15 cells, Q and L had an 
additive effect on apoptosis when combined with 5-FU. Q was the most efficient 
compound in enhancing the apoptotic effect of 5-FU in CO115 cells where a synergistic 
effect was observed. This effect seems to involve the mitochondrial caspase pathway 
since a remarkable increase in the expression of cleaved caspase 9, caspase 3 and PARP 
and a decrease in Bcl-2 expression were observed. 
Conclusion: This study suggests the potential applicability of these phytochemicals, 
especially Q, for enhancement 5-FU efficiency in CRC therapy in resistant MSI p53 
wild-type cells. 
 
Keywords: Quercetin, Luteolin, Colorectal carcinoma, Apoptosis, 5-Fluorouracil 
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Introduction 
 
  Chemotherapy with 5-fluorouracil (5-FU) is the basis for treatment of colorectal 
carcinoma (CRC), which is the third most common form of cancer in developed 
countries [1]. However, significant resistance to this drug has been reported [2]. Drugs 
such as irinotecan and oxaliplatin are used in combination with 5-FU and have 
demonstrated increase treatment efficacy although not in all patients [3-5]. Genetic 
variability is one important factor that regulates the response and toxicity of a drug and 
should be taken in account when a therapy is chosen [5]. The enzyme thymidylate 
synthase (TS) is essential for the synthesis of deoxythymidine-5’-monophosphate, a 
precursor for DNA replication. An inhibition of this enzyme by the active metabolite of 
5-FU (5-fluoro-2 -´deoxyuridine-5´monophosphatate) is the main mechanism of 5-FU 
action, resulting in DNA strand breaks and inhibition of DNA synthesis, induction of 
apoptosis and cell cycle arrest [6]. A constitutive activation of TS contributes to 5-FU 
resistance in some tumors [5]. 
Mutations in mismatch repair (MMR) genes result in the inability of the MMR 
system to correct DNA replication errors leading to the accumulation of mutations and 
giving rise to microsatellite instability (MSI). Tumors presenting MSI occur 
approximately in 15% of patients with sporadic CRC and are generally associated with 
resistance to 5-FU [7-9] . In vitro studies have shown that DNA MMR deficiency may 
be responsible for tumor resistance to 5-FU and clinical evidence is suggestive of little 
or no benefit from 5-FU treatment in MSI patients [7,8]. Previous studies have also 
shown that mutations in the gene P53 contribute to 5-FU resistance in CRC and have 
profound effects on drug responses [10] with reduced induction of apoptosis and 
inhibition of cell cycle [11,12]. In agreement with this, prognosis in patients having an 
MSI tumor with p53 mutation have been shown to be poor compared to the ones with 
wild-type p53 [13].  
The induction of apoptosis by 5-FU occurs through both the intrinsic and 
extrinsic pathways with activation of caspases [14]. In the intrinsic pathway, Bcl-2 
family proteins modulate mitochondrial membrane permeabilization, which leads to the 
release of cytochrome c and activation of caspase-9 that in turn activates the effector 
caspase-3. Activation of death receptors on the cell membrane (extrinsic pathway), 
which subsequently activates caspase-8 and caspase-3, may also be induced by 5-FU 
[14].  
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The c-Jun N-terminal kinase (JNK) and p38 are two stress-activated protein 
kinases of the family of the mitogen activated protein kinase (MAPK) that have key 
roles in inflammation, in controlling cell proliferation, differentiation and apoptosis, and 
their effects appear to be largely dependent on cell type and/or cellular context [15-18]. 
They are activated by diverse cellular stresses, including UV irradiation, oxidative 
stress, DNA damage, heat and osmotic shock [15]. Several studies in CRC cells show 
the ability of some phytochemicals, such as silibinin, curcumin and flavones to induce 
apoptosis through different signalling pathways [19-21]. Some of these dietary 
phytochemicals to which anticarcinogenic effects have been attributed are involved in 
the modulation of JNK and p38 signalling [22,23]. 
Compounds that alter the expression of apoptotic proteins may, therefore, 
contribute to decrease tumor malignance and chemoresistance [23]. In our previous 
study, we showed that quercetin (Q) and luteolin (L), two flavonoids found in fruits and 
vegetables, have antiproliferative effects in HCT15 and CO115 human CRC cells 
through regulation of KRAS and both MAPK/ERK and PI3K pathways [24]. HCT15 
and CO115 are two cell lines derived from sporadic MSI CRC: HCT15 harbors a P53 
inactivating mutation whereas CO115 is wild-type for this gene [25,26]. In the present 
study, we investigate the ability of Q and L to induce apoptosis in these MSI CRC cell 
lines and their possible therapeutic enhancing effect when used in combination with the 
pharmaceutical drug 5-FU. Our data suggest a therapeutic potential of these 
phytochemicals in combination with 5-FU in CRC, particularly for Q, in the MSI p53 
wild-type background.  
 
Material and methods 
 
Reagents and antibodies 
 Quercetin (Q), z-VAD-fmk (zVAD), staurosporine (STS), 5-Fluorouracil (5-FU) 
and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Luteolin (L) was purchased from 
Extrasynthese (Genay, France). Stock solutions of test compounds were made in 
dimethyl sulfoxide (DMSO) and aliquots were kept at -20ºC. All other reagents and 
chemicals used were of analytical grade. 
 Primary antibodies were purchased to the following sources: anti-cleaved 
caspase-9 and anti-phospho-p38 MAPK (Thr180/Tyr182) to Cell Signaling (Danvers, 
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MA, USA); anti-caspase-3 to Calbiochem (San Diego, CA); anti-Bcl-2, anti-Bax, anti-
PARP-1, anti-phospho-JNK, anti-JNK, anti-p38 total and anti-p53 to Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA) and anti-β-actin to Sigma-Aldrich. 
Secondary antibodies HRP donkey anti-rabbit and sheep anti-mouse were purchased to 
GE Healthcare (Bucks, UK).   
 
Cell lines  
 HCT15 and CO115 human colon carcinoma-derived cell lines were maintained 
at 37ºC in a humidified 5% CO2 atmosphere in RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 10mM HEPES, 0.1mM pyruvate, 1% antibiotic/antimycotic solution 
(Sigma-Aldrich) and 10% fetal bovine serum (FBS; EU standard, Lonza, Verviers, 
Belgium). Cells were seeded onto six (2ml) and twelve (1ml) well plates at a density of 
0.75×105 (HCT15) and 1.0×105 (CO115) cells/ml.  
 
Cell proliferation/viability assay  
 To investigate the effects of 5-FU on cell viability/proliferation in HCT15 and 
CO115 cells, the MTT reduction assay were used as described previously [24]. Cells 
were treated with different concentrations of 5-FU for 46h and then two more hours in 
the presence of MTT (final concentration 0.5 mg/ml). Hydrogen chloride 0.04M in 
isopropanol was then used to dissolve the formazan crystals. The number of viable cells 
in each well was estimated by the cell capacity to reduce MTT using a 
spectrophotometer. Results are presented as mean ± SEM of at least three independent 
experiments. 
 
TUNEL assay  
  TUNEL (TdT mediated dUTP Nick End Labelling) assay was performed to 
estimate the percentage of apoptotic cells in both cell lines treated for 48h with different 
concentrations of 5-FU alone and in combination with Q and L. The concentrations of Q 
and L used induce significant inhibition of cell proliferation without substantial necrotic 
death, as determined by BrdU assay and MTT test in our previous work using the same 
cells and conditions [24]. Both cell lines were also treated with Q and L in combination 
with 20µM z-VAD-fmk (zVAD), a general caspase inhibitor, for 48h, to assess the 
involvement of caspases activation in the apoptotic process induced by the test 
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compounds. Staurosporine (STS) 0.25µM, an apoptotic inducer, was also used as a 
positive control.  
After treatments, cells were collected (both floating and attached cells), fixed 
with 4% paraformaldehyde for 15min at room temperature and attached into a 
polylysine treated slide using a Shandon Cytospin. Cells were then washed in PBS and 
permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2min on ice. TUNEL 
assay was performed using a kit from Roche (Mannheim, Germany), following the 
manufacturer’s instructions. Hoechst was used for nuclei staining. The percentage of 
apoptotic cells was calculated from the ratio between TUNEL positive cells and total 
number of cells, from a count higher than 500 cells per slide under a fluorescent 
microscope. Results are presented as mean ± SEM of at least three independent 
experiments. 
 
Western blot analysis  
 Cells were treated with Q, L, 5-FU and STS alone and co-incubated with Q and 
5-FU for 48h and total cell lysates were prepared to measure the expression of different 
proteins. The cells were washed with PBS and lysed for 15min at 4ºC with ice cold 
RIPA buffer (1% NP-40 in 150mM NaCl, 50mM Tris (pH 7.5), 2mM EDTA), 
supplemented with 20mM NaF, 1mM phenylmethylsulfonyl fluoride (PMSF), 20mM 
Na2V3O4 and protease inhibitor cocktail (Roche, Mannheim, Germany). Protein 
concentration was quantified using a Bio-Rad DC protein assay (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA) and BSA used as a protein standard. To perform western blot 
analysis, 20µg of protein were resolved by SDS-polyacrylamide gel and then 
electroblotted onto a Hybond-P polyvinylidene difluoride membrane (GE Healthcare). 
Membranes were blocked in TPBS (PBS with 0.05% Tween-20) containing 5% (w/v) 
non-fat dry milk or BSA (bovine serum albumin), washed in TPBS and then incubated 
with primary antibody. After washing, membranes were incubated with secondary 
antibody conjugated with IgG horseradish peroxidase and immunoreactive bands were 
detected using the Immobilon solutions (Millipore, Billerica, MA, USA) under a 
chemiluminescence detection system, the Chemi Doc XRS (Bio-Rad Laboratories, 
Inc.). Band area intensity was quantified using the Quantity One software from Bio-
Rad. β-actin was used as loading control. 
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Statistical analysis 
 Statistical analyses were done using t-test, GraphPad Prism 4.0 software (San 
Diego, CA, USA). P-values ≤ 0.05 were considered statistically significant.  
 
Results  
 
Colon cancer cells` sensitivity to 5-FU  
 The effect of 5-FU on cell growth and apoptosis in HCT15 and CO115 cells 
were established by the MTT and TUNEL assays, respectively. As shown in Figure 1a, 
5-FU was more effective in inhibiting cell growth in CO115 than HCT15. The 
concentrations that inhibit cell growth by 50% (IC50) are around 100µM in HCT15 and 
1µM in CO115. The differences in susceptibility of the two cell lines to 5-FU were also 
observed for the induction of apoptosis (Figure 1b). The concentrations of 5-FU that 
inhibited cell proliferation by around 50% and significantly increased apoptosis were 
selected for the next experiments (100µM for HCT15 and 1µM for CO115). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Effect on cell proliferation/viability (a) and apoptosis (b) of different concentrations of 5-
fluorouracil (5-FU), for 48h, in HCT15 and CO115 colon cancer cells, using MTT and TUNEL assay, 
respectively. Results are presented as mean ± SEM of at least 3 independent experiments. * P≤ 0.05, ** 
P≤ 0.01 and *** P≤ 0.001. In A, full line represents quantity of cells in the beginning of the assay (t=0h) 
and values below this after 48h incubation with test compound mean cell toxicity by necrosis; dot line 
represents the concentrations that inhibit cell growth by around 50% (IC50). 
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Combined effect of 5-FU and test compounds on apoptosis  
 The induction of apoptosis in both cell lines treated with Q or L, at 
concentrations that induce significant inhibition of cell proliferation without substantial 
necrotic death, as tested previously [24], and 5-FU (IC50) was monitored by the 
TUNEL assay. As shown in Fig.2, flavonoids induced a high rate of apoptosis in CO115 
cells when compared with HCT15. In HCT15 cells, L or Q in combination with 5-FU 
demonstrated an additive effect in the induction of apoptosis (Figure 2a). In CO115 
cells, L in combination with 5-FU showed an additive effect in apoptosis induction 
while Q demonstrated to synergistically induce apoptotic cell death when combined 
with 5-FU (Figure 2b). In all cases, the effects on apoptosis of co-incubations were 
higher than 5-FU alone or test compound alone.  
 
 
Fig.2. Effect on apoptosis by 5-fluorouracil (FU) 500, 100 and 1µM, quercetin 12µM (Q12) and luteolin 
12µM (L12) alone, as well as the natural compounds co-incubated with FU for 48h, in HCT15 (a) and 
CO115 (b) cells, using TUNEL assay. Results are presented as mean ± SEM of at least 3 independent 
experiments. *** P≤ 0.001, when compared with control; ++ P≤ 0.01, when compared with the respective 
natural compound alone; ## P≤ 0.01 and ### P≤ 0.001, when compared with FU alone; NS, not 
significant differences observed between each other.  
 
Effects on caspases and other molecular markers of apoptosis 
 In order to determine the role of caspase activation on the apoptotic effects of 
the test compounds, the caspase inhibitor zVAD was used and apoptosis measured by 
TUNEL assay. As shown in Figure 3a, apoptosis induced by the test compounds, Q and 
L, and the apoptotic inducer, STS, were not inhibited by zVAD in HCT15 cells. In 
contrast, in CO115 cells apoptosis was totally suppressed when test compounds and 
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STS were co-incubated with zVAD (Figure 3b). In addition, effects on caspase-3, 
caspase-9 and PARP expressions were analysed using western blot. As shown in Figure 
3c, in HCT15 cells, the test compounds, 5-FU and STS did not induce cleaved (active) 
caspase-9, and only STS induced cleavage of caspase-3 (active form) and cleavage 
PARP (inactive form). On the other hand, in CO115 cells cleaved caspase-9 and 
caspase-3 was observed with all test compounds as well as cleavage of PARP and/or a 
remarkable decreased of uncleaved PARP (active form). Interestingly, the expression 
levels of PARP are higher in HCT15 than in CO115. 
 
 
 
Fig.3. Effect of a caspase inhibitor zVAD-FMK (zVAD) 20µM on the apoptosis induction by quercetin 
12µM (Q12), luteolin 12µM (L12) and staurosporine (STS) 0.25µM, for 48h, in HCT15 (a) and CO115 
(b) cells, using TUNEL assay. Results are presented as mean ± SEM of at least 3 independent 
experiments. * P≤ 0.05, *** P≤ 0.001, when compared to control; ++ P≤ 0.01 and +++ P≤ 0.001, when 
compared with the respective compound alone; ## P≤ 0.01 and ### P≤ 0.001, when compared with 
zVAD alone; NS, not significant differences observed between each other. (c) Effects on caspase-9, 
caspase-3 and PARP-1 expressions, for 48h, of Q, L, 5-FU (FU) and STS alone, in HCT15 and CO115 
cells, by western blot. Images are representative of at least 3 independent experiments. 
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To further elucidate the apoptotic effects of the test compounds and 5-FU, the 
expression of p53, Bax and Bcl-2 were also analysed by western blot (Figure 4). It was 
observed that Q, L and 5-FU induce p53 in both cell lines, this effect being more 
remarkable for Q in CO115 cells. Expression of Bcl-2 was notably decreased by all the 
compounds in both cell lines and Bax expression increased only in HCT15 since CO115 
does not express Bax, as also shown by others [27].      
 
Fig.4. Effects on p53, Bax and Bcl-2 expressions, for 48h, of quercetin 12µM (Q12), luteolin 12µM 
(L12), staurosporine (STS) 0.25µM and 5-fluorouracil (FU) 1µM and 100µM, in HCT15 and CO115 
cells, by western blot. Images are representative of at least 3 independent experiments.  
 
Effects of Q and 5-FU in co-incubation on molecular markers of apoptosis 
To determine the possible causes of the synergistic effect of Q with 5-FU on the 
induction of apoptosis in CO115 cells, the expression of molecular markers was further 
evaluated. Co-incubation of Q and 5-FU synergistically increased the cleavage of 
caspase-3, caspase-9 and PARP and decreased Bcl-2 expression, but had no effect on 
p53 expression (Figure 5).  
 
Effects on JNK and p38 pathways  
 The possible involvement of the JNK and p38 pathways in the induction of 
apoptosis by the test compounds and 5-FU was also evaluated. Our results show no 
effect on phospho-JNK expression by Q, L and 5-FU in neither of the cell lines (Figure 
6a). In HCT15 cells no effect on phospho-p38 expression was observed by the 
flavonoids and 5-FU while in CO115 cells Q and L slightly increased the expression of 
phospho-p38 (Figure 6b). STS, an apoptotic inducer, significantly induced phospho-
JNK expression and decreased the expression of phospho-p38 in both cell lines. 
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Fig.5. Effects on caspase-9, caspase-3, PARP-1, p53 and  Bcl-2 expressions, for 48h, of co-incubation of 
quercetin 12µM (Q12) and 5-fluorouracil 1µM (FU1) in CO115 cells, by western blot. Images are 
representative of at least 3 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. Effect on phospho-JNK and total JNK (a) and phospho-p38 and total P38 (b) expressions, for 48h, 
of quercetin 12µM (Q12), luteolin 12µM (L12), 5-fluorouracil 1µM (FU1) and 100µM (FU100) and 
staurosporine (STS) 0.25µM, in HCT15 and CO115 cells, by western blot. Images are representative of at 
least 3 independent experiments.  
 
Chapter V                                                                          Combined effects of quercetin, luteolin and ursolic acid with 5-Fluorouracil 
119 
 
Discussion 
 
5-Fluorouracil (5-FU) is the pharmacological drug most commonly used in CRC 
chemotherapy, however tumor cell resistance to this drug remains a significant concern. 
Several mechanisms of resistance involving failure to induce apoptosis have been 
reported to reduce the efficacy of 5-FU [6,12], such as MSI and mutant p53 [7,11,12]. 
Thus, new compounds are needed to use in combination with 5-FU to increase 
treatment efficacy. The potential of Q and L, two structurally related natural flavonoids, 
to enhance the apoptosis induction when used in combination with 5-FU on two MSI 
CRC cell lines, as well as their possible mechanisms of action, are presently reported. 
Inhibition of cell proliferation and induction of apoptosis by 5-FU were observed in a 
dose-dependent manner in both cell lines that showed, however, different 
susceptibilities to the drug. As expected, HCT15 cells harboring a p53 mutation were 
more resistant to 5-FU than CO115 cells (wild-type for p53). The anticancer effects of 
flavonoids are widely known, and we previously reported that both Q and L inhibited 
cell proliferation and induced apoptosis on CRC cells [24]. Here, we show that Q and L 
differently affect 5-FU cell death induction in two different genetic background CRC 
cell lines. 
Our data show a significant ability of Q and L to increase 5-FU induced 
apoptosis in both MSI cell lines. Q (in HCT15 cells) and L (in both cell lines) additively 
enhanced apoptosis induced by 5-FU. A remarkable synergistic effect was detected 
when treating CO115 cells with Q and 5-FU. The effect of this combination was even 
more pronounced than that of a 100 times higher concentration of 5-FU when tested 
alone. However, this synergistic enhancement of apoptosis in Q combined with 5-FU 
was only obtained in the p53 wild-type background of CO115 MSI cells. Other natural 
compounds, such as triptolide and rosiglitazone, have also been studied in combination 
with 5-FU and shown to enhance the anticancer effect of this drug in the microsatellite 
stable (MSS) HT-29 CRC cell line [28,29]. In another study, notoginseng and its 
ginsenosides were also shown to enhance the antiproliferative and pro-apoptotic effects 
induced by 5-FU in the MSI p53 wild type HCT116 cell line [30] using, however, high 
concentrations of compounds. 
 In a previous study, we have shown that Q and L induce apoptosis in both 
CO115 and HCT15 cells [24], at the concentrations tested here. The mechanisms of 
apoptosis induction by these flavonoids have, however, not been studied previously in 
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these cells and, as shown here, appear to be cell line dependent. We observed that, in 
CO115 cells, the caspase inhibitor zVAD totally abrogated apoptosis induction by Q 
and L. This was in agreement with the expression of apoptotic-associated markers, such 
as induction of cleavage (activation) of caspase-9 and caspase-3 as well as a decrease in 
Bcl-2 expression. It seems, therefore, that Q and L induce apoptosis via caspase 
dependent pathways in CO115 cells with a contribution of the mitochondrial pathway, 
even in the absence of Bax expression. The test compounds also induced p53 
expression, which indicate that they may induce apoptosis in p53 wild-type CO115 cells 
by modulating p53. The induction of apoptosis by 1µM 5-FU in CO115 cells was low, 
but caspase dependent. Although Q was the compound that more remarkably induced 
p53 expression, the synergism with 5-FU observed for Q in CO115 cells seems not be 
due to a further increase in p53 expression. A remarkable increase in the expression of 
cleaved caspase 9, caspase 3 and PARP as well as a decrease in Bcl-2 expression were 
observed when Q and 5-FU were combined, as compared with compounds alone. In 
addition, since Q and L inhibit the PI3K/Akt pathway in CO115 cells [24] and Akt is 
involved in the suppression of apoptosis contributing to the resistance of CRC cells to 
chemotherapy [31-33], the effect observed here may also have a contribution of an 
inhibition of Akt. 
On the other hand, in HCT15 cells zVAD did not inhibit apoptosis induced by 
any of the compounds or the reference inducer STS. The lack of caspase-dependent 
apoptosis was corroborated by the absence of cleaved caspase-9 and caspase-3 when 
these cells were incubated with Q and L, as well as with 5-FU. Low levels of cleavage 
of caspase 3 and PARP were, however, observed when these cells were treated with 
STS. It seems, therefore, that in HCT15 the test compounds did not induce apoptosis 
through caspase activation although they decreased Bcl-2 and increased Bax expression. 
Q, L and 5-FU also induced p53 expression in these cells. However, since HCT15 
harbors a P53 inactivating mutation, alteration in the expression of this protein is not 
expected to be of functional significance for apoptosis in these cells. In a previous study 
[24], we showed that the Q and L in HCT15 have an inhibitory effect on MAPK/ERK 
pathway. Since this pathway is also associated with an inhibition of apoptosis and drug 
resistance [34,35], this effect may also contribute to the enhancement of apoptosis of Q 
and L with 5-FU. 
Regarding the two stress-activated protein kinases, none of the flavonoids 
induced the JNK pathway in neither of the cell lines; they seem, however, to induce the 
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p38 pathway in CO115 cells. 5-FU also did not alter JNK or p38 expressions in neither 
of the cell lines.  The induction of apoptosis by Q and L in combination with 5-FU 
could, therefore, also have a contribution of an induction of p38 pathway in CO115 
cells. The lack effect of 5-FU on JNK pathway was also observed by others in HT-29 
cells [36], and effects of 5-FU on p38 stimulation have been reported in KM12C CRC 
cells [37]. On the other hand, our results show that STS induces phosphorylation of 
JNK and decreases p38 expression in both cells. The activation of JNK pathway by STS 
associated with an induction of apoptosis has only been reported in breast cancer cells 
[38] and the effect of this compound on these two stress activated kinases in CRC is not 
well established. The effect of 5-FU and the two flavonoids on these MAP kinase 
pathways seems to be largely dependent on cell type and treatment conditions.  
In conclusion, this study shows the potential applicability of Q and L in the 
enhancement of the apoptotic effects of 5-FU in MSI CRC cells. CRC MSI patients 
would gain from customized treatment modalities based on p53 status in order to 
enhance therapeutic efficacy. Although, the data provided here cannot be generalized to 
all CRC MSI cases, it suggests that treatment strategies, in particular with Q, may 
benefit selectively p53 wild-type MSI patients.  
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Abstract  
 
  Colorectal carcinoma (CRC) is a common cause of cancer-related death. 
Microsatellite instability (MSI) tumors with P53 mutation and thymidylate synthase 
(TS) activation have been shown to be resistant to chemotherapy with 5-fluorouracil (5-
FU), the most widely used pharmacological drug for CRC treatment. Here we tested 
effects of ursolic acid (UA), a natural triterpenoid, on cell death mechanisms in two 
MSI human CRC derived cell lines, one with mutant p53 and TS activation (HCT15) 
and the other wild-type for these two genes (CO115). In this study, we demonstrated 
that UA synergistically enhances apoptosis induced by 5-FU in HCT15 cells. This effect 
was associated with an activation of JNK by UA. A production of ROS levels by UA 
also showed to contribute to apoptosis induction. The increased apoptosis induced by 
UA in HCT15 and CO115 cell lines does, however, not explain all the cell death 
observed, which suggests the involvement of other types of cell death independent of 
caspases. The involvement of UA in the autophagic process was investigated. UA 
demonstrated to induce LC3 accumulation, an effect suppressed by inhibition of JNK. 
In conclusion, this study emphasises the potential of UA for enhancement apoptosis 
induced by 5-FU and suggest a role for UA on autophagy related cell death. 
Importantly, UA had a more pronounced effect on induction of cell death than 5-FU.  
 
 
 
Keywords: Ursolic acid, Colorectal carcinoma, Apoptosis, LC3, JNK, 5-Fluorouracil  
Cristina Xavier 
128 
 
Introduction 
 
 Colorectal carcinoma (CRC) is the second cause of death for cancer worldwide 
and 5-fluorouracil (5-FU) is the main chemotherapeutic agent used in the treatment of 
this disease.1 However, significant resistance to 5-FU has been reported, and drugs such 
as irinotecan and oxaliplatin are used in combination with 5-FU to increase treatment 
efficacy.2, 3 The enzyme thymidylate synthase (TS), essential for the synthesis of a 
precursor (deoxythymidine-5’-monophosphate) for DNA replication, is inhibited by the 
active metabolite of 5-FU (5-fluoro-2 -´deoxyuridine-5´monophosphatate) resulting in 
the induction of cell cycle arrest.1, 4 Resistance to 5-FU has associated with TS 
activation.1, 4 In addition, cells that harbour P53 mutations when exposed to 5-FU have 
also showed reduced apoptosis.5, 6 Tumors presenting microsatellite instability (MSI) 
status, which accounts for 15% of sporadic CRC, have demonstrated in vitro resistance 
to 5-FU,7-9 suggesting, little or no benefit from 5-FU treatment in MSI patients, 
although clinical evidences are not always consistent.9 These patients would clearly gain 
from new treatment modalities with enhanced efficacy.      
Apoptotic cell death is a fundamental cellular process that plays an important 
role during development and tissue homeostasis, that also has profound effects on 
cancer growth and progression.10 Apoptosis is one form of regulated cell death, also 
called programmed cell death. The apoptotic pathway is mediated by death receptors on 
the cell membrane (extrinsic pathway) or by the mitochondrial pathway (intrinsic 
pathway) and involves the activation of caspases.10, 11 Death by necrosis occurs when 
the cellular contents are released in an uncontrolled manner into the cell´s environment, 
due to a rapid and drastic induction of death. Necrosis is often associated with an 
inflammatory response.10 Other alternative cell death mechanisms have been proposed. 
Autophagy, or called type II cell death or autophagic cell death, although considered a 
mechanism of survival, has also been demonstrated to assume a role in cell death, 
especially when apoptosis is not functional.10, 11 Some natural products have 
demonstrated the ability to modulated apoptosis and autophagy through different 
signalling pathways in CRC, thereby contributing to reduce cell growth and increase 
cell death.12, 13  
The c-Jun N-terminal kinase (JNK), a stress-activated protein kinase of the 
family of the mitogen activated protein kinase (MAPK), has been implicated in many 
cellular events including apoptosis signalling.14, 15 JNK is activated by diverse cellular 
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stresses, such as UV irradiation, DNA damage, heat and osmotic shock and oxidative 
stress, and its function has been shown to be dependent on cell type and stimulus.15 JNK 
has been shown to induce apoptosis through TNF-α and via modulation of proapoptotic 
Bcl-2 family proteins.14 More recently, JNK was found to be a mediator of autophagy, 
contributing for autophagic cell death in some types of cancer cells.16-20 Studies have 
shown that an activation of JNK can mediate Beclin-1 expression18, regulate damage-
regulated autophagy modulator (DRAM),17, 21 as well as, mediate p53 
phosphorylation,16 leading to autophagic cell death.   
Ursolic acid (UA) is a naturally occurring triterpenoid that is found in fruits and 
medicinal herbs.22 Several biological properties have been attributed to UA including 
anti-inflammatory and anticancer activities.22 In our previous study23 we demonstrated 
that UA has anticancer activity through effects on PI3K pathway, in two human 
derived-colorectal cancer cell lines, HCT15 and CO115. These are MSI CRC cell lines. 
HCT15 harbors additionally a P53 inactivating mutation and a TS activating mutation 
while CO115 is wild-type for these two genes.24, 25 Our data shows that UA induces cell 
death through apoptosis and other death mechanisms that seem to involve autophagy, 
being more efficient than 5-FU in inducing cell death. A therapeutic potential for UA in 
combination with 5-FU on the induction of cell death, in cells with a apoptosis resistant 
profile, was demonstrated.  
 
Material and methods 
 
Reagents and antibodies 
 Ursolic acid (UA), z-VAD-fmk (zVAD), staurosporine (STS), 5-Fluorouracil (5-
FU), SP600125 (SP), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and N-Acetyl-L-cysteine (NAC) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). All the compounds were resuspended in dimethyl sulfoxide (DMSO). 
 Primary antibodies were purchased to the following sources: anti-phospho-JNK, 
anti-JNK, anti-p53 and anti-MAPLC3 to Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA, USA); anti-phospho-mTOR and anti-mTOR to Cell Signaling (Danvers, MA, 
USA); and anti-β-actin to Sigma-Aldrich. Secondary antibodies HRP donkey anti-rabbit 
and sheep anti-mouse were purchased to GE Healthcare (Bucks, UK).  
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Cell lines  
 HCT15 and CO115human colon carcinoma-derived cell lines were maintained at 
37ºC in a humidified 5% CO2 atmosphere in RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 10mM HEPES, 0.1mM pyruvate, 1% antibiotic/antimycotic solution 
(Sigma-Aldrich) and 10% fetal bovine serum (FBS; EU standard, Lonza, Verviers, 
Belgium). Cells were seeded onto six (2ml) and twelve (1ml) well plates at a density of 
0.75×105 (HCT15) and 1.0×105 (CO115) cells/ml.  
 
Apoptosis analysis by TUNEL assay  
  TUNEL (TdT mediated dUTP Nick End Labelling) assay was performed to 
estimate the percentage of apoptotic cells. After different treatments for 48h, cells were 
collected (both floating and attached cells), fixed with 4% paraformaldehyde for 15min 
at room temperature and attached into a polylysine treated slide using a Shandon 
Cytospin. Then, cells were washed in PBS and permeabilized with 0.1% Triton X-100 
in 0.1% sodium citrate for 2min on ice. TUNEL assay was performed using a kit from 
Roche (Mannheim, Germany), following the manufacturer’s instructions. Cells were 
incubated with Hoechst for nuclei staining. The percentage of apoptotic cells was 
calculated from the ratio between TUNEL positive cells and total number of cells 
(nuclei staining with Hoechst), from a count higher than 500 cells per slide under a 
fluorescent microscope. Results are presented as mean ± SEM of at least three 
independent experiments. 
 
Cell death analysis by PI staining  
After different treatments, cells were collected (both floating and attached cells) 
and washed in ice cold PBS containing 5% (v/v) FBS. Then, cells were resuspended in 
the previous ice cold buffer and propidium iodide (PI) solution added to a final 
concentration of 0.5 mg/ml. Cells were maintained on ice, protected from light, until 
microscope observation. Twenty microliters of the stained suspension were placed on 
clean microscope slides and overlaid carefully with coverslips. Immediately, cells were 
visualized on a fluorescent microscope and photos taken from different fields. The 
percentage of death cells (PI positive) was calculated from the ratio between PI positive 
cells and total number of cells (visualized under phase contrast), from a count higher 
than 500 cells per slide. Results are presented as mean ± SEM of at least three 
independent experiments. 
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Western blot analysis  
 Cells were subjected to different combinations for 48h, and total cell lysates 
were prepared to measure protein expressions. The cells were washed with PBS 1X and 
lysed for 15min at 4ºC with ice cold RIPA buffer (1% NP-40 in 150mM NaCl, 50mM 
Tris (pH 7.5), 2mM EDTA), supplemented with 20mM NaF, 1mM 
phenylmethylsulfonyl fluoride (PMSF), 20mM Na2V3O4 and protease inhibitor cocktail 
(Roche, Mannheim, Germany). Protein concentration was quantified using a Bio-Rad 
DC protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and BSA used as a 
protein standard. To perform western blot analysis, 20µg of protein were resolved by 
SDS-polyacrylamide gel and then electroblotted to a Hybond-P polyvinylidene 
difluoride membrane (GE Healthcare). Membranes were blocked in TPBS (PBS with 
0.05% Tween-20) containing 5% (w/v) non-fat dry milk or BSA (bovine serum 
albumin), washed in TPBS and then incubated with primary antibody. After washing, 
membranes were incubated with secondary antibody conjugated with IgG horseradish 
peroxidase and immunoreactive bands were detected using the Immobilon solutions 
(Millipore, Billerica, MA, USA) under a chemiluminescence detection system, the 
Chemi Doc XRS (Bio-Rad Laboratories, Inc.). Band area intensity was quantified using 
the Quantity One software from Bio-Rad. β-actin was used as loading control. 
 
Statistical analysis 
 Statistical analyses were done using t-test, using GraphPad Prism 4.0 software 
(San Diego, CA, USA). P-values ≤ 0.05 were considered statistically significant. All 
results are presented as mean ± SEM of at least 3 independent experiments. Images are 
representative of three independent experiments.  
 
Results  
 
UA synergistically enhances apoptosis induced by 5-FU in HCT15 
The cell lines HCT15 and CO115 were found to have different susceptibilities to 
UA in a previous work.23 For this study, we choose a concentration of UA (based in 
MTT and BrdU assays) 23 and 5-FU (Xavier et al., unpublished data) that decreased cell 
growth by about 50% after 48h of incubation. In HCT15 cells, UA at 4µM and 5-FU at 
100µM were used, while in CO115 UA at 10µM and 5-FU at 1µM were used. The 
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induction of apoptosis in the cells treated with UA and/or 5-FU was monitored by the 
TUNEL assay (Fig. 1A). A synergistic effect was observed when UA is combined with 
5-FU in HCT15 cells, with an increase of about 6 times when compared with 5-FU 
alone. This synergistic effect was not observed for CO115 cells.  
 To study the involvement of caspase activation in UA-induced apoptosis, cells 
treated with UA were incubated with 0.250µM z-VAD-fmk (z-VAD), a general caspase 
inhibitor, for 48h (Fig. 1B). We observed that zVAD significantly inhibited apoptosis 
induced by UA and staurosporine (STS), a classical inductor of caspases used here as a 
control, in CO115 cells. Contrarily, no effect on apoptosis induced by UA and STS was 
observed for zVAD in HCT15 cells, suggesting a mechanism independent of caspase 
pathways in this resistant cell line.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Effect on apoptosis of 5-fluorouracil 100µM (FU100) and 1µM (FU1) co-incubated with 
ursolic acid 4µM (UA4) and 10µM (UA10), as well as, these compounds alone (A) and effect of a 
caspase inhibitor zVAD-FMK (zVAD) 20µM on the apoptosis induction by UA and staurosporine (STS) 
0.25µM (B), in HCT15 and CO115, for 48h, using TUNEL assay. * P≤ 0.05 and *** P≤ 0.001, when 
compared with control; ++ P≤ 0.01 and +++ P≤ 0.001, when compared with UA alone; ## P≤ 0.01 and 
### P≤ 0.001, when compared with FU (A) or zVAD (B) alone; NS, not significant differences observed 
between each other. 
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Induction of apoptosis by UA is dependent on JNK activation in HCT15 
 Numerous evidences show that JNK contributes to apoptosis induced by various 
stresses.14 Thus, the involvement of this kinase in the UA-induced apoptosis was 
evaluated. Firstly, using western blot analysis, we observed that UA induces phospho-
JNK expression in both cell lines, with a remarkable effect in HCT15 (Figure 2A). An 
increase of phospho-JNK expression was also observed for STS in both cell lines, and 
no effect was detected for 5-FU.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Effect on phospho-JNK and total JNK expressions, for 48h, of ursolic acid 4µM (UA4) and 
10µM (UA10), 5-fluorouracil 1µM (FU1) and 100µM (FU100) and staurosporine (STS) 0.25 µM, in 
HCT15 and CO115 cells, by western blot. Effect of SP600125 (SP), a JNK inhibitor at 20µM, on the 
apoptosis induced by UA and STS, for 48h, in HCT15 and CO115 cells, using TUNEL assay. * P≤ 0.05, 
** P≤ 0.01 and *** P≤ 0.001, when compared to control; + P≤ 0.05 and ++ P≤ 0.01, when compared with 
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the respective compound alone; # P≤ 0.05, when compared with SP alone (A). Effect on cell death of 
FU100 and UA4 co-incubated with SP, for 48h in HCT15 cells, using PI staining. ++ P≤ 0.01 and +++ P≤ 
0.001, when compared with the control and with the co-incubation FU+UA+SP; ** P≤ 0.01, *** P≤ 
0.001, when compared with UA alone; θ P≤ 0.05 and θθ P≤ 0.01, when compared with SP alone; ### P≤ 
0.001, when compared with FU alone (B). NS, not significant differences observed between each other. 
 
 
To assess whether apoptosis induction was due to an activation of the JNK, 
TUNEL assay was performed in the presence of 25µM SP600125 (SP), a JNK inhibitor 
(Figure 3A). It was observed that SP totally inhibited apoptosis induced by UA in 
HCT15 cells and no effect was observed in CO115 cells. SP also inhibited the apoptosis 
induced by STS in both cell lines. Thus, it seems that the UA induction of apoptosis in 
HCT15 cells is dependent on JNK pathway.  
In a further experiment, it was tested whether the activation of JNK by UA was 
the responsible for the synergistic effect of UA combined with 5-FU in HCT15 cells. 
We observed that SP did not inhibit the apoptosis induced by 5-FU, and, again, an 
inhibition of UA-induced apoptosis was observed in the presence of SP (Figure 2B). A 
total abrogation the synergistic effect on apoptosis of the combination of UA with 5-FU 
was observed in the presence of SP. These results suggest a dependence on JNK 
activation for UA-induced apoptosis in HCT15 cells, which seems to be the responsible 
of the synergistic effect with 5-FU. 
 
Oxidative stress induced by UA contributes to apoptosis induction in HCT15 
The role of oxidative stress on apoptosis induced by UA was tested using a 
common antioxidant N-acetylcysteine (NAC). When NAC was used in combination 
with UA for 48h, the induction of apoptosis was partially inhibited in HCT15 cells, but 
not in CO115 cells (Figure 3). This result suggests an implication of oxidative stress as 
a contributor for UA-induced apoptosis in HCT15.  
 
UA induces cell death in colon cancer cells 
  The apoptosis induced by UA in HCT15 and CO115 cells at 48h, although 
significantly, only represents around 4% and 10% of total cell number, respectively, 
which does not correspond to the extensive morphological changes observed. Therefore, 
cell death was subsequently measured using PI staining, at 2h and 48h. As shown in 
Figure 4, UA did not increase remarkably cell death after 2h of incubation, suggesting 
there is no acute necrotic effect induced by UA. However, after 48h, UA induced cell 
Chapter V                                                                          Combined effects of quercetin, luteolin and ursolic acid with 5-Fluorouracil 
135 
 
death to around 50% of cells, in both cell lines, as shown by the increase number of PI 
positive cells. On the other hand, 5-FU did not induce significant cell death in either of 
the cell lines after 48h. Cell death induced by the combined treatment of UA with 5-FU 
seems, therefore, to be due to UA. Therefore, UA induces cell death in HCT15 and 
CO115 cells, by mechanisms other than apoptosis or necrosis.  
 
 
 
 
 
 
 
 
 
 
Figure 3 – Effect of N-Acetyl-L-cysteine (NAC) at 5mM, on the apoptosis induced by ursolic acid 4µM 
(UA4) and 10µM (UA10) in HCT15 and CO115 cells respectively, for 48h using TUNEL assay. ** P≤ 
0.01 and *** P≤ 0.001, when compared to control; ## P≤ 0.01 and ### P≤ 0.001, when compared with 
NAC alone; ++ P≤ 0.01, when compared with the respective compound alone; NS, not significant 
differences observed between each other.  
 
 
Figure 4 – Effect on cell death of 5-fluorouracil 100µM (FU100) and 1µM (FU1) co-incubated with 
ursolic acid 4µM (UA4) and 10µM (UA10), as well as these compounds alone, for 2h and 48h, in HCT15 
and CO115 cells, using PI staining. * P≤ 0.05, ** P≤ 0.01 and *** P≤ 0.001, when compared with 
control; ## P≤ 0.01 when compared with FU alone; NS, not significant differences observed between 
each other. 
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JNK is also implicated in other mechanisms of UA-induced cell death in HCT15  
 Previously, we demonstrated that JNK pathway was implicated in apoptosis 
induced by UA in HCT15 cells. Then, we tested whether this pathway was involved in 
total cell death, indicated by PI staining. As shown in Figure 5, SP partially inhibited 
the cell death induced by UA in HCT15 cells, as well as, the cell death induced by the 
combination of UA with 5-FU. No significant effect of SP on cell death induced by UA 
and UA combined with 5-FU was observed in CO115 cells. This data suggest that JNK 
activation by UA not only induces apoptosis, but also other forms of cell death seem to 
be partially dependent on this pathway in HCT15 cells. Contrarily, JNK seems not be 
involved in UA-induced cell death in CO115 cells.  
 
Figure 5 – Effect on cell death of 5-fluorouracil 100µM (FU100) and 1µM (FU1) co-incubated with 
ursolic acid 4µM (UA4) and 10µM (UA10) and SP600125 20µM (SP20), as well as, these compounds 
alone, for 48h in HCT15 and CO115 cells, using PI staining. ++ P≤ 0.01 and +++ P≤ 0.001, when 
compared with the control and with the co-incubation FU+UA+SP; *** P≤ 0.001, when compared with 
UA alone; θθθ P≤ 0.001, when compared with SP alone; ## P≤ 0.01 and ### P≤ 0.001, when compared 
with FU alone. NS, not significant differences observed between each other.  
 
 
UA induces LC3 accumulation: involvement of JNK, mTOR and p53  
It was observed that the percentage of apoptosis induced by UA, in both HCT15 
and CO115 cells after 48h, does not explain all the cell death observed, suggesting an 
involvement of other types of cell death independent of caspase. Therefore, we 
investigated the possible role of UA on autophagy and in some regulators of autophagy, 
such as p53 and mTOR, as well as, the involvement of JNK, using immunoblotting 
analysis. One of the hallmarks of autophagy is the conversion of cytosolic LC3-I into 
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autophagosome-associated LC3-II, the amount of which reflects the abundance of 
autophagosomes. Our results showed that UA induces an accumulation of LC3-II 
expression levels in both cell lines, which was reduced in the presence of SP with a 
more remarkable effect in HCT15 cells (Figure 6A). In contrast, no effect on LC3-II 
expression was detected in cells treated with 5-FU or SP alone. The accumulation of 
LC3 observed in cells treated with UA and 5-FU seems to be due to UA, and this effect 
was inhibited in the presence of SP. The effect was more noticeable in HCT15 cells. 
These results suggest that UA interferes with autophagy, in both cell lines, and that JNK 
may be involved.  
The autophagic process is modulated by a number of molecules such as p53 and 
mTOR.26 The possible effect of UA on the levels of these regulators was also evaluated. 
UA decreased p53 levels in both cell lines, as well as, the p53 induced by 5-FU, 
suggesting a regulatory effect of UA on this protein. In addition, UA decreased 
phospho-mTOR levels in both cell lines, indicating a possible effect in this protein. 
These effects of p53 and mTOR are compatible with an induction of autophagy by UA. 
 
 
 
Figure 6 – Effect on the expression of LC3, p53, phospho-mTOR, total mTOR, phospho-JNK, and total 
JNK of ursolic acid (UA), 5-fluorouracil (FU) and SP600125 (SP) in HCT15 and CO115 cells, for 48h 
using western blot.  
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Discussion 
 
The modulation of cell death, which includes apoptosis and autophagy, has 
demonstrated to be an important strategy in the fight against cancer. Defects in 
apoptosis play a central role in tumorigenesis and confer resistance to anticancer 
therapies.27 5-Flurouracil (5-FU) is the most commonly used pharmacological drug in 
CRC chemotherapy, however, several mechanisms of resistance have been reported to 
reduce its efficacy.4, 5 CRC cells with defects in Bcl-2 family proteins and/or loss of p53 
function have demonstrated to fail to respond to 5-FU treatment.5, 6 Combinations of 
therapeutic agents with different modes of action have been suggested to increase 
treatment efficacy. 
In a previous work23, we demonstrated that UA, a naturally occurring 
triterpenoid, induces apoptosis in two human CRC cells (HCT15 and CO115). In the 
present study, the combined effect of UA with 5-FU on total cell death and in death by 
apoptosis were evaluated. UA showed to significantly induce total cell death and to a 
smaller extent death by apoptosis, in both cell lines, being more efficient than 5-FU 
alone. Furthermore, UA showed to induce apoptosis via caspase-independent pathway 
in HCT15 cells, contrarily to observed for CO115 cells. When UA and 5-FU were used 
in combination, UA synergistically enhanced apoptosis induced by 5-FU in HCT15 
cells. Because this effect was observed in the MSI cells that harbour a p53 mutation and 
a TS activation, suggest a relevant effect of UA in combination with 5-FU in a cell type 
resistant to apoptosis and 5-FU treatment.1, 5, 8, 9, 28  
The JNK MAP kinase has been implicated in many cellular events including 
apoptosis 29-33 and autophagy.16-20 In our study, we found that UA activates JNK in both 
cell lines, with a remarkable effect in HCT15 cells, whereas no effect on JNK induction 
was observed for 5-FU. In addition, through the use of the JNK inhibitor SP600125, 
JNK activation by UA showed to be involved in the apoptosis and total cell death 
induction in HCT15 but not in CO115 cells. The synergistic effect on apoptosis induced 
by the combination of UA with 5-FU in HCT15 cells was also shown to be dependent 
on JNK activation. Furthermore, the combination of UA with 5-FU was demonstrated to 
be partially dependent on JNK in HCT15 but not in CO115 cells. Therefore, both 
apoptosis and total cell death induced by UA alone or UA plus 5-FU in the resistant 
HCT15 cells demonstrated to be JNK-dependent, possible in response to oxidative 
stress produced by UA in these cells. Contrarily, this was not observed for apoptosis or 
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cell death induced by UA in CO115 cells, where a caspase-involvement was detected. 
The importance of JNK activation as one contributor mechanism to induce cell death in 
CRC is demonstrated by the drug atorvastatin. Atorvastatin, one of the 
chemotherapeutic drugs used in CRC, showed to induce apoptosis involving JNK 
activation.34 This drug has a synergistic interaction with celecoxib, a selective 
cyclooxyhenase-2 inhibitor, in killing human CRC cancer cells.34  
Nevertheless, apoptosis induced by UA comprises only a small percentage of 
death induction in both cell lines. PI results at 2 hours suggest that there was no necrotic 
cell death involved, indicating other types of cell death induced by UA. Autophagy, also 
called type II cell death or autophagic cell death is activated under stress conditions, 
such as nutrient and/or growth factor deprivation. This process represents a mechanism 
of survival but it may assume a cell death function when apoptosis is deregulated.10, 35 
Our results showed that UA induces accumulation of LC3-II in both cell lines, which is 
inhibited in the presence of SP (more remarkable in HCT15), suggesting UA’s 
modulation of autophagy and a role for JNK also in this process. On the other hand, in 
our study, 5-FU seems not to affect the autophagic process because there were no 
changes in LC3-II. An accumulation of LC3-II, however, was recently found not be a 
certain indicative of autophagic induction.36 LC3-II, a marker of autophagosomes, may 
increase when autophagic flux is activated, but it can also be accumulated when a 
blockage occurs downstream of autophagosomes formation.36 Thus, our results indicate 
a role of UA in autophagy in both cell lines, an effect reported here for the first time, 
and suggest the autophagic cell death as a possible way of UA-induced cell death. 
The proteins p53 and mTOR have been shown to be important regulators of the 
autophagic process.26, 37 The cytosolic p53, both mutant and wild-type form, has been 
demonstrated to inhibit autophagy.38, 39 On the other hand, an inhibition of mTOR is 
associated with an induction of autophagy.26, 37 Our results showed that UA decreases 
mTOR, as well as, both wild-type and mutant p53 (in CO115 and HCT15 cells, 
respectively), corroborating a possible effect of UA on the induction of autophagy. 
Recent studies demonstrated the ability of an inhibitor of autophagy, 3-methyladenine, 
to enhance apoptosis induced by 5-FU in CRC cells40, 41. Thus, the effect of UA on 
autophagy should be further explored and the possibility that UA inhibits autophagy 
thereby increasing cell death should also be taken into consideration. 
In conclusion, this study found that UA induces apoptosis, as well as, total cell 
death more efficiently than 5-FU alone. In addition, it suggests the potential 
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applicability of UA in the enhancement of the apoptotic effect of 5-FU in the resistant 
CRC cell line, where an activation of JNK seems to be responsible for this synergistic 
effect with a contribution of ROS. A role in the modulation of autophagy by UA and the 
role for JNK in this process were also found in both cell lines. The effect of UA on 
autophagy needs, however, to be better clarified in the future.  
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Abstract  
 
Autophagy is the lysosomal recycling of intracellular constituents that offers a 
survival mechanism to the cells under metabolic stresses. In cancer cells, autophagy has 
demonstrated a dual role through promotion of cell survival or induction of tumor 
suppression. Ursolic acid (UA), a natural triterpenoid, has various anticancer activities 
in autophagic-associated signalling pathways. However, its role in autophagy is still 
unknown.  
In the present study, we characterized the effect of UA in the autophagic 
process, in MCF-7 and HCT15, breast and colon cancer cells, respectively. An 
accumulation of autophagosomal structures in both cell types without colocalization 
with LAMP-2 was observed, indicating that UA inhibits autophagy at the maturation 
step. This effect was further confirmed by the increased levels of p62 and by the LC3 
turnover, using a luciferase-based real-time assay, showing UA-blockage of the 
autophagic flux. UA was also able to inhibit rapamycin-induced autophagy. These 
events were simultaneous with no effect on apoptosis induction, decreased cell survival 
and morphological changes, indicating an involvement of autophagy in UA induced cell 
death. Additionally, an effect of UA on lysosomal membrane permeabilization was 
observed, suggesting that UA destabilizes lysosomes probably also inducing lysosomal 
cell death pathway. Moreover, p38 and JNK MAP kinases seem not mediate UA-
inhibition of autophagy in MCF-7 cells.  
In conclusion, UA blocks autophagy at the maturation step probably through 
effect on lysosomes, suggesting this natural triterpenoid as a novel compound to be 
exploited in cancer therapy. 
 
 
Keywords: Ursolic acid, colorectal and breast cancer cells, autophagy, LC3, lysosomes, signalling 
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Introduction 
 
Macroautophagy (hereafter referred to as autophagy) is a lysosomal degradation 
pathway which, under basal conditions, maintains the metabolism of the cells providing 
them with nutrients by removing damage organelles.1 Autophagy can be rapidly 
increased in response to numerous conditions of extracellular and/or intracellular 
stresses, such as nutrient and/or growth factor deprivation, hypoxia, hormones and DNA 
damage.2 During autophagy initiation, organelles and parts of the cytoplasm are 
engulfed and double-membrane vacuoles, the autophagosomes, are formed. The 
autophagosomes fuse with lysosomes, forming the autolysosomes, where the cargoes 
are degraded by lysosomal hydrolases and recycled back to the cytoplasm (maturation 
step).2 Autophagy has, therefore, been considered a survival mechanism when it is 
moderately activated, however, it can be implicated in autophagic cell death, when it is 
impaired3, 4 or when it is massively activated.5 
The autophagic process is commonly altered in cancer, at the levels of induction, 
regulation and lysosomal degradation. The reduced levels of oxygen and nutrients, 
genetic alterations in cancer-associated genes that modulate autophagy, and alterations 
of lysosomal activity and trafficking, were shown to influence the autophagic flow.5 
However, also in cancer cells, autophagy has been demonstrated to possess a dual role.2, 
6
 Autophagy may contribute to tumor promotion providing the cells with a selective 
advantage for survival, but it can also function as a tumor suppression mechanism.6 
Lysosomes are cytoplasmatic organelles that control cell death at several levels.7, 
8
 These organelles take part of the autophagic cell death, since the fusion between 
autophagosomes and lysosomes and the lysosomal degradative capacity are crucial for 
the completion of the autophagic process.5 Additionally, an induction of lysosomal 
membrane permeabilization (LMP) causes the release of lysosomal hydrolases, such as 
cathepsin proteases and other hydrolases, from the lysosomal lumen to the cytosol, 
triggering apoptosis through activation of mitochondrial and mitochondrial-independent 
cell death pathway.7-10 A massive LMP, i.e., a complete disruption of lysosomes can 
also result in necrotic death.8, 9 Compounds that directly target lysosomes by inducing 
LMP have recently been shown to be effective in killing cancer cells, especially 
apoptosis resistant cancer cells.9, 10  
Ursolic acid (UA) is a natural triterpenoid found in some traditional medicinal 
herbs and in fruits, such as apples, blueberries, cranberries and guava.11 A variety of 
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biological properties, such as anti-inflammatory, hepatoprotective and anticarcinogenic, 
combined with low toxicity, have been demonstrated for UA.11 In breast cancer cells, 
UA has been reported to induce apoptosis by downregulating bcl-2 expression12 and to 
suppress invasion by inhibiting phosphorylation of c-Jun NH-terminal kinase (JNK), 
Akt and mammalian target rapamycin (mTOR).13 In colon cancer cells, UA showed 
anticancer effects by decreasing the level of phospho-Akt14, bcl-2 expression, caspase 
cleavage and by inhibiting MAP kinases.15, 16 The signalling pathways PI3K/Akt/mTOR 
and MAP Kinases have also been demonstrated to be implicated in the regulation of the 
autophagic process, in response to different intra- or extracellular stimuli.1, 17  
In the present study, we attempted to identify and characterize the role of UA in 
the autophagic process, in colon and breast cancer cells, and its possible effect on 
lysosomes.     
 
Results  
 
UA induces cancer cell death  
UA 8µM significantly decreased cell viability over time, in both MCF-7 and 
HCT15 cells, (Fig. 1A) with no significant effect on the survival of HBL-100 
nontumorigenic breast-derived epithelial cells (data not shown). Additionally, no 
remarkable apoptosis (no more than 3% apoptosis of total cell number) induced by UA 
were observed over time, in both cell lines (Fig. 1B). Nevertheless, from 24 hours of 
UA treatment, cells were rounding up and detaching with increased effect over time, 
suggesting occurrence of cell death (Fig. 1C).  
 
UA induces an accumulation of autophagosomes 
 To investigate the effect of UA on autophagy, we performed a LC3 puncta 
formation assay in MCF-7-eGFP-LC3 cells. In these cells that were treated with 
different concentrations of UA (5, 8, 10µM) for 24 hours, a significant increase of 
eGFP-LC3 translocation from a diffuse distribution to a puncta cytoplasmatic 
accumulation of LC3-II, the lipidated autophagosome-associated form of eGFPLC3, 
was observed (Fig. 2A,B). The accumulation of autophagosomes was confirmed by a 
remarkable accumulation of LC3-II expression levels, assessed by immunoblotting (Fig. 
2C). In contrast, LC3 accumulation was not observed for oleanolic acid (OA) treatment, 
Cristina Xavier 
150 
 
a triterpenoid acid structurally related with UA, and wortmannin (W), a classical 
inhibitor of PI3K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Effect of ursolic acid (UA) over time on (A) MTT reduction, (B) apoptosis using TUNEL 
assay and (C) cell morphology, in HCT15 and MCF-7 cells treated with DMSO (control, CT) or UA 
8µM. In A, full line represents the concentrations that inhibited cell growth by around 50%.* P≤ 0.05, ** 
P≤ 0.01 and *** P≤ 0.001, when compared to control. 
 
 
UA blocks the fusion step in the autophagic process  
 LC3 accumulation, although an indicative of effects on autophagy, does not 
distinguish between induction or inhibition of autophagic flux.18 Thus, to characterize 
the autophagic process, an immunofluorescence assay was performed on MCF-7 cells 
expressing the tandem fluorescent construct mRFP-GFP-LC3 in association with an 
antibody against the lysosomal-associated membrane protein 2 (LAMP-2). The tandem-
tagged proteins GFP and mRFP have different sensitivities to the lysosomal pH 
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environment, GFP fluorescence signal decreasing after fusion between autophagosomes 
and lysosomes while mRFP signal remains unchanged (red fluorescence).19 In MCF-7 
cells, treatment with UA 8µM induces an accumulation of autophagosomal structures 
over time represented by the very large yellow dots (red plus green signal). 
Interestingly, these structures were not colocalized with LAMP-2, suggesting that no 
fusion events between lysosomes and autophagosomes take place and therefore, an 
impaired autophagosomal turnover (Fig. 3A). The same results were observed for 
HCT15 cells stained with LC3 and LAMP-2 antibodies (data not shown). Furthermore, 
MCF-7 cells were treated with 3-MA, an inhibitor of the initial steps of the autophagic 
process, and rapamycin, an inducer of autophagy, and these compounds were combined 
with UA during 24 hours. As expected, cells incubated with rapamycin alone presented 
purple colour (red plus LAMP-2 signal), whereas cells incubated with 3-MA alone had 
no LC3 accumulation (Fig. 3B). In cells incubated with 3-MA plus UA, yellow dots 
were not observed, which indicates that LC3 accumulation induced by UA is autophagy 
specific. On the other hand, cells incubated with rapamycin plus UA showed LC3 
accumulation, demonstrating that UA really blocks the autophagic process at the 
maturation step.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – (A) Effect of different concentrations of ursolic acid (UA) 5µM (UA5), 8µM (UA8) and 
10µM (UA10), oleonolic acid 15µM (OA15) and wortmannin 2.5µM (W2.5) on LC3 translocation in 
MCF-7 cells, at 24 hours. The numbers of cells with more than five GFP-LC3 puncta were considered 
Cristina Xavier 
152 
 
positive for LC3 translocation. (B) Representative images of UA and control. * P≤ 0.05 and ** P≤ 0.01, 
when compared to control. (C) Effect of UA8, OA15 and W2.5 on LC3-II expression levels measured by 
western blot at 24 hours.  
 
Additionally, the effect of UA on p62 expression was assessed to confirm the 
inhibition of autophagy. The protein p62 incorporates into autophagosomes through 
direct binding to LC3 being required for the formation and degradation of intracellular 
protein aggregates.20 This protein has been shown to be efficiently degraded by 
autophagy, even more specifically than LC3, being, therefore, a reliable marker to 
monitor the autophagic flux.18, 20 Our results showed an accumulation of p62 expression 
levels over time, in MCF-7 and HCT15 cell lines, confirming that UA blocks autophagy 
(Fig. 3C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – (A) Representative images of different time incubations (12, 24 and 48 hours) with ursolic 
acid (UA) 8µM and (B) 24 hours of incubation with UA 8µM, rapamycin 100nM and 3-Metyladenine (3-
MA) 10mM, in MCF-7 cells expressing mRFP-GFP-LC3 stained for anti-LAMP-2 (C) Effect of UA 8µM 
on p62 expression levels over time, in MCF-7 and HCT15 cells, using western blot.  
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UA inhibits autophagy flux and blocks the rapamycin-induction effect   
A study in LC3 turnover using a luciferase-based real-time assay was then 
performed to corroborate the UA-inhibition of autophagy flux.21 The cell kinetic assay 
was carried out for 20 hours with 2 hours intervals between measurements. In this 
assay, the ratio between the levels of RLucLC3wt (LC3 that is targeted for autophagy-
dependent degradation) and RLucLC3G120A (mutated LC3 that is degraded at a much 
lower rate than RLucLC3wt) reflects the autophagic flux, where a decrease of the ratio 
corresponds to an induction of the autophagic flux. As observed in Fig. 4A, UA 8µM 
started gradually to inhibit the autophagic flux from 8 hours. In contrast, rapamycin-
induced autophagy was blocked from 8 hours when the cells were co-incubated with 
UA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Effect of ursolic acid (UA) 8µM, rapamycin (RAPA) 20nM, concamycin A (ConA) 2nM and 
KU 2µM on autophagic flux in MCF-7 cells stably expressing RLuc-LC3wt or RLuc-LC3G120A. (A) 
Luciferase activity measured with 2 hours intervals during 20 hours and the ratio of the two cell lines 
were expressed as percentages of the corresponding ratio in untreated cells at T0. (B) Luciferase activity 
measured after 12 hours treatment. * P≤ 0.05, ** P≤ 0.01 and *** P≤ 0.001, when compared to control; 
## P≤ 0.01 and ### P≤ 0.001, when compared with UA alone; θθθ P≤ 0.001, when compared to RAPA 
alone; δδ P≤ 0.01 and δδδ P≤ 0.001, when compared to KU alone. 
Cristina Xavier 
154 
 
Moreover, two inhibitors of autophagy, ConA (an inhibitor of V-ATPase and 
therefore of the lysosomal function, but with a minimal impact on autophagic flux21) 
and KU (an inhibitor of autophagy; unpublished observations) were also used. We 
observed that KU inhibited autophagy, as well as, inhibited the effect of rapamycin and 
its effect was further increased in presence of UA. ConA also showed to block the effect 
of rapamycin.  
Furthermore, the RLucLC3wt/RLucLC3G120A was also measured at 12 hours.  
A significant inhibition of autophagy was observed for UA and KU while rapamycin 
showed a significant stimulatory effect (Fig. 4B). The inhibition of rapamycin-induced 
autophagy by UA was confirmed. Additionally, a cooperative effect between UA and 
KU in the inhibition of the autophagic flux was detected, suggesting different 
mechanisms of action for these two compounds. Overall, we validated our results that 
UA blocks autophagic flux and it is able to block the rapamycin-induction effect. 
 
UA induces lysosome membrane permeabilization (LMP)    
 By immunocytofluorescence experiments, an induction of perinuclear clustering 
of LAMP-2 positive compartments was observed (Fig. 3). In addition, a decrease of 
acidic compartments, such as lysosomes, was visualized using acridine orange (data not 
shown). These results suggested that UA could interfere with lysosome integrity or 
functionality. Thus, effect on lysosomal membrane stability by UA was hypothesized. 
We observed that UA significantly decreased the total lysosomal hydrolases activities of 
cathepsins and NAG, indicating a possible impact on lysosomal biogenesis and/or a 
direct destabilizing effect on lysosomal membranes (Fig. 5A). Interestingly, UA 
significantly increased the release of cathepsins and NAG to the cytosol (Fig. 5B), 
which demonstrates an LMP induction. ConA and TNF were used as positive controls 
in the induction of LMP. 
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Figure 5 – Effect of ursolic acid (UA) 8µM, concamycin A (ConA) 2nM and TNF 10ng/ml on the release 
of (A) total and (B) cytoplasmatic cysteine cathepsin and β-N-acetyl-glucosaminidase (NAG) in MCF-7 
cells at 24 hours. Lactate dehydrogenase (LDH) activity of the cytosol was used as an internal standard. * 
P≤ 0.05; ** P≤ 0.01 and *** P≤ 0.001, when compared to control. 
 
Involvement of p38 and JNK signalling on UA-inhibits autophagy  
 In a previous study, we observed an activation of JNK pathway in HCT15 cells 
by UA, which seemed to play a role in autophagy in those cells (unpublished 
observations). Therefore, the involvement of p38 and JNK signalling on UA-inhibited 
autophagy in MCF-7 cells was tested, using the luciferase-based real-time assay. For 
that, SP600125 (SP), an inhibitor of JNK and other kinases, 22 a peptide that specifically 
inhibits JNK and SB203580 (SB), a specific inhibitor of p38, were used. Our results 
showed that both SP and SB inhibited the autophagic flux in MCF-7 cells and that this 
effect increased in the presence of UA, demonstrating that these inhibitors and UA may 
act through different mechanisms (Fig. 6). In contrast, the peptide alone had no effect 
on autophagic flux and when it was combined with UA, an inhibition of autophagy was 
observed to UA values, suggesting an inhibition of autophagy only mediated by UA. It 
seems that p38 interferes with the autophagic flux contrarily to JNK and neither JNK 
nor p38 mediated UA-effect on autophagic flow in MCF-7 cells, although JNK seems to 
have a role at least in some colon cancer cells (unpublished observations). 
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Figure 6 – Effect of ursolic acid (UA) 8µM, SP600125 (SP) 20µM, SB203580 (SB) 20µM and C-Jun N-
terminal kinase peptide inhibitor 1 (Pept) 2µM on autophagic flux in MCF-7 cells stably expressing 
RLuc-LC3wt or RLuc-LC3G120A. Luciferase activity was measured with 2 hours intervals during 20 
hours and the ratio of the two cell lines were expressed as percentages of the corresponding ratio in 
untreated cells at T0. 
 
Discussion 
 
The modulation of autophagy, as well as, effects on lysosome functions have 
been shown to trigger cancer cell death and suggested as therapeutic target to be 
addressed by new anticancer drugs.5, 9 In the present study, we demonstrate that the 
natural triterpenoid ursolic acid (UA) is an inhibitor of autophagy through effects on 
lysosomes. This effect on autophagy induces death in colon and breast cancer cells 
without significant effects on nontumorogenic cells.  
Our results show that UA induced accumulation of lipidated LC3-II to the 
autophagosomal membrane. These events were simultaneous with decreased cell 
survival and morphological changes in the cells, although without effect on apoptosis 
induction, suggesting the involvement of autophagy in cell death. Since an 
accumulation of autophagic structures is not always correlated with an induction of 
autophagy,18 several approaches were used to identify and characterize the effect of UA 
on autophagic flux.  
Effects on the autophagic process may occur at several levels: at the initiation 
step, in the control of autophagosome formation; at the maturation step, involving the 
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fusion between autophagosomes and lysosomes; or at the degradation process.1, 5 Our 
data showed that UA inhibits autophagy at the maturation step since no fusion events 
between autophagosomes and lysosomes were detected, which results in an 
accumulation of autophagosomal structures, an observation consistent with an 
accumulation of LC3-II. The absence of colocalization between autophagosomes and 
lysosomes was evident at 24 hour UA incubations in both breast MCF-7 and colon 
HCT15 cancer cells. The UA-inhibitory effect on autophagy was corroborated by an 
increase in p62 levels from 24 hours in both cell lines. Furthermore, the luciferase-based 
real-time assay that measured the LC3 turnover by following the kinetics of the 
autophagic flux over time 21, showed that UA exerts a gradual inhibition of autophagy 
from 8 hours. Interestingly, UA also efficiently blocked the effect of rapamycin-induced 
autophagy. A cooperative effect between UA and KU in inhibiting autophagy was also 
observed, indicating that these two inhibitors may act through different mechanisms. 
These effects were further supported by the same assay at 12 hours.  
In addition to the absence of fusion events, the induction of perinuclear 
clustering of lysosomes were indications that UA could affect lysosomal integrity. Thus, 
UA´s effects on lysosomal membrane permeabilization (LMP) were measured in MCF-
7 cells. Our results show that, at 24 hours, UA induced the release of the lysosomal 
hydrolases cathepsins and N-acetyl-β-glucosaminidase to the cytosol, as well as, 
decreased their total activities. These data indicate a role of UA in lysosome 
destabilization and in disruption of the integrity of lysosomal membranes. The induction 
of LMP is, however, not a rapid and a strong effect since a decrease of cell viability and 
morphological changes in the cells were only detected from 24 hours, with a gradual 
effect over time. The release of lysosomal contents, especially cathepsins, to the cytosol 
is considered an important step for lysosomal death pathway activation,7 suggesting 
that, besides its role on autophagy, UA can also be involved in the activation of this 
pathway without classical apoptosis induction. 
Recently, changes in the intracellular lipid composition were reported to have 
pronounced effects on vesicular fusion efficiency, thus affecting autophagy.23 The 
reduced levels of lipids, in particular cholesterol, in both autophagosomes and 
lysosomes, were associated with lower fusogenic capability and reduced rates of 
autophagy.23 In fact, previous studies demonstrated that UA may have a role in lipid 
metabolism by stimulating lipolysis in primary-culture adipocytes,24 as well as, 
increasing sphingomyelinase activity during initiation and progression of colon cancer 
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that lead to aberrant crypt foci inhibition.25 Therefore, UA, a lipophylic molecule, may 
induce LMP due to effects on lysosomal membrane composition, causing inhibition of 
the maturation step in the autophagic process.  
Several cell signalling pathways modulate autophagy at the initiation and 
maturation of autophagosomes.1 Recently also the stress kinases, JNK and p38, were 
found to play a role in the control of autophagy. 1, 17, 26, 27 An activation of JNK in 
cancer cells showed to be involved in the induction of autophagic cell death through 
mediation of Beclin 1 expression28 and/or activation of the protein Atg7.27 In contrast, a 
p38 activation was associated with an inhibition of autophagy in colorectal cancer 
cells29 and an inhibitory effect at the maturation step was found.26 UA has recently been 
reported to inhibit JNK in colon16 and breast13 cancer cells. Our previous observations 
showed that UA induced activation of JNK in HCT15 cells with a possible involvement 
of this stress MAP Kinase in autophagy. Here, results demonstrated that neither JNK 
nor p38 pathways seem to be involved in the inhibition of autophagy induced by UA in 
MCF-7 cells. 
Additionally, although UA demonstrated to modulate PI3K/Akt pathway 
through inhibition of phospho-Akt,13, 14 the classical inhibitor of PI3K class I, 
wortmannin,30 was not able to induce LC3 accumulation, suggesting that UA inhibits 
autophagy independently of effects on this pathway. Interestingly, oleanolic acid, a 
compound with a similar chemical structure of UA for which similar biological 
properties have been reported,11 did not show effect on autophagy. UA and oleanolic 
acid differ in the position of one methyl group on their E ring, which could contribute to 
this difference. 
In conclusion, the data presented here shows the ability of ursolic acid to block 
the autophagic process at the maturation step due to effects on lysosomal membrane 
stability in breast and colon cancer cells. This effect on the autophagic maturation 
probably triggers death in cancer cells, which seems to be independent of JNK and p38 
pathways in MCF-7 cells. Hence, ursolic acid shows potential as a lysosome-
destabilizing drug or as an autophagic inhibitor that could be used in combination 
therapy in order to increase treatment efficacy. 
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Material and Methods 
 
Chemicals  
 Ursolic acid (UA), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), rapamycin (RAPA), 3-Methyladenine (3-MA), concanamycin A 
(ConA), wortmannin (W), etoposide and oleonolic acid (OA) were purchased from 
Sigma-Aldrich. C-Jun N-terminal kinase peptide inhibitor 1 (Pept) was purchased from 
Enzo Life Science. All the compounds were resuspended in dimethyl sulfoxide 
(DMSO).   
  
Cell culture  
 HCT15 human colorectal carcinoma and MCF-7 human breast carcinoma cell 
lines were grown in RPMI-1640 (Gibco, 61870) supplemented with 6% fetal calf 
serum, penicillin and streptomycin and maintained at 37ºC in a humidified 5% CO2 
atmosphere. When plating for luciferase reported assays, RPMI-1640 without phenol 
red (Gibco, 11835) was used. The MCF-7-eGFP-LC3 cell line is a single cell clone of 
MCF-7 cells expressing a fusion protein consisting of enhanced green fluorescence 
protein (eGFP) and rat microtubule-associated protein light chain 3  (LC3).  MCF-7-
mRFP-GFP-LC3 are MCF-7 cells stably expressing the tandem fluorescent construct 
consisting in two fluorescent proteins, GFP and monomeric ref fluorescent protein 
(mRFP), tagged with LC3 (construct kindly provided by Dr T. Yoshimori19). MCF-7 
cells stably expressing Renilla-luciferase (RLuc) tagged with LC3 wild type or with a 
C-terminal glycine mutant of LC3 that is defective in ubiquitin-like conjugation with 
phosphatidylethanolamine (GFP-LC3G120A31) were used to monitor autophagy 
capacity.21 
 
Cell viability, Apoptosis and Morphological analysis  
 MTT reduction assay was used as described previously.14 Briefly, MCF-7 and 
HCT15 cells were treated with UA 8µM for 22, 46 and 70 hours and then two more 
hours in the presence of MTT at final concentration 0.5 mg/ml. Hydrogen chloride 
0.04M in isopropanol was then used to dissolve the formazan crystals. The viable cells 
in each well were estimated by the cell capacity to reduce MTT using a 
spectrophotometer.  
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To estimate the percentage of apoptotic cells, TUNEL (TdT mediated dUTP 
Nick End Labelling) assay was performed. After incubation of HCT15 and MCF-7 cell 
lines with UA 8µM for 24, 48 and 72 hours, cells were collected (both floating and 
attached cells), fixed with 4% paraformaldehyde for 15 minutes at room temperature 
and attached into a polylysine treated slide using a Shandon Cytospin. Then, cells were 
washed in PBS and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 
2min on ice. TUNEL assay was performed using a kit from Roche (Mannheim, 
Germany), following the manufacturer’s instructions. Cells were incubated with 
Hoechst for nuclei staining. The percentage of apoptotic cells was calculated from the 
ratio between TUNEL positive cells and total number of from a count higher than 500 
cells per slide under a fluorescent microscope.  
The morphology of the cells incubated with UA 8µM during 24 hours and 48 
hours was observed and images were taken using Olympus fluorescence microscope.  
 
LC3 puncta formation assay  
MCF-7-eGFP-LC3 cells were incubated with different concentrations of UA 
(5µM, 8µM and 10µM), 15µM OA and 2.5µM W for 24 hours. Autophagosomes were 
detected in the cells fixed in 3,7% formaldehyde for 10 minutes at room temperature, by 
counting the percentage of cells with more than five eGFP-LC3 positive dots (a 
minimum of 100 cells/sample) applying Olympus fluorescence microscope.  
 
Immunofluorescence  
MCF-7-mRFP-GFP-LC3 cells on coverslides were treated with UA 8µM at 
different hours (12, 24 and 48 hours) and/or with rapamycin 100nM and/or 3-MA 
10mM for 24 hours. Then cells were fixed using ice-cold methanol for 2 minutes or 
3,7% formaldehyde for 10 minutes at room temperature. Cells were stained with 
followed primary antibodies at 4ºC, overnight: mouse anti-human LC3 (Nanotools), 
mouse anti-human LAMP-2 (clone H4B4 Developmental Studies Hybridoma Bank, 
University of Iowa) and p62 (Enzo Life Science). After washing, samples were 
incubated with the appropriated Alexa Fluor-488 and Alexa Fluor-647-coupled 
secondary antibodies (Invitrogen). Confocal images were taken using a Zeiss Axiovert 
100 M Confocal Laser Scanning Microscope equipped with LSM 510 system (Carl 
zeiss MicroImaging).  
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Immunoblotting  
MCF-7 and HCT15 cells after treatment with UA 8µM at different hours were 
extracted in SDS-lysis buffer. Extracts (20µg protein) were separated on SDS-PAGE 
and transferred to nitrocellulose membranes. Protein concentration was quantified using 
a BCA Protein assay kit (Bio-Rad Laboratories). The primary antibodies used were: p62 
(Enzo Life Science) and LC3 (Nanotools), followed by appropriated peroxidase-
conjugated secondary antibodies from DAKO (Glostrup, Denmark). Anti-β-actin (from 
Sigma-Aldrich) was used as loading control. 
 
Reporter assays 
 For luciferase-based real-time assay21 in living cells, MCF-7 cells stably 
expressing RLucLC3wt and RLuc-LC3G120A were plated in the uneven and even 
numbered columns of white 96 wells dishes (Nunc, 136101) respectively at 
8x104cells/ml. The following day, 60µl medium containing 50nM EnduRenTM 
(Promega) were added to the cells and incubated for 2 hours. The luminescence was 
measured (Enspire 2300 Multilabel reader, Perkin Elmer) after 2 hours corresponding to 
time zero (To) define as 100%. The readout was obtained by calculating the ratio in 
luminescence between RLucLC3wt and RLucLC3G120A, which gives the autophagic 
flux. Thereafter, the compounds dissolved in EnduRenTM containing medium were 
added in the volume of 30µl and luminescence measurements were performed in 
intervals of 2 hours during 20 hours.  
 For the reporter assay21 at 12 hours, MCF-7 cells expressing RLuc-LC3wt and 
RLuc-LC3G120A were used and Renilla-luciferase detected using the reagents in the 
Dual-Luciferase® Reporter assay System (Promega), according to the manufacturer’s 
instructions. Briefly, after 12 hours of incubation with compounds, cells were lysed in 
40µl /well of 1x lysis buffer and subjected to a single freeze/thaw cycle. Renilla-
Luciferase was further measured in white half area 96-well plates (Costar, 3694) by 
adding 80µl of lysate and Stop&Glo® Reagent to 6µl of sample. 
  
Cathepsin and NAG activities   
The cysteine cathepsin (zFR-AFC, Enzyme System Products) and N-acetyl-β-
glucosaminidase (NAG) activities of MCF-7 cells treated with UA 8µM, ConA 2nM 
and TNF 10ng/ml were measured after 24 hours.32 Briefly, the cytosolic fraction was 
extracted with 20µg/ml digitonin and the total cellular fraction with 200µg/ml digitonin. 
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The rate of the appropriate substrate hydrolysis Vmax was measured over 20 minutes at 
30 ºC on a SpectraMax Gemini fluorometer (Molecular Devices, Sunnyvale). Lactate 
dehydrogenase (LDH) activity of the cytosol, determined by a cytotoxicity detection kit 
(Roche), was used as an internal standard. 
 
Statistical analysis 
 All values represent the mean ration ± SEM of at least three independent 
experiments. Statistical analyses were done using a two-tailed unpaired t-test in 
GraphPad Prism 4.0 software. P-values ≤ 0.05 were considered statistically significant. 
Images are representative of at least three independent experiments.   
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1. General Discussion and Conclusions 
 
 In recent years, natural products have received great attention for cancer research 
owing to their various health benefits, associated with low of toxicity and side effects. 
Colorectal cancer (CRC), a common cause of cancer-related death, has been increasing 
over time and the main reason for its high incidence has been associated to diet. The 
work developed in the scope of this thesis contributed to support the importance of 
dietary constituents in certain genetic profiles of CRC and to increase the value of 
potential dietary natural compounds as anticancer agents.  
In the first part of this work (chapter II and III), the possible anticarcinogenic 
effects of Salvia sp. and Hypericum sp. water extracts, prepared as a tea, which is one of 
the most common forms of human consumption of these plants, and the main phenolic 
compounds rosmarinic acid and chlorogenic acid present in these extracts, were 
evaluated in CRC cell lines. These medicinal plants are popular for different reasons 
and they have been experimentally investigated and their benefits confirmed. 
Nevertheless, their anticarcinogenic effects in CRC have never been explored. The 
second part of the work (chapter IV, V and VI) focused on two phenolic compounds 
(quercetin and luteolin), which are active compounds present in the extracts tested 
above, as well as, the triterpenoid ursolic acid that is present in sage extracts. Although 
the anticancer effects, especially of the phenolic compounds, have been widely studied, 
their effects on particularly CRC mutation patterns and their possible combination with 
5-fluorouracil (5-FU) is not known. The chemotherapeutic agent 5-FU is currently the 
most widely used drug, however some resistances have been arising, and thus 
combinatory drugs have been developed to improve CRC treatment. Therapies targeting 
pathways involved in CRC carcinogenesis have increased benefits when in combination 
with this traditional chemotherapeutic agent, overcoming current limitations of the 
agent.      
Due to the high frequency of mutations in components of the PI3K/Akt and 
MAP Kinases pathways present in CRC humans the focus of this study was on these 
relevant molecular targets. Therefore, the experiments were performed using different 
CRC cell lines: HCT15 harbors a KRAS mutation and CO115 harbors a BRAF 
mutation and overexpresses Akt. Moreover, the effects of compounds on molecular 
targets of apoptotic and non-apoptotic pathways of cell death were studied. The 
antiproliferative and proapoptotic effects were evaluated using different in vitro tests, 
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such as MTT, BrdU and TUNEL assays. To assess the possible effects on different 
molecular targets western blot were performed.  
Firstly, the potential effect of water extracts of S. fruticosa (SF) and S. 
officinalis (SO) was evaluated (chapter II). These sages showed to significantly inhibit 
cell proliferation and induce apoptosis (50µg/ml). Different effects were found for the 
two CRC cell lines. The results revealed that those effects may be associated, at least in 
part, with the inhibition of MAPK/ERK pathway through effects upstream of BRAF. 
The presence of the BRAF mutation showed to act as a barrier for the antiproliferative 
effect of these sages. The main phenolic compound present in the sages, rosmarinic 
acid, did, however, not show the same effects, even at higher concentrations (100µM), 
presenting only proapoptotic effects. Thus, other active compounds present in the 
extracts at lower concentrations, or the mixture between them, may be responsible for 
the antiproliferative effects of SF and SO. 
Subsequently, the anticarcinogenic activities of three Hypericum water extracts 
sp., Hypericum androsaemum (HA), Hypericum perforatum (HP) and Hypericum 
undulatum (HU), were investigated in the same CRC cell lines (chapter III). The study 
demonstrated that HA efficiently inhibits cell proliferation and induces apoptosis in 
both genetic backgrounds. These effects seem to be related to suppression of the mutant 
BRAF and PI3K/Akt pathway (at 65µg/ml). Interestingly, this extract only interferes 
with mutant BRAF without affecting wild type BRAF, suggesting a more specific effect 
of this extract on CRC. Moreover, HA also increased p38 and JNK activation, which 
may explain the extracts’ proapoptotic effects. In order to find the active compound of 
HA plant, the main phenolic compound present in HA, chlorogenic acid, was tested. 
This compound did, however, not show any of the observed effects, even at very higher 
concentrations. On the other hand, the study demonstrated that HU and HP species are 
different from HA, since no effects on CRC cells viability, at reasonable concentrations, 
were detected. The results demonstrated new beneficial effects of Hypericum 
androsaemum and, more significantly, it showed to be a source of compounds that 
specifically act in BRAF mutation, frequently found in CRC tumors.     
All these observations showed the ability of these medicinal plants in decreasing 
CRC progression by affecting the expression of important molecular targets of 
proliferation and apoptosis. In addition, they suggest them as sources of potential 
anticarcinogenic compounds. Sage extracts are very rich in several derivates of luteolin, 
whereas Hypericum extract possess quercetin and a variety of glycosides in its 
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composition. Since these conjugated glycosides have been shown to be converted into 
their active aglycones quercetin (Q) and luteolin (L) in the intestine, we decided to 
study the aglycones as the most important players in the cell. In addition, we also 
studied a triterpenoid, ursolic acid (UA), which is also present in sage water extracts.    
In chapter IV, the antiproliferative and proapoptotic effects of Q, L and UA 
were evaluated and the possible involvement of PI3K/Akt and MAPK signalling 
pathways on their mechanism of action were analysed. All the compounds showed 
significant inhibition of cell proliferation and induction of apoptosis in CRC cell lines. 
The effects of Q (around 20µM) and L (around 15µM) seem to be due, at least in part, 
to effects on KRAS through regulation of both MAPK/ERK and PI3K pathways. 
However, the presence of a BRAF mutation prevents these compounds from having 
effect on the MAPK/ERK pathway. On the other hand, UA (10µM) seems to be 
efficient in suppressing PI3K, at concentration below the other compounds. In addition, 
these natural compounds demonstrated to be even more efficient in inhibiting the 
pathways than the reference inhibitors commonly used to study the involvement of 
PI3K/Akt and MAPK/ERK pathways.     
Taken together, sage extracts inhibit MAPK/ERK pathway through suppression 
of KRAS probably due to derivates of luteolin, since this compound alone showed the 
same effects. However, L additionally demonstrated to decrease PI3K/Akt pathway, 
thereby affecting other molecular targets. An effect on PI3K was also observed for UA. 
Regarding HA, the inhibition of PI3K/Akt pathway could probably be due to the 
presence of Q, one constituent of this extract that showed the same effect. Surprisingly, 
HA also suppresses mutant BRAF, effect that was not found for Q, which instead acts 
on KRAS, or for the main phenolic compound chlorogenic acid. To look for the active 
compound responsible to the effect on mutant BRAF should be considered in future 
experiments. These recent findings highlight the impact of compounds that specifically 
act on mutant BRAF like HA water extract. It must also be taken in account that 
possible applications of the flavonoids Q and L as inhibitors of MAPK/ERK pathway 
seem to be restricted to tumors without BRAF mutation. Effects of extracts are not due 
to main phenolic compounds present and may result from other classes of compounds 
and/or for synergism between constituents.      
In chapter V, the effects of Q, L and UA in combination with 5-FU were tested, 
in order to find agents that could overcome 5-FU-resistance and improve treatment 
efficacy. One mechanism of action of this chemotherapeutic 5-FU is apoptosis 
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induction, which was the focus of this work. The results showed that Q and L (both at 
12µM) efficiently enhance apoptosis induced by 5-FU and a synergistic effect was 
observed for Q in the p53 wild-type cell line. Q seems to increase the effect of 5-FU 
through induction of the mitochondrial pathway because an increased on cleaved 
caspase 3, caspase 9 and PARP and a decrease in Bcl-2 expression were detected when 
Q in co-incubated with 5-FU in the CO115 p53 wild type cell line. This suggest the 
possible applicability of this flavonoid in combination with 5-FU to improve cell death 
dependent on p53. UA (4µM) was also tested in combination with 5-FU and a 
synergistic enhancement of apoptosis was observed in the HCT15 mutant p53 cells. In 
this case, UA did not induce caspase activity, but was able to induce JNK activation, 
where the inhibitor of the JNK, SP600125, almost completely abrogated UA-induced 
apoptosis. These results suggest that UA induces apoptosis through JNK pathway when 
p53 is not functional, being the possible reason for the synergistic effect with 5-FU. 
Moreover, UA-induced cell death (other than by apoptosis) also seems to be partially 
dependent on JNK. Interestingly, this triterpenoid demonstrated to be more efficient in 
inducing cell death than 5-FU alone, suggesting UA as a potential chemotherapeutic 
candidate against CRC. Since apoptosis induced by UA did not explain all the cell death 
observed, effects on autophagy, another type of cell death, were elucidated. UA induced 
accumulation of LC3, an effect inhibited by SP, indicating an involvement of this 
compound in autophagy and a role of JNK in this process, in HCT15 cells.  
  Finally (chapter VI), a characterization of the role of UA in autophagy was 
made. Agents that have a role in the autophagic process have been appearing and seem 
promising as anticancer agents. An accumulation of LC3, as demonstrated in the 
previous study, may be an indication of both induction or inhibition of the autophagic 
process. The expression of p62, as well as, immunohistochemistry stained with 
autofagosomes and lysosomes markers were further analyzed. This study found that UA 
inhibits autophagy in HCT15 cells over time. Moreover, this inhibition appears to be at 
the maturation step since no fusion event between lysosomes and autophagosomes was 
observed. Taking advantage of some currently new techniques, MCF-7 breast cancer 
cell line was used to confirm the inhibitory effect of UA on autophagy process at the 
maturation step. Interestingly, UA also showed to revert the effect of rapamycin, a 
classical inducer of autophagy, and to cooperate with another inhibitor of autophagy, 
increasing its effect. Moreover, neither JNK nor p38 pathways seem to be involved in 
the inhibition of autophagy induced by UA in MCF-7 cells, contrarily to what was 
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previously observed for HCT15 cells. The role of JNK in autophagy seems be dual 
depending on the cell type. In order to understand more deeply how UA inhibits the 
maturations step, effects on lysosomal integrity was tested. The results showed that UA 
increased the release of the lysosomal hydrolases to the cytosol and decreased their total 
activities, suggesting an induction of lysosomal membrane permeabilization, as well as, 
a possible impact on lysosomal biogenesis and/or a direct destabilizing effect on 
lysosomal membranes. The effect of UA on the destabilization of lysosomes structure 
helps to explain the lack of fusion between them and autophagosomes. Taken together, 
this work found a new effect for UA in the inhibition of autophagy, which is probably 
due to effects on lysosome integrity.  
In general, this work uses a new methodological approach by using CRC cell 
lines that harbor different mutations and characterizes mechanisms of action of extracts 
and individual compounds of medicinal plants of the genus Salvia and Hypericum, on 
particular molecular targets comparativelly. The sage water extracts demonstrated 
capacity to inhibit MAPK/ERK upstream of BRAF, while Hypericum androsaemum 
acted specifically on mutated BRAF, effects that explain, at least in part, the 
antiproliferative and proapoptotic effects of these plants. In addition, these effects were 
not due to the most representative antioxidant compounds present in the extracts 
(rosmarinic acid and chlorogenic acid, respectively), suggesting the effects are 
independent of reactive oxygen species (ROS)-mediated signaling. Concerning the 
isolated compounds, Q, L and UA, it was shown, for the first time, in this work the 
impact of their effects on molecular targets on different genetic patters in CRC and their 
possible use in combination with the chemotherapeutic drug 5-FU. Q and L 
demonstrated to act on KRAS, affecting both MAPK/ERK and PI3K/Akt pathways, 
although the effect on MAPK/ERK inhibition is no longer observed in the presence of 
BRAF mutation. The combination of Q with 5-FU showed a synergistic induction of 
apoptosis probably through via mitochondrial pathway in the p53 wild-type background 
of CO115. Finally, UA demonstrated to inhibit PI3K pathway and to synergistically 
enhance apoptosis induced by 5-FU via JNK. For the first time, UA was found to inhibit 
autophagy at the maturation step of autophagosomes lysosomes fusion, possibly by 
affecting the lysosomal membrane, contributing to cell death.   
 In conclusion, the plant extracts and the isolated natural compounds used in this 
thesis demonstrated to be promising agents against CRC in different molecular targets 
by decreasing proliferation and in sensitizing cancer cells to death apoptosis. This study 
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contributes to add Salvia fruticosa, Salvia officinalis, and Hypericum androsaemum to 
the list of plants with potential anticarcinogenic effects. Moreover, the isolated 
compounds quercetin and luteolin demonstrated to be effective on a variety of 
molecular targets and to be promising agents in combination with 5-FU. During this 
work, UA was the most promissory compound since it was able to target the lysosomes 
at lower concentrations inhibiting the autophagic process and thus leading CRC and 
breast cancer cells to death. More research is needed, however, to safely add these 
dietary natural compounds as therapeutic tool against cancer and especially we should 
be aware that in vivo studies are needed to confirm our data.  
 
2. Future Perspectives 
 
The studies enclosed in this thesis were carried out to find potential 
anticarcinogenic effects of Salvia and Hypericum species and, if possible, to identify 
active principles, characterizing the mechanism of action. In spite of the advances 
obtained in this work, there are still many questions unanswered.  
Presently, we found that Salvia fruticosa, Salvia officinalis and Hypericum 
androsaemum possess anticarcinogenic in CRC. In an attempt to find which compounds 
are responsible the effects observed, we tested the main phenolic compounds present in 
the water extracts. However, neither of the compounds, rosmarinic acid and chlorogenic 
acid, respectively, showed the ability to suppress KRAS or BRAF, the active principle 
of these extracts being still unknown. Since the Hypericum water extract was only 
effective in inhibiting mutant BRAF without affecting the wild-type BRAF, to find in 
the plant the possible responsible for this effect constitute a good challenge. As future 
work, a screening of compounds present in the Hypericum water extract should be 
performed. Although phenolic compounds have been demonstrated to have a wide range 
of effects against several cancer cell types, other classes of compounds present in these 
extracts must be taken into account.  
The isolated compounds quercetin and luteolin showed to inhibit MAPK/ERK 
and PI3K/Akt pathways through inhibition of KRAS. However, more studies should be 
performed in order to clarify how these compounds interact and decrease the expression 
of this protein. Both flavonoids also demonstrated to enhance apoptosis induced by 5-
FU and, moreover, a synergistic effect was observed with quercetin in the p53 wild type 
Chapter VII                                                                                                                                                                Final Considerations                                                                    
173 
 
cells. Nevertheless, to confirm and validate these results, studies in vivo should be 
carried out. 
The triterpenoid ursolic acid induced cell death at small concentrations and had 
effect on lysosome integrity, which leads to a blockage of the maturation step during the 
autophagic process. According to some recent studies, UA affects the metabolism of 
lipids, which could explain the observed effects on lysosomal membrane. It would be 
interesting to explore more in detail the interference of UA with lysosomes and cell 
membranes in general.  
Finally, since an ideal anticancer agent should be toxic to malignant cells with 
minimum toxicity towards normal cells, it is important to evaluate the effects of these 
plant water extracts and isolated compounds in cells considered “normal”. In fact, UA 
was tested in HBL-100 nontumorogenic breast-derived epithelial cells and no 
significant effect on its survival, at the concentration used, was observed. The same 
should be investigated for quercetin and luteolin. Moreover, to further reveal the impact 
of the applicability of these natural compounds in CRC therapy, effects in animal 
models are essential.     
 
 
 
 
 
 
 
 
 
 
 
 
                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
